<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007790</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4741</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The breast journal</Title>
            </Journal>
            <ArticleTitle>Unusual case of ductal breast carcinoma with vulvar metastasis.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/tbj.14067</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Doval</LastName>
                    <ForeName>Dinesh Chandra</ForeName>
                    <Initials>DC</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-6191-563X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Rajiv Gandhi Cancer Institute &amp; Research Centre, Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tripathi</LastName>
                    <ForeName>Rupal</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Research, Rajiv Gandhi Cancer Institute &amp; Research Centre, Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gupta</LastName>
                    <ForeName>Manoj</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute &amp; Research Centre, Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mehta</LastName>
                    <ForeName>Anurag</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Rajiv Gandhi Cancer Institute &amp; Research Centre, Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goyal</LastName>
                    <ForeName>Pankaj</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Rajiv Gandhi Cancer Institute &amp; Research Centre, Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Agrawal</LastName>
                    <ForeName>Chaturbhuj</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Rajiv Gandhi Cancer Institute &amp; Research Centre, Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>Shweta</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Research, Rajiv Gandhi Cancer Institute &amp; Research Centre, Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Upreti</LastName>
                    <ForeName>Kalpana</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Research, Rajiv Gandhi Cancer Institute &amp; Research Centre, Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varghese</LastName>
                    <ForeName>Sony</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Research, Rajiv Gandhi Cancer Institute &amp; Research Centre, Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Breast J</MedlineTA>
            <NlmUniqueID>9505539</NlmUniqueID>
            <ISSNLinking>1075-122X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>21</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007790</ArticleId>
            <ArticleId IdType="doi">10.1111/tbj.14067</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007593</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7565</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>197</Volume>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Computer methods and programs in biomedicine</Title>
            </Journal>
            <ArticleTitle>An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device.</ArticleTitle>
            <Pagination>
                <MedlinePgn>105758</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0169-2607(20)31591-1</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmpb.2020.105758</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The most common breast cancer detection modalities are generally limited by radiation exposure, discomfort, high costs, inter-observer variabilities in image interpretation, and low sensitivity in detecting cancer in dense breast tissue. Therefore, there is a clear need for an affordable and effective adjunct modality that can address these limitations. The Cyrcadia Breast Monitor (CBM) is a non-invasive, non-compressive, and non-radiogenic wearable device developed as an adjunct to current modalities to assist in the detection of breast tissue abnormalities in any type of breast tissue.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The CBM records thermodynamic metabolic data from the breast skin surface over a period of time using two wearable biometric patches consisting of eight sensors each and a data recording device. The acquired multi-dimensional temperature time series data are analyzed to determine the presence of breast tissue abnormalities. The objective of this paper is to present the scientific background of CBM and also to describe the history around the design and development of the technology.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The results of using the CBM device in the initial clinical studies are also presented. Twenty four-hour long breast skin temperature circadian rhythm data was collected from 93 benign and 108 malignant female study subjects in the initial clinical studies. The predictive model developed using these datasets could differentiate benign and malignant lesions with 78% accuracy, 83.6% sensitivity and 71.5% specificity. A pilot study of 173 female study subjects is underway, in order to validate this predictive model in an independent test population.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results from the initial studies indicate that the CBM may be valuable for breast health monitoring under physician supervision for confirmation of any abnormal changes, potentially prior to other methods, such as, biopsies. Studies are being conducted and planned to validate the technology and also to evaluate its ability as an adjunct breast health monitoring device for identifying abnormalities in difficult-to-diagnose dense breast tissue.</AbstractText>
                <CopyrightInformation>Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>S</LastName>
                    <ForeName>Vinitha Sree</ForeName>
                    <Initials>VS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cyrcadia Health, 1325 Airmotive Way, Ste. 175-L, Reno, NV 89502, United States; Cyrcadia Asia, Ltd., Hong Kong. Electronic address: vsree@cyrcadiahealth.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Royea</LastName>
                    <ForeName>Rob</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cyrcadia Asia, Ltd., Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buckman</LastName>
                    <ForeName>Kevin J</ForeName>
                    <Initials>KJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cyrcadia Health, 1325 Airmotive Way, Ste. 175-L, Reno, NV 89502, United States; Adventist Health Lodi Memorial Hospital, Lodi, CA 95240, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Benardis</LastName>
                    <ForeName>Matt</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cyrcadia Health, 1325 Airmotive Way, Ste. 175-L, Reno, NV 89502, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holmes</LastName>
                    <ForeName>Jim</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cyrcadia Health, 1325 Airmotive Way, Ste. 175-L, Reno, NV 89502, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fletcher</LastName>
                    <ForeName>Ronald L</ForeName>
                    <Initials>RL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cyrcadia Health, 1325 Airmotive Way, Ste. 175-L, Reno, NV 89502, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eyk</LastName>
                    <ForeName>Ng</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Mechanical and Aerospace Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rajendra Acharya</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Engineering, Division of ECE, Ngee Ann Polytechnic, Singapore 599489; Department of Biomedical Engineering, School of Science and Technology, Singapore University of Social Sciences, Singapore; Department of Biomedical Informatics and Medical Engineering, Asia University, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ellenhorn</LastName>
                    <ForeName>Joshua D I</ForeName>
                    <Initials>JDI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cyrcadia Health, 1325 Airmotive Way, Ste. 175-L, Reno, NV 89502, United States; Cyrcadia Asia, Ltd., Hong Kong; Surgery Group LA, Cedars-Sinai Medical Towers, Los Angeles, CA 90048, United States; John Wayne Cancer Clinics, Santa Monica, CA 90404, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Comput Methods Programs Biomed</MedlineTA>
            <NlmUniqueID>8506513</NlmUniqueID>
            <ISSNLinking>0169-2607</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Circadian rhythm</Keyword>
            <Keyword MajorTopicYN="N">Data mining</Keyword>
            <Keyword MajorTopicYN="N">Machine learning</Keyword>
            <Keyword MajorTopicYN="N">Predictive analytics</Keyword>
            <Keyword MajorTopicYN="N">Thermal metabolomics</Keyword>
            <Keyword MajorTopicYN="N">Wearable device</Keyword>
        </KeywordList>
        <CoiStatement>Declaration of Competing Interest The authors of this work declare that they have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>12</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007593</ArticleId>
            <ArticleId IdType="pii">S0169-2607(20)31591-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cmpb.2020.105758</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007526</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2468-7847</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of gynecology obstetrics and human reproduction</Title>
            </Journal>
            <ArticleTitle>Comparison of mammography results from individual and organized screening for breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>101926</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S2468-7847(20)30290-7</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jogoh.2020.101926</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In France, the coexistence of individual screening (IS) and organized screening (OS) for breast cancer induces difficulties for primary care practitioners to position themselves. This study assessed whether the risk of having a mammography with a high risk of malignancy (BI-RADS 4 or 5) was different between patients aged from 50 to 74 year performing it as part of an IS or of the OS.</AbstractText>
                <AbstractText Label="METHOD" NlmCategory="METHODS">This cross-sectional multicenter study included women aged 50-74, with no personal history of breast cancer, performing mammography in radiology centers in Paris (France). The nature of the screening (OS or IS), breast cancer risk (high risk: BI-RADS 4 or 5), risk factors and clinical breast examination (CBE) abnormalities were collected. Patients in the IS and OS group were matched on age, breast density, history of benign lesions and family history of breast cancer using a propensity score. The association between the nature of screening and the risk of malignancy was evaluated by conditional logistic regression.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 2190 included patients, 77 % performed a mammography with the IS and had more CBE abnormalities (23 % vs 11 %, p &lt; 0,001), a history of benign lesion (15 % vs 11 %, p = 0.01) and a family history of breast cancer (42 % vs 29 %, p &lt; 0,001). After matching 503 OS patients with 941 IS patients, the risk of malignancy and the nature of the screening were not associated (OR = 0.72 [0.35-1.47], p = 0.50).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The risk of malignancy was not different whether the mammography was performed as part of the OS or IS.</AbstractText>
                <CopyrightInformation>Copyright © 2020 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tron</LastName>
                    <ForeName>Arthur</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Université de Paris, Faculté de Santé, UFR de Médecine, Département de médecine générale, F-75014, Paris, France. Electronic address: arthur.tron@parisdescartes.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caulliez</LastName>
                    <ForeName>Ségolène</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Université de Paris, Faculté de Santé, UFR de Médecine, Département de médecine générale, F-75014, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malmartel</LastName>
                    <ForeName>Alexandre</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Université de Paris, Faculté de Santé, UFR de Médecine, Département de médecine générale, F-75014, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>J Gynecol Obstet Hum Reprod</MedlineTA>
            <NlmUniqueID>101701588</NlmUniqueID>
            <ISSNLinking>2468-7847</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>
            <Keyword MajorTopicYN="N">Diagnostic screening programs</Keyword>
            <Keyword MajorTopicYN="N">Early detection of cancer</Keyword>
            <Keyword MajorTopicYN="N">Mass screening</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>10</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007526</ArticleId>
            <ArticleId IdType="pii">S2468-7847(20)30290-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jogoh.2020.101926</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007434</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-355X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of radiation oncology, biology, physics</Title>
            </Journal>
            <ArticleTitle>Positron Emission Tomography Imaging of Functional TGFβ Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0360-3016(20)34345-5</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijrobp.2020.09.043</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Transforming growth factor β (TGFβ) promotes cell survival by endorsing DNA damage repair and mediates an immunosuppressive tumor microenvironment. Thus, TGFβ activation in response to radiation therapy is potentially targetable because it opposes therapeutic control. Strategies to assess this potential in the clinic are needed.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">&amp; Materials: We evaluated positron emission tomography (PET) to image <sup>89</sup>Zr -fresolimumab, a humanized TGFβ neutralizing monoclonal antibody, as means to detect TGFβ activation in intracranial tumor models. TGFβ pathway activity was validated by immunodetection of phosphorylated SMAD2 and TGFβ target, tenascin. The contribution of TGFβ to radiation response was assessed by Kaplan Meier survival analysis of mice bearing intracranial murine tumor models, GL261 and SB28 glioblastoma and brain-adapted 4T1 breast cancer (4T1-BrA) treated with TGFβ neutralizing monoclonal antibody, 1D11, and/or focal radiation (10 Gy).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS"><sup>89</sup>Zr-fresolimumab PET imaging detected engineered, physiological and radiation-induced TGFβ activation, which was confirmed by immunostaining of biological markers. GL261 glioblastoma tumors had more PET signal compared to similar sized SB28 glioblastoma tumors, whereas widespread PET signal of 4T1-BrA intracranial tumors is consistent with its highly dispersed histological distribution. Survival of mice bearing intracranial tumors treated with 1D11 neutralizing antibody alone was similar to that of mice treated with control antibody whereas 1D11 improved survival when given in combination with focal radiation. The extent of survival benefit of combination of radiation and 1D11 was associated with the degree of TGFβ activity detected by PET.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrates that <sup>89</sup>Zr -fresolimumab PET imaging detects radiation-induced TGFβ activation in tumors. Functional imaging indicated a range of TGFβ activity in intracranial tumors, but TGFβ blockade provided survival benefit only in the context of radiation treatment. These studies are further evidence that radiation-induced TGFβ activity opposes therapeutic response to radiation.</AbstractText>
                <CopyrightInformation>Copyright © 2020. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gonzalez-Junca</LastName>
                    <ForeName>Alba</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, School of Medicine, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reiners</LastName>
                    <ForeName>Oliver</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, School of Medicine, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Borrero-Garcia</LastName>
                    <ForeName>Luis D</ForeName>
                    <Initials>LD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, School of Medicine, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beckford-Vera</LastName>
                    <ForeName>Denis</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lazar</LastName>
                    <ForeName>Ann A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California San Francisco, San Francisco, CA, USA; Division of Oral Epidemiology, School of Dentistry, University of California San Francisco, San Francisco, CA, USA; Division of Biostatistics, School of Medicine, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chou</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, School of Medicine, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Braunstein</LastName>
                    <ForeName>Steve</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, School of Medicine, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>VanBrocklin</LastName>
                    <ForeName>Henry</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Franc</LastName>
                    <ForeName>Benjamin L</ForeName>
                    <Initials>BL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA; Current address: Department of Radiology, Stanford University, School of Medicine, Palo Alto, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barcellos-Hoff</LastName>
                    <ForeName>Mary Helen</ForeName>
                    <Initials>MH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, School of Medicine, University of California San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California San Francisco, San Francisco, CA, USA. Electronic address: MaryHelen.Barcellos-Hoff@ucsf.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Int J Radiat Oncol Biol Phys</MedlineTA>
            <NlmUniqueID>7603616</NlmUniqueID>
            <ISSNLinking>0360-3016</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Glioblastoma</Keyword>
            <Keyword MajorTopicYN="N">TGFβ</Keyword>
            <Keyword MajorTopicYN="N">brain metastases</Keyword>
            <Keyword MajorTopicYN="N">functional imaging</Keyword>
            <Keyword MajorTopicYN="N">ionizing radiation</Keyword>
            <Keyword MajorTopicYN="N">positron emission tomography</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>10</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007434</ArticleId>
            <ArticleId IdType="pii">S0360-3016(20)34345-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijrobp.2020.09.043</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007383</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0333</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
            </Journal>
            <ArticleTitle>MST2 silencing induces apoptosis and inhibits tumor growth for estrogen receptor alpha-positive MCF-7 breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>115257</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0041-008X(20)30383-5</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2020.115257</ELocationID>
            <Abstract>
                <AbstractText>Mammalian sterile 20-like kinase 1/2 (MST1/2) plays an important role in cell growth and apoptosis and functions as a tumor suppressor. Previously, we showed that MST2 overexpression activates Estrogen receptor alpha (ERα) in human breast cancer MCF-7 cells in the absence of a ligand. Here, we examined the role of MST2 in the growth of ER-positive MCF-7 cells. Cell cycle, apoptosis, and mammosphere formation assay method were implemented to detect the biological effects of MST2 ablation on the growth of MCF-7 cells in vitro. The effect of MST2-siRNA on MCF-7 cells tumor growth in vivo was studied in tumor-bearing mouse model. Kaplan-Meier plotter analysis was used to determine the effect of MST2 on overall survival in breast cancer patients. MST2 overexpression increased cell viability marginally. The ablation of MST2 using siRNA dramatically suppressed the viability of the MCF-7 cells, but not ER-negative MDA-MB-231 breast cancer cells. Furthermore, MST2 knockdown increased caspase-dependent apoptosis and led to decreased mammosphere formation. Treatment of MCF-7 tumor-bearing mice with MST2 siRNA significantly inhibited tumor growth. The tumor weight was reduced further when tamoxifen was added. Patients with ER-positive breast cancer with low MST2 expression had better overall survival than did those with high MST2 expression in Kaplan-Meier survival analyses using public datasets. Our results provide new insight into the role of MST2, a key component of the Hippo signaling pathway, in mediating breast cancer progression.</AbstractText>
                <CopyrightInformation>Copyright © 2020. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Joonwoo</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Bioscience and Biotechnology, College of Life Science, Sejong University, Kwangjin-gu, Seoul 05006, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Ga Hee</ForeName>
                    <Initials>GH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jeonggeun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Bioscience and Biotechnology, College of Life Science, Sejong University, Kwangjin-gu, Seoul 05006, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Phuong</LastName>
                    <ForeName>Bui Thi Chau</ForeName>
                    <Initials>BTC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Bioscience and Biotechnology, College of Life Science, Sejong University, Kwangjin-gu, Seoul 05006, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>Byounguk</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Bioscience and Biotechnology, College of Life Science, Sejong University, Kwangjin-gu, Seoul 05006, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Won</LastName>
                    <ForeName>Ji Eun</ForeName>
                    <Initials>JE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Won</LastName>
                    <ForeName>Gun Woo</ForeName>
                    <Initials>GW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Yong Hee</ForeName>
                    <Initials>YH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Hee Dong</ForeName>
                    <Initials>HD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea. Electronic address: hanhd@kku.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>YoungJoo</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Integrative Bioscience and Biotechnology, College of Life Science, Sejong University, Kwangjin-gu, Seoul 05006, South Korea. Electronic address: yjlee@sejong.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ERα-positive breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Gene silencing</Keyword>
            <Keyword MajorTopicYN="N">MST2</Keyword>
            <Keyword MajorTopicYN="N">Nanoparticle</Keyword>
            <Keyword MajorTopicYN="N">siRNA</Keyword>
        </KeywordList>
        <CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>10</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007383</ArticleId>
            <ArticleId IdType="pii">S0041-008X(20)30383-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.taap.2020.115257</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007379</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1569-8041</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
            </Journal>
            <ArticleTitle>Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0923-7534(20)42468-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.annonc.2020.09.018</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Grinda</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Medicine, Gustave Roussy, Villejuif, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Delaloge</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Medicine, Gustave Roussy, Villejuif, France; Inserm U931, Cancer Biomarkers, Paris Saclay University, Gustave Roussy, Villejuif, France. Electronic address: suzette.delaloge@gustaveroussy.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016421">Editorial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Ann Oncol</MedlineTA>
            <NlmUniqueID>9007735</NlmUniqueID>
            <ISSNLinking>0923-7534</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>10</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007379</ArticleId>
            <ArticleId IdType="pii">S0923-7534(20)42468-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.annonc.2020.09.018</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007352</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0887</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</Title>
            </Journal>
            <ArticleTitle>Optimization and auto-segmentation of a high risk cardiac zone for heart sparing in breast cancer radiotherapy.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0167-8140(20)30819-7</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.radonc.2020.09.044</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Breast radiotherapy is associated with a risk of ischemic heart disease. Limiting left anterior descending coronary artery (LADCA) exposure might possibly reduce coronary risk. However, its manual delineation is poorly reproducible and its auto-segmentation remains unreliable. This study aims to define and characterize a high-risk cardiac zone (HRCZ) as a LADCA surrogate and to implement its auto-segmentation.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Forty breast cancer patients treated with adjuvant IMRT were included. We delineated the LADCA and eight HRCZ, defined as 1 cm-thick cardiac wall segments centered on the LADCA with symmetrical lateral margins defining the HRCZ width (ranging between 1 and 8 cm). We retrieved mean and maximum doses to the LADCA and to the HRCZ and calculated relative dose variations. We constituted an atlas with the HRCZ contours of 20 patients. Based on this latter, a commercial atlas-based auto-segmentation software delineated HRCZ for the remaining 20 patients and performances were evaluated using distance metrics.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Relative maximum dose variations were systematically positive and increased with HRCZ width, rising from 7.2% to 112.8% for right-sided irradiation (with a sharp increase above 4 cm), and from 9.5% to 30.4% for left-sided irradiation. Auto-segmentation performances asymptotically improved with HRCZ width: Dice similarity coefficient values were 0.62 for a 3 cm width and 0.69 for an 8 cm width.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">a 3.5 cm-wide HRCZ is a reliable LADCA surrogate for breast radiotherapy. Applying maximum dose constraints to the HRCZ could limit LADCA exposure. Auto-segmentation algorithms can reliably delineate HRCZ.</AbstractText>
                <CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Loap</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Curie, Department of Radiation Oncology, Paris, France. Electronic address: pierre.loap@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tkatchenko</LastName>
                    <ForeName>Nicolas</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Curie, Department of Radiation Oncology, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nicolas</LastName>
                    <ForeName>Eliot</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Curie, Department of Radiation Oncology, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fourquet</LastName>
                    <ForeName>Alain</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Curie, Department of Radiation Oncology, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kirova</LastName>
                    <ForeName>Youlia</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Curie, Department of Radiation Oncology, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Radiother Oncol</MedlineTA>
            <NlmUniqueID>8407192</NlmUniqueID>
            <ISSNLinking>0167-8140</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cardiotoxicity</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">breast radiotherapy</Keyword>
            <Keyword MajorTopicYN="N">coronary artery</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>9</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007352</ArticleId>
            <ArticleId IdType="pii">S0167-8140(20)30819-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.radonc.2020.09.044</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007330</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-2596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochimica et biophysica acta. Molecular cell research</Title>
            </Journal>
            <ArticleTitle>FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling.</ArticleTitle>
            <Pagination>
                <MedlinePgn>118877</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0167-4889(20)30235-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbamcr.2020.118877</ELocationID>
            <Abstract>
                <AbstractText>Metformin has been suggested as an anti-cancer agent. However, increasing reports show that some tumors are resistant to metformin. Identification of factors affecting metformin mediated cancer therapy is of great significance. FGFR1 is a receptor-tyrosine-kinase that is frequently overexpressed in breast cancer, which is associated with poor-prognosis. To investigate the effect of FGFR1 overexpression on metformin-induced inhibition of breast cancer cells, we demonstrated that FGFR1 overexpression rendered MCF-7 and T47D cells resistant to metformin. In particular, we found that, in addition to AKT and ERK1/2 activation, FGFR1-induced activation of IRS1 and IGF1R, key regulators connecting metabolism and cancer, was associated with metformin resistance. Targeting IRS with IRS1 KO or IRS inhibitor NT157 significantly sensitized FGFR1 overexpressing cells to metformin. Combination of NT157 with metformin induced enhanced inhibition of p-IGF1R, p-ERK1/2 and p-mTOR. Moreover, we demonstrated that IRS1 functions as a critical mediator of the crosstalk between FGFR1 and IGF1R pathways, which involves a feedback loop between IRS1 and MAPK/ERK. Our study highlights the significance of FGFR1 status and IRS1 activation in metformin-resistance, which will facilitate the development of strategies targeting FGFR overexpression-associated metformin resistance.</AbstractText>
                <CopyrightInformation>Copyright © 2020. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Yujie</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, PR China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Zhikun</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Julius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, Kannapolis, North Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cheng</LastName>
                    <ForeName>Qiong</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, PR China; Julius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, Kannapolis, North Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Yudan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Julius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, Kannapolis, North Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parris</LastName>
                    <ForeName>Amanda B</ForeName>
                    <Initials>AB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Julius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, Kannapolis, North Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>Lingfei</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, PR China. Electronic address: lfkong9@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Xiaohe</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Julius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, Kannapolis, North Carolina, USA; Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: xyang@nccu.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Biochim Biophys Acta Mol Cell Res</MedlineTA>
            <NlmUniqueID>101731731</NlmUniqueID>
            <ISSNLinking>0167-4889</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">FGFR1</Keyword>
            <Keyword MajorTopicYN="N">IRS1</Keyword>
            <Keyword MajorTopicYN="N">MAPK/ERK</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">metformin resistance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>03</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>9</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007330</ArticleId>
            <ArticleId IdType="pii">S0167-4889(20)30235-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2020.118877</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007289</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7786</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chemico-biological interactions</Title>
            </Journal>
            <ArticleTitle>Molecular mechanisms underlying the effects of the small molecule AMC-04 on apoptosis: Roles of the activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway.</ArticleTitle>
            <Pagination>
                <MedlinePgn>109277</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0009-2797(20)31155-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cbi.2020.109277</ELocationID>
            <Abstract>
                <AbstractText>The unfolded protein response (UPR) is an emerging target pathway for cancer treatment owing to its ability to induce cell death. In our previous analysis of UPR-modulating small molecules, we had reported that piperazine oxalate derivative compounds (AMC-01-04) are able to promote increased phosphorylation of eukaryotic translation initiation factor-2 alpha (eIF2α). In this study, we found that AMC-04 induces apoptotic cell death via the activation of UPR in human breast and liver cancer cells. AMC-04 upregulated the expression of activating transcription factor-4 (ATF4)-C/EBP homologous protein (CHOP) and death receptor 5 (DR5) in cancer cells, as revealed by microarray analysis, small-interference RNA assay, and western blotting. From a mechanistic perspective, cytotoxic UPR pathway activation by AMC-04 is mediated by reactive oxygen species (ROS) and p38 mitogen-activated protein kinase (p38 MAPK) signaling. A chemical informatics approach predicted that AMC-04 modulates histone methyltransferase activity. Based on biochemical analysis, the activity of histone methyltransferases, including SUV39H1, SUV39H2, SETDB1, and EHMT1, was inhibited by AMC-04. Furthermore, chemical inhibition of the identified target proteins induced UPR activation and apoptotic cell death, suggesting that inhibition of histone methyltransferases is a promising strategy for cancer therapy. Taken together, we showed that the small molecule AMC-04 modulates epigenetic enzyme activity and mediates the link between cytotoxic UPR and histone modifications.</AbstractText>
                <CopyrightInformation>Copyright © 2020. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>So Young</ForeName>
                    <Initials>SY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Research Center, ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, 05505, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>Supyong</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Convergence Medicine Research Center (CREDIT), ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, 05505, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Min Kyung</ForeName>
                    <Initials>MK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Convergence Medicine Research Center (CREDIT), ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, 05505, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Sojung</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Convergence Medicine Research Center (CREDIT), ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, 05505, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nam</LastName>
                    <ForeName>Ky Youb</ForeName>
                    <Initials>KY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharos IBT, Heungan Daero 427, Anyang, Gyeonggido, Republic of Korea. Electronic address: ik.kim@amc.seoul.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Inki</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Convergence Medicine Research Center (CREDIT), ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, 05505, Republic of Korea; Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea. Electronic address: kyn@pharosibt.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Chem Biol Interact</MedlineTA>
            <NlmUniqueID>0227276</NlmUniqueID>
            <ISSNLinking>0009-2797</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">C/EBP homologous Protein</Keyword>
            <Keyword MajorTopicYN="N">Death receptor-5</Keyword>
            <Keyword MajorTopicYN="N">Histone methyl transferase</Keyword>
            <Keyword MajorTopicYN="N">Human cancer cell</Keyword>
            <Keyword MajorTopicYN="N">Reactive oxygen species</Keyword>
            <Keyword MajorTopicYN="N">Unfolded protein response</Keyword>
        </KeywordList>
        <CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>9</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007289</ArticleId>
            <ArticleId IdType="pii">S0009-2797(20)31155-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cbi.2020.109277</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007277</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-6017</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of pharmaceutical sciences</Title>
            </Journal>
            <ArticleTitle>Expanding the efflux in vitro assay toolbox: A CRISPR-Cas9 edited MDCK cell line with human BCRP and completely lacking canine MDR1.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0022-3549(20)30569-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xphs.2020.09.039</ELocationID>
            <Abstract>
                <AbstractText>The Breast Cancer Resistance Protein (BCRP) is a key transporter in drug efflux and drug-drug interactions. However, endogenous expression of Multidrug Resistance Protein 1 (MDR1) confounds the interpretation of BCRP-mediated transport in in vitro models. Here we used a CRISPR-Cas9 edited Madin-Darby canine kidney (MDCK) II cell line (MDCK<sup>cMDR1-KO</sup>) for stable expression of human BCRP (hBCRP) with no endogenous canine MDR1 (cMDR1) expression (MDCK-hBCRP<sup>cMDR1-KO</sup>). Targeted quantitative proteomics verified expression of hBCRP, and global analysis of the entire proteome corroborated no or very low background expression of other drug transport proteins or metabolizing enzymes. This new cell line, had similar proteomes like MDCK<sup>cMDR1-KO</sup> and a previously established, corresponding cell line overexpressing human MDR1 (hMDR1), MDCK-hMDR1<sup>cMDR1-KO</sup>. Functional studies with MDCK-hBCRP<sup>cMDR1-KO</sup> confirmed high hBCRP activity. The MDCK-hBCRP<sup>cMDR1-KO</sup> cell line together with the MDCK-hMDR1<sup>cMDR1-KO</sup> easily and accurately identified shared or specific substrates of the hBCRP and the hMDR1 transporters. These cell lines offer new, improved in vitro tools for the assessment of drug efflux and drug-drug interactions in drug development.</AbstractText>
                <CopyrightInformation>Copyright © 2020. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wegler</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Uppsala University, Uppsala, Sweden; Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Department of Pharmacy, Uppsala, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gazit</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Uppsala University, Uppsala, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Issa</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Uppsala University, Uppsala, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Subramaniam</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Uppsala University, Uppsala, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Artursson</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Uppsala University, Uppsala, Sweden; Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Department of Pharmacy, Uppsala, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karlgren</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Uppsala University, Uppsala, Sweden; Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Department of Pharmacy, Uppsala, Sweden. Electronic address: maria.karlgren@farmaci.uu.se.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Pharm Sci</MedlineTA>
            <NlmUniqueID>2985195R</NlmUniqueID>
            <ISSNLinking>0022-3549</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ATP-Binding Cassette (ABC) transporter(s)</Keyword>
            <Keyword MajorTopicYN="N">Breast Cancer Resistance Protein (BCRP)</Keyword>
            <Keyword MajorTopicYN="N">Drug transport</Keyword>
            <Keyword MajorTopicYN="N">Efflux pumps</Keyword>
            <Keyword MajorTopicYN="N">MDCK cells</Keyword>
            <Keyword MajorTopicYN="N">Membrane transporter</Keyword>
            <Keyword MajorTopicYN="N">P-glycoprotein (P-gp)</Keyword>
            <Keyword MajorTopicYN="N">Permeability</Keyword>
            <Keyword MajorTopicYN="N">Proteomics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>9</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007277</ArticleId>
            <ArticleId IdType="pii">S0022-3549(20)30569-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.xphs.2020.09.039</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007268</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-4172</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell</Title>
            </Journal>
            <ArticleTitle>Regulation of Collective Metastasis by Nanolumenal Signaling.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0092-8674(20)31087-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2020.08.045</ELocationID>
            <Abstract>
                <AbstractText>Collective metastasis is defined as the cohesive migration and metastasis of multicellular tumor cell clusters. Disrupting various cell adhesion genes markedly reduces cluster formation and colonization efficiency, yet the downstream signals transmitted by clustering remain largely unknown. Here, we use mouse and human breast cancer models to identify a collective signal generated by tumor cell clusters supporting metastatic colonization. We show that tumor cell clusters produce the growth factor epigen and concentrate it within nanolumina-intercellular compartments sealed by cell-cell junctions and lined with microvilli-like protrusions. Epigen knockdown profoundly reduces metastatic outgrowth and switches clusters from a proliferative to a collective migratory state. Tumor cell clusters from basal-like 2, but not mesenchymal-like, triple-negative breast cancer cell lines have increased epigen expression, sealed nanolumina, and impaired outgrowth upon nanolumenal junction disruption. We propose that nanolumenal signaling could offer a therapeutic target for aggressive metastatic breast cancers.</AbstractText>
                <CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wrenn</LastName>
                    <ForeName>Emma D</ForeName>
                    <Initials>ED</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Program, Public Health Sciences and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Molecular and Cellular Biology Graduate Program, University of Washington, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamamoto</LastName>
                    <ForeName>Ami</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Program, Public Health Sciences and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Molecular and Cellular Biology Graduate Program, University of Washington, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moore</LastName>
                    <ForeName>Breanna M</ForeName>
                    <Initials>BM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Program, Public Health Sciences and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Yin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Program, Public Health Sciences and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McBirney</LastName>
                    <ForeName>Margaux</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Program, Public Health Sciences and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thomas</LastName>
                    <ForeName>Aaron J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Program, Public Health Sciences and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greenwood</LastName>
                    <ForeName>Erin</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Program, Public Health Sciences and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rabena</LastName>
                    <ForeName>Yuri F</ForeName>
                    <Initials>YF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Program, Public Health Sciences and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Breast Specimen Repository, Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rahbar</LastName>
                    <ForeName>Habib</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Partridge</LastName>
                    <ForeName>Savannah C</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cheung</LastName>
                    <ForeName>Kevin J</ForeName>
                    <Initials>KJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Program, Public Health Sciences and Human Biology Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: kcheung@fredhutch.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cell</MedlineTA>
            <NlmUniqueID>0413066</NlmUniqueID>
            <ISSNLinking>0092-8674</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CTC clusters</Keyword>
            <Keyword MajorTopicYN="N">basal-like 2 breast cancer</Keyword>
            <Keyword MajorTopicYN="N">collective invasion</Keyword>
            <Keyword MajorTopicYN="N">collective metastasis</Keyword>
            <Keyword MajorTopicYN="N">collective signaling</Keyword>
            <Keyword MajorTopicYN="N">epigen</Keyword>
            <Keyword MajorTopicYN="N">nanolumenal signaling</Keyword>
            <Keyword MajorTopicYN="N">nanolumina</Keyword>
            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>
            <Keyword MajorTopicYN="N">tumor cell clusters</Keyword>
        </KeywordList>
        <CoiStatement>Declaration of Interests E.D.W. and K.J.C. are inventors on a pending patent application related to this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>9</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007268</ArticleId>
            <ArticleId IdType="pii">S0092-8674(20)31087-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cell.2020.08.045</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33007263</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1097-4172</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>183</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell</Title>
            </Journal>
            <ArticleTitle>Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs.</ArticleTitle>
            <Pagination>
                <MedlinePgn>197-210.e32</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0092-8674(20)30997-1</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2020.08.006</ELocationID>
            <Abstract>
                <AbstractText>Cancer genomes often harbor hundreds of somatic DNA rearrangement junctions, many of which cannot be easily classified into simple (e.g., deletion) or complex (e.g., chromothripsis) structural variant classes. Applying a novel genome graph computational paradigm to analyze the topology of junction copy number (JCN) across 2,778 tumor whole-genome sequences, we uncovered three novel complex rearrangement phenomena: pyrgo, rigma, and tyfonas. Pyrgo are &quot;towers&quot; of low-JCN duplications associated with early-replicating regions, superenhancers, and breast or ovarian cancers. Rigma comprise &quot;chasms&quot; of low-JCN deletions enriched in late-replicating fragile sites and gastrointestinal carcinomas. Tyfonas are &quot;typhoons&quot; of high-JCN junctions and fold-back inversions associated with expressed protein-coding fusions, breakend hypermutation, and acral, but not cutaneous, melanomas. Clustering of tumors according to genome graph-derived features identified subgroups associated with DNA repair defects and poor prognosis.</AbstractText>
                <CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hadi</LastName>
                    <ForeName>Kevin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yao</LastName>
                    <ForeName>Xiaotong</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; New York Genome Center, New York, NY 10013, USA; Tri-institutional PhD Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Behr</LastName>
                    <ForeName>Julie M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; New York Genome Center, New York, NY 10013, USA; Tri-institutional PhD Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deshpande</LastName>
                    <ForeName>Aditya</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; New York Genome Center, New York, NY 10013, USA; Tri-institutional PhD Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xanthopoulakis</LastName>
                    <ForeName>Charalampos</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tian</LastName>
                    <ForeName>Huasong</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kudman</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosiene</LastName>
                    <ForeName>Joel</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Darmofal</LastName>
                    <ForeName>Madison</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; New York Genome Center, New York, NY 10013, USA; Tri-institutional PhD Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DeRose</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mortensen</LastName>
                    <ForeName>Rick</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adney</LastName>
                    <ForeName>Emily M</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shaiber</LastName>
                    <ForeName>Alon</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; New York Genome Center, New York, NY 10013, USA; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gajic</LastName>
                    <ForeName>Zoran</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sigouros</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eng</LastName>
                    <ForeName>Kenneth</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wala</LastName>
                    <ForeName>Jeremiah A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; School of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wrzeszczyński</LastName>
                    <ForeName>Kazimierz O</ForeName>
                    <Initials>KO</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arora</LastName>
                    <ForeName>Kanika</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shah</LastName>
                    <ForeName>Minita</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Emde</LastName>
                    <ForeName>Anne-Katrin</ForeName>
                    <Initials>AK</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Felice</LastName>
                    <ForeName>Vanessa</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frank</LastName>
                    <ForeName>Mayu O</ForeName>
                    <Initials>MO</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA; Laboratory of Molecular Neuro-Oncology and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Darnell</LastName>
                    <ForeName>Robert B</ForeName>
                    <Initials>RB</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA; Laboratory of Molecular Neuro-Oncology and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghandi</LastName>
                    <ForeName>Mahmoud</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Franklin</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; School of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dewhurst</LastName>
                    <ForeName>Sally</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Cell Biology and Genetics, The Rockefeller University, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maciejowski</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Lange</LastName>
                    <ForeName>Titia</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Cell Biology and Genetics, The Rockefeller University, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Setton</LastName>
                    <ForeName>Jeremy</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Riaz</LastName>
                    <ForeName>Nadeem</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reis-Filho</LastName>
                    <ForeName>Jorge S</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Powell</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Knowles</LastName>
                    <ForeName>David A</ForeName>
                    <Initials>DA</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA; Department of Computer Science, Columbia University, New York, NY 10027, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reznik</LastName>
                    <ForeName>Ed</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mishra</LastName>
                    <ForeName>Bud</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Computer Science, Mathematics and Cell Biology, Courant Institute and NYU School of Medicine, New York University, New York, NY 10012, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beroukhim</LastName>
                    <ForeName>Rameen</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zody</LastName>
                    <ForeName>Michael C</ForeName>
                    <Initials>MC</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robine</LastName>
                    <ForeName>Nicolas</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York Genome Center, New York, NY 10013, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oman</LastName>
                    <ForeName>Kenji M</ForeName>
                    <Initials>KM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanchez</LastName>
                    <ForeName>Carissa A</ForeName>
                    <Initials>CA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuhner</LastName>
                    <ForeName>Mary K</ForeName>
                    <Initials>MK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Lucian P</ForeName>
                    <Initials>LP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Bioengineering, University of Washington, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Galipeau</LastName>
                    <ForeName>Patricia C</ForeName>
                    <Initials>PC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paulson</LastName>
                    <ForeName>Thomas G</ForeName>
                    <Initials>TG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reid</LastName>
                    <ForeName>Brian J</ForeName>
                    <Initials>BJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiaohong</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilkes</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sboner</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mosquera</LastName>
                    <ForeName>Juan Miguel</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elemento</LastName>
                    <ForeName>Olivier</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Imielinski</LastName>
                    <ForeName>Marcin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; New York Genome Center, New York, NY 10013, USA; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA. Electronic address: mski@mskilab.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cell</MedlineTA>
            <NlmUniqueID>0413066</NlmUniqueID>
            <ISSNLinking>0092-8674</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">aneuploidy</Keyword>
            <Keyword MajorTopicYN="N">cancer evolution</Keyword>
            <Keyword MajorTopicYN="N">cancer genomics</Keyword>
            <Keyword MajorTopicYN="N">chromothripsis</Keyword>
            <Keyword MajorTopicYN="N">fragile sites</Keyword>
            <Keyword MajorTopicYN="N">genome graphs</Keyword>
            <Keyword MajorTopicYN="N">mutational processes</Keyword>
            <Keyword MajorTopicYN="N">phasing</Keyword>
            <Keyword MajorTopicYN="N">structural variation</Keyword>
            <Keyword MajorTopicYN="N">superenhancers</Keyword>
        </KeywordList>
        <CoiStatement>Declaration of Interests J.S.R.-F. reports receiving personal/consultancy fees from VolitionRx, Paige.AI, Goldman Sachs, REPARE Therapeutics, GRAIL, Ventana Medical Systems, Roche, Genentech, and InviCRO outside of the scope of the submitted work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>04</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>20</Hour>
                <Minute>9</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33007263</ArticleId>
            <ArticleId IdType="pii">S0092-8674(20)30997-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cell.2020.08.006</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006950</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2194-802X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>05</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Diagnosis (Berlin, Germany)</Title>
            </Journal>
            <ArticleTitle>Differentiating solid breast masses: comparison of the diagnostic efficacy of shear wave elastography and magnetic resonance imaging.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1515/dx-2020-0056</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">/j/dx.ahead-of-print/dx-2020-0056/dx-2020-0056.xml</ELocationID>
            <Abstract>
                <AbstractText>Objectives Shear wave elastography (SWE) quantitatively determines the nature of the breast lesions. Few previous studies have compared the diagnostic value of this modality with other imaging techniques. The present study aimed to compare the diagnostic value of SWE with that of magnetic resonance imaging (MRI) in detecting the nature of the breast masses. Methods In this cross-sectional study, 80 patients with breast lumps who had Breast Imaging Reporting and Data System (BI-RADS) score of three or higher based on mammography and/or screening ultrasonography, underwent 3D SWE and MRI. The lesions were classified according to MRI BI-RADS scoring; Mean elasticity (Emean) and elasticity ratio (Eratio) for each lesion were also determined by SWE. The results of these two modalities were compared with histopathologic diagnosis as the gold standard method; diagnostic value and diagnostic agreement were then calculated. Results Of the masses, 46.2% were histopathologically proven to be malignant. The Emean for benign and malignant masses was 34.04 ± 19.51 kPa and 161.92 ± 58.14 kPa, respectively. Both modalities had diagnostic agreement with histopathologic results (p&lt;0.001). Kappa coefficient was 0.87 for SWE and 0.42 for MRI. The sensitivity of both methods was 94.59% (95% CI: 81.81-99.34), while the specificity and accuracy were 48.84% [95% CI: 33.31-64.54] and 70.0% [95% CI: 58.72-79.74] for MRI, and 93.02% [95% CI: 80.94-98.54] and 93.75% [95% CI: 86.01-97.94] for SWE. Conclusions SWE has better diagnostic value in terms of determining the nature of the breast masses. SWE can increase the diagnostic function of differentiating benign masses from malignant ones.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Farghadani</LastName>
                    <ForeName>Maryam</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Cancer Prevention Research Center, School of medicine, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barikbin</LastName>
                    <ForeName>Rozbeh</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rezaei</LastName>
                    <ForeName>Mostafa Haji</ForeName>
                    <Initials>MH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hekmatnia</LastName>
                    <ForeName>Ali</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aalinezhad</LastName>
                    <ForeName>Marzieh</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zare</LastName>
                    <ForeName>Hosein</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Diagnosis (Berl)</MedlineTA>
            <NlmUniqueID>101654734</NlmUniqueID>
            <ISSNLinking>2194-802X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">breast mass</Keyword>
            <Keyword MajorTopicYN="N">diagnostic index</Keyword>
            <Keyword MajorTopicYN="N">magnetic resonance imaging</Keyword>
            <Keyword MajorTopicYN="N">shear wave elastography</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>17</Hour>
                <Minute>8</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006950</ArticleId>
            <ArticleId IdType="doi">10.1515/dx-2020-0056</ArticleId>
            <ArticleId IdType="pii">/j/dx.ahead-of-print/dx-2020-0056/dx-2020-0056.xml</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006889</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-6025</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of natural products</Title>
            </Journal>
            <ArticleTitle>Cytotoxic Naphthoquinone Analogues, Including Heterodimers, and Their Structure Elucidation Using LR-HSQMBC NMR Experiments.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jnatprod.0c00856</ELocationID>
            <Abstract>
                <AbstractText>Approximately 1700 naphthoquinones have been reported from a range of natural product source materials, but only 283 have been isolated from fungi, fewer than 75 of those were dimers, and only 2 were heterodimers with a head-to-tail linkage. During a search for anticancer leads from fungi, a series of new naphthoquinones (<b>1</b>-<b>4</b>), including two heterodimers (<b>3</b> and <b>4</b>), were isolated from <i>Pyrenochaetopsis</i> sp. (strain MSX63693). In addition, the previously reported 5-hydroxy-6-(1-hydroxyethyl)-2,7-dimethoxy-1,4-naphthalenedione (<b>5</b>), misakimycin (<b>6</b>), 5-hydroxy-6-[1-(acetyloxy)ethyl]-2,7-dimethoxy-1,4-naphthalenedione (<b>7</b>), 6-ethyl-2,7-dimethoxyjuglone (<b>8</b>), and kirschsteinin (<b>9</b>) were isolated. While the structure elucidation of <b>1</b>-<b>9</b> was achieved using procedures common for natural products chemistry studies (high-resolution electrospray ionization mass spectrometry (HRESIMS), 1D and 2D NMR), the elucidation of the heterodimers was facilitated substantially by data from the long-range heteronuclear single quantum multiple bond correlation (LR-HSQMBC) experiment. The absolute configuration of <b>1</b> was established by analysis of the measured vs calculated ECD data. The racemic mixture of <b>4</b> was established via X-ray crystallography of an analogue that incorporated a heavy atom. All compounds were evaluated for cytotoxicity against the human cancer cells lines MDA-MB-435 (melanoma), MDA-MB-231 (breast), and OVCAR3 (ovarian), where the IC<sub>50</sub> values ranged between 1 and 20 μM.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Flores-Bocanegra</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1393-7834</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27412, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Raja</LastName>
                    <ForeName>Huzefa A</ForeName>
                    <Initials>HA</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0824-9463</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27412, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bacon</LastName>
                    <ForeName>Jeffrey W</ForeName>
                    <Initials>JW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry, Boston University, Boston, Massachusetts 02215, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maldonado</LastName>
                    <ForeName>Amanda C</ForeName>
                    <Initials>AC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois 60612, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burdette</LastName>
                    <ForeName>Joanna E</ForeName>
                    <Initials>JE</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7271-6847</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois 60612, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pearce</LastName>
                    <ForeName>Cedric J</ForeName>
                    <Initials>CJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mycosynthetix, Inc., Hillsborough, North Carolina 27278, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oberlies</LastName>
                    <ForeName>Nicholas H</ForeName>
                    <Initials>NH</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0354-8464</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27412, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Nat Prod</MedlineTA>
            <NlmUniqueID>7906882</NlmUniqueID>
            <ISSNLinking>0163-3864</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>17</Hour>
                <Minute>7</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006889</ArticleId>
            <ArticleId IdType="doi">10.1021/acs.jnatprod.0c00856</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006750</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2211-3436</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cellular oncology (Dordrecht)</Title>
            </Journal>
            <ArticleTitle>BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13402-020-00537-1</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Stemming from a myriad of genetic and epigenetic alterations, triple-negative breast cancer (TNBC) is tied to poor clinical outcomes and aspires for individualized therapies. Here we investigated the therapeutic potential of co-inhibiting integrin-dependent signaling pathway and BRD4, a transcriptional and epigenetic mediator, for TNBC.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Two independent patient cohorts were subjected to bioinformatic and IHC examination for clinical association of candidate cancer drivers. The efficacy and biological bases for co-targeting these drivers were interrogated using cancer cell lines, a protein kinase array, chemical inhibitors, RNAi/CRISPR/Cas9 approaches, and a 4 T1-Balb/c xenograft model.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that amplification of the chromosome 8q24 region occurred in nearly 20% of TNBC tumors, and that it coincided with co-upregulation or amplification of c-Myc and FAK, a key effector of integrin-dependent signaling. This co-upregulation at the mRNA or protein level correlated with a poor patient survival (p &lt; 0.0109 or p &lt; 0.0402, respectively). Furthermore, we found that 14 TNBC cell lines exhibited high vulnerabilities to the combination of JQ1 and VS-6063, potent pharmacological antagonists of the BRD4/c-Myc and integrin/FAK-dependent pathways, respectively. We also observed a cooperative inhibitory effect of JQ1 and VS-6063 on tumor growth and infiltration of Ly6G<sup>+</sup> myeloid-derived suppressor cells in vivo. Finally, we found that JQ1 and VS-6063 cooperatively induced apoptotic cell death by altering XIAP, Bcl2/Bcl-xl and Bim levels, impairing c-Src/p130Cas-, PI3K/Akt- and RelA-associated signaling, and were linked to EMT-inducing transcription factor Snail- and Slug-dependent regulation.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Based on our results, we conclude that the BRD4/c-Myc- and integrin/FAK-dependent pathways act in concert to promote breast cancer cell survival and poor clinical outcomes. As such, they represent promising targets for a synthetic lethal-type of therapy against TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Respiratory Medicine, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Bingwei</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Junfeng</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Jieming</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center of Drug Discovery, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Xinlan</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, the First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shanxi Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Statistics, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Helen</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamad</LastName>
                    <ForeName>Nevean</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chi</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Napier</LastName>
                    <ForeName>Dana</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Shuixiang</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, the First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shanxi Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Chunming</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Zeyi</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Respiratory Medicine, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qian</LastName>
                    <ForeName>Hai</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center of Drug Discovery, China Pharmaceutical University, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Xiaowei</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>Xucai</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Affiliated Hospital of University of Science &amp; Technology of China and Provincial Hospital, Hefei, Anhui Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Jian-An</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Respiratory Medicine, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thibault</LastName>
                    <ForeName>Olivier</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Craven</LastName>
                    <ForeName>Rolf</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Dongping</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China. weidongping2001@hotmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pan</LastName>
                    <ForeName>Yueyin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Affiliated Hospital of University of Science &amp; Technology of China and Provincial Hospital, Hefei, Anhui Province, People's Republic of China. yueyinpan@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Binhua P</ForeName>
                    <Initials>BP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA. peter.zhou@uky.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Yadi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA. yadi.wu@uky.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Xiuwei H</ForeName>
                    <Initials>XH</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5591-6951</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, Department of Molecular and Cellular Biochemistry, and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA. xiuwei-yang@uky.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>5P20GM121327-03</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30CA177558</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5P20GM121327-03</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Cell Oncol (Dordr)</MedlineTA>
            <NlmUniqueID>101552938</NlmUniqueID>
            <ISSNLinking>2211-3428</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRD4</Keyword>
            <Keyword MajorTopicYN="N">FAK</Keyword>
            <Keyword MajorTopicYN="N">Integrin</Keyword>
            <Keyword MajorTopicYN="N">Targeted therapy</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
            <Keyword MajorTopicYN="N">c-Myc</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>12</Hour>
                <Minute>9</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006750</ArticleId>
            <ArticleId IdType="doi">10.1007/s13402-020-00537-1</ArticleId>
            <ArticleId IdType="pii">10.1007/s13402-020-00537-1</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006711</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-4978</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular biology reports</Title>
            </Journal>
            <ArticleTitle>Osteopontin-4 and Osteopontin-5 splice variants are expressed in several tumor cell lines.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11033-020-05867-9</ELocationID>
            <Abstract>
                <AbstractText>Among osteopontin splice variants (OPN-SV), the expression profile of osteopontin-4 (OPN4) and osteopontin-5 (OPN5) has not been addressed in distinct cancer types. We herein aimed to investigate their expression in several cancer cell lines, besides comparing it in relation to the three previously described OPN-SV: OPNa, OPNb and OPNc. Total RNA from cancer cell lines, including prostate (PC3 and DU145), ovarian (A2780), breast (MCF-7 and MDA-MB-231), colorectal (Caco-2, HT-29 and HCT-116), thyroid (TT, TPC1 and 8505c) and lung (A549 and NCI-H460) was extracted, followed by cDNA synthesis. OPN-SV transcript analysis by RT-PCR or RT-qPCR were performed using OPN-SV specific oligonucleotides and gapdh and actin transcripts were used as housekeeping controls. OPN4 and OPN5 transcripts displayed co-expression in most tested cell lines. OPN4 was found expressed in similar or higher levels in relation to OPN5. Moreover, in most tested cell lines, OPN4 is also expressed in similar levels to OPNa or OPNb. The expression of OPN5 is also generally variable in relation to the other OPN-SV, but expressed in similar or higher levels in relation to OPNc, depending on each tested cell line. OPN4 and OPN5 seem to be co-expressed in several tumor types and OPN4 is one of the most overexpressed OPN-SV in distinct tumor cell lines. Once both OPN4 and OPN5 are differentially expressed and also evidence tumor-specific expression patterns, we hypothesize that similarly to the other OPN-SV, they also possibly contribute to key aspects of tumor progression, what should be further functionally investigated in distinct tumor models.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Silva</LastName>
                    <ForeName>Gabriela Ribeiro</ForeName>
                    <Initials>GR</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3047-1092</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Programa de Oncobiologia Celular e Molecular, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Programa de Pós-Graduação Em Ciências Biomédicas, Fisiologia E Farmacologia, Instituto Biomédico, Av. Prof. Hernani Melo, Niterói, 101, CEP24210-130, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mattos</LastName>
                    <ForeName>Daniella Santos</ForeName>
                    <Initials>DS</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-9337-1393</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Programa de Oncobiologia Celular e Molecular, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Programa de Pós-Graduação Stricto Sensu em Oncologia, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bastos</LastName>
                    <ForeName>Ana Clara Fonseca</ForeName>
                    <Initials>ACF</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0145-6619</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Programa de Oncobiologia Celular e Molecular, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Programa de Pós-Graduação Stricto Sensu em Oncologia, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Viana</LastName>
                    <ForeName>Bruna Prunes Pena Baroni</ForeName>
                    <Initials>BPPB</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8196-1609</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Programa de Oncobiologia Celular e Molecular, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Programa de Pós-Graduação Stricto Sensu em Oncologia, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brum</LastName>
                    <ForeName>Mariana Concentino Menezes</ForeName>
                    <Initials>MCM</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3097-0676</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Programa de Oncobiologia Celular e Molecular, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Programa de Pós-Graduação Stricto Sensu em Oncologia, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferreira</LastName>
                    <ForeName>Luciana Bueno</ForeName>
                    <Initials>LB</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-9120-7004</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Programa de Oncobiologia Celular e Molecular, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Programa de Pós-Graduação Stricto Sensu em Oncologia, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gimba</LastName>
                    <ForeName>Etel Rodrigues Pereira</ForeName>
                    <Initials>ERP</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-7091-2206</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Programa de Oncobiologia Celular e Molecular, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil. etelgimba@id.uff.br.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Programa de Pós-Graduação Stricto Sensu em Oncologia, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil. etelgimba@id.uff.br.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Divisão de Pesquisa Clínica, Instituto Nacional de Câncer, Rua André Cavalcanti, 37, 3° andar, Rio de Janeiro, CEP: 20 231 050, Brazil. etelgimba@id.uff.br.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Ciências da Natureza, Instituto de Humanidades E Saúde, Universidade Federal Fluminense, Rua Recife 1-7, Bairro Bela Vista, Rio das Ostras, RJ, CEP 28880-000, Brazil. etelgimba@id.uff.br.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Programa de Pós-Graduação Em Ciências Biomédicas, Fisiologia E Farmacologia, Instituto Biomédico, Av. Prof. Hernani Melo, Niterói, 101, CEP24210-130, Brazil. etelgimba@id.uff.br.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>E-26/010.002007/2014; E-26/203.204/2015</GrantID>
                    <Agency>FAPERJ</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>310591/2014-7; 312158/2017-3</GrantID>
                    <Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Mol Biol Rep</MedlineTA>
            <NlmUniqueID>0403234</NlmUniqueID>
            <ISSNLinking>0301-4851</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cancer cell lines</Keyword>
            <Keyword MajorTopicYN="N">OPN4</Keyword>
            <Keyword MajorTopicYN="N">OPN5</Keyword>
            <Keyword MajorTopicYN="N">Osteopontin</Keyword>
            <Keyword MajorTopicYN="N">Splice variants</Keyword>
            <Keyword MajorTopicYN="N">Splicing</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>12</Hour>
                <Minute>9</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006711</ArticleId>
            <ArticleId IdType="doi">10.1007/s11033-020-05867-9</ArticleId>
            <ArticleId IdType="pii">10.1007/s11033-020-05867-9</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006676</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1433-7339</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</Title>
            </Journal>
            <ArticleTitle>Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy facility.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00520-020-05793-3</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">In the last months, Italy faced a COVID-19 emergency and implemented preventive measures in order to protect patients and healthcare providers from a disease outbreak. The pandemic control strategies impacted patient experience directly. Questionnaires evaluating patients reported measures (PREMs) may assess critical issues and represent a helpful tool to measure the patient perception of healthcare service. Our aim was to prospectively assess patient satisfaction about doctor-patient interaction in a high-volume radiation therapy and oncology center during the COVID-19 pandemic.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Cancer patients receiving either systemic and/or radiation treatment underwent a survey. Two validated questionnaires (EORTC QLQ-C30, FACIT-TS-G version 1) and 14 specific questions evaluating patients' perception of COVID-19 measures were administered.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred twenty-five patients admitted to our department from 1-30 April 2020 completed the questionnaires. The majority (66.4%) of patients were women and the most common disease was breast cancer (40%). The average Global Health Status (GHS) of EORTC QLQ-C30 was 61.67. Emotional functioning, social, and cognitive domains obtained scores of 75.48, 80.13, and 84.67, respectively. FACIT-TS-G results revealed 120 patients rated the treatments effective and 108 patients thought the side effects were the same as expected or better. Most (89.6%) rated their treatment good, very good, or excellent. Concerning COVID-19-related questions, patients reported overall very good level of information.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite the introduction of strict COVID-19 control measures, there was a high level of cancer outpatient satisfaction. The satisfaction levels may influence compliance, continuity of treatments, and patient-doctor communication, impacting the quality of clinical care in the next phases of the pandemic.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Desideri</LastName>
                    <ForeName>Isacco</ForeName>
                    <Initials>I</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-9880-8387</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical, Experimental, and Clinical Sciences &quot;Mario Serio&quot;, University of Florence, Viale Morgagni 85, 50134, Florence, Italy. isacco.desideri@unifi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Francolini</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Unit, University of Florence, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CyberKnife Center, Istituto Fiorentino di Cura ed Assistenza, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ciccone</LastName>
                    <ForeName>L P</ForeName>
                    <Initials>LP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical, Experimental, and Clinical Sciences &quot;Mario Serio&quot;, University of Florence, Viale Morgagni 85, 50134, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stocchi</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical, Experimental, and Clinical Sciences &quot;Mario Serio&quot;, University of Florence, Viale Morgagni 85, 50134, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salvestrini</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical, Experimental, and Clinical Sciences &quot;Mario Serio&quot;, University of Florence, Viale Morgagni 85, 50134, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aquilano</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical, Experimental, and Clinical Sciences &quot;Mario Serio&quot;, University of Florence, Viale Morgagni 85, 50134, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greto</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonomo</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meattini</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical, Experimental, and Clinical Sciences &quot;Mario Serio&quot;, University of Florence, Viale Morgagni 85, 50134, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scotti</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scoccianti</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simontacchi</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Livi</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical, Experimental, and Clinical Sciences &quot;Mario Serio&quot;, University of Florence, Viale Morgagni 85, 50134, Florence, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Support Care Cancer</MedlineTA>
            <NlmUniqueID>9302957</NlmUniqueID>
            <ISSNLinking>0941-4355</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">COVID-19</Keyword>
            <Keyword MajorTopicYN="N">Patient satisfaction</Keyword>
            <Keyword MajorTopicYN="N">QoL</Keyword>
            <Keyword MajorTopicYN="N">Radiotherapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>12</Hour>
                <Minute>8</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006676</ArticleId>
            <ArticleId IdType="doi">10.1007/s00520-020-05793-3</ArticleId>
            <ArticleId IdType="pii">10.1007/s00520-020-05793-3</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006668</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1436-2813</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Surgery today</Title>
            </Journal>
            <ArticleTitle>Determining the protective characteristics and risk factors for the development of anastomotic leakage after low anterior resection for rectal cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00595-020-02133-0</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Anastomotic leakage is one of the most serious postoperative complications associated with surgery for rectal cancer. The present study aimed to identify the protective characteristics and risk factors associated with anastomotic leakage after low anterior resection for rectal cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This was a retrospective, single-center study conducted between January 2009 and December 2017 at our institution. In total, 136 rectal cancer patients who underwent low anterior resection were included in the study. We analyzed preoperative and intraoperative factors. In addition, the pelvic dimensions were measured using computed tomography in all cases.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 136 patients, anastomotic leakage occurred in 21 (15.4%), including 18 males and 3 females. The median body mass index was 21.1 kg/m<sup>2</sup>. The construction of a covering stoma was found to be a protective factor. In addition, the operation time (≥ 373 min), intraoperative blood loss (≥ 105 ml), and size of the pelvic inlet (≥ 113 mm) were identified as risk factors for anastomotic leakage.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The construction of a covering stoma was a possible protective factor. However, a longer operation time, higher intraoperative blood loss, and larger pelvic inlet dimensions were possible risk factors for developing anastomotic leakage after low anterior resection in patients with rectal cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>Nobuaki</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoshida</LastName>
                    <ForeName>Shin</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomochika</LastName>
                    <ForeName>Shinobu</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakagami</LastName>
                    <ForeName>Yuki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Translational Research and Developmental Therapeutics Against Cancer, Yamaguchi University School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shindo</LastName>
                    <ForeName>Yoshitaro</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tokumitsu</LastName>
                    <ForeName>Yukio</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iida</LastName>
                    <ForeName>Michihisa</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takeda</LastName>
                    <ForeName>Shigeru</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hazama</LastName>
                    <ForeName>Shoichi</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Translational Research and Developmental Therapeutics Against Cancer, Yamaguchi University School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ueno</LastName>
                    <ForeName>Tomio</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nagano</LastName>
                    <ForeName>Hiroaki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan. hnagano@yamaguchi-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Surg Today</MedlineTA>
            <NlmUniqueID>9204360</NlmUniqueID>
            <ISSNLinking>0941-1291</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anastomotic leak</Keyword>
            <Keyword MajorTopicYN="N">Colorectal surgery</Keyword>
            <Keyword MajorTopicYN="N">Pelvic index</Keyword>
            <Keyword MajorTopicYN="N">Rectal cancer</Keyword>
            <Keyword MajorTopicYN="N">Risk factor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>12</Hour>
                <Minute>8</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006668</ArticleId>
            <ArticleId IdType="doi">10.1007/s00595-020-02133-0</ArticleId>
            <ArticleId IdType="pii">10.1007/s00595-020-02133-0</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006582</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1543-0790</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>18</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical advances in hematology &amp; oncology : H&amp;O</Title>
            </Journal>
            <ArticleTitle>Intratumoral HER2 heterogeneity in breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>535-537</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pegram</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Stanford University Medical Center, Stanford, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017203">Interview</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Adv Hematol Oncol</MedlineTA>
            <NlmUniqueID>101167661</NlmUniqueID>
            <ISSNLinking>1543-0790</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>12</Hour>
                <Minute>8</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006582</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006452</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1827-1626</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Minerva chirurgica</Title>
            </Journal>
            <ArticleTitle>Axillary surgery in breast cancer: evolution and de-escalation.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.23736/S0026-4733.20.08598-3</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Veronesi</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Surgery Division, European Institute of Oncology IRCCS, Milan, Italy - paolo.veronesi@ieo.it.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy - paolo.veronesi@ieo.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghidinelli</LastName>
                    <ForeName>Federico</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Spedali Civili di Brescia, Brescia, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Corso</LastName>
                    <ForeName>Giovanni</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Surgery Division, European Institute of Oncology IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Minerva Chir</MedlineTA>
            <NlmUniqueID>0400726</NlmUniqueID>
            <ISSNLinking>0026-4733</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>8</Hour>
                <Minute>41</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006452</ArticleId>
            <ArticleId IdType="pii">S0026-4733.20.08598-3</ArticleId>
            <ArticleId IdType="doi">10.23736/S0026-4733.20.08598-3</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006431</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-7634</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer medicine</Title>
            </Journal>
            <ArticleTitle>Disparities in mortality-to-incidence ratios by race/ethnicity for female breast cancer in New York City, 2002-2016.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.3309</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Racial disparities in New York City (NYC) breast cancer incidence and mortality rates have previously been demonstrated. Disease stage at diagnosis and mortality-to-incidence ratio (MIR) may present better measures of differences in screening and treatment access. Racial/ethnic trends in NYC MIR have not previously been assessed.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Mammogram rates were compared using the NYC Community Health Survey, 2002-2014. Breast cancer diagnosis, stage, and mortality were from the New York State Cancer Registry, 2000-2016. Primary outcomes were MIR, the ratio of age-adjusted mortality to incidence rates, and stage at diagnosis. Joinpoint regression analysis identified significant trends.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Mammogram rates in 2002-2014 among Black and Latina women ages 40 and older (79.9% and 78.4%, respectively) were stable and higher than among White (73.6%) and Asian/Pacific-Islander women (70.4%) (P &lt; .0001). There were 82 733 incident cases of breast cancer and 16 225 deaths in 2000-2016. White women had the highest incidence, however, rates among Black, Latina, and Asian/Pacific Islander women significantly increased. Black and Latina women presented with local disease (Stage I) less frequently (53.2%, 57.6%, respectively) than White (62.5%) and Asian/Pacific-Islander women (63.0%). Black women presented with distant disease (Stage IV) more frequently than all other groups (Black 8.7%, Latina 5.8%, White 6.0%, and Asian 4.2%). Black women had the highest breast cancer mortality rate and MIR (Black 0.25, Latina 0.18, White 0.17, and Asian women 0.11).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">More advanced disease at diagnosis coupled with a slower decrease in breast cancer mortality among Black and Latina women may partially explain persistent disparities in MIR especially prominent among Black women. Assessment of racial/ethnic differences in screening quality and access to high-quality treatment may help identify areas for targeted interventions to improve equity in breast cancer outcomes.</AbstractText>
                <CopyrightInformation>Published 2020. This article is a U.S. Government work and is in the public domain in the USA. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nobel</LastName>
                    <ForeName>Tamar B</ForeName>
                    <Initials>TB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Environmental Medicine and Public Health, Mount Sinai Hospital, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asumeng</LastName>
                    <ForeName>Charles K</ForeName>
                    <Initials>CK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Prevention and Control Program, Bureau of Chronic Disease Prevention, New York City Department of Health and Mental Hygiene, Queens, NY, 11101, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jasek</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research and Evaluation, Bureau of Chronic Disease Prevention, NYC DOHMH, Queens, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Beck</LastName>
                    <ForeName>Kellie C</ForeName>
                    <Initials>KC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Prevention and Control Program, Bureau of Chronic Disease Prevention, New York City Department of Health and Mental Hygiene, Queens, NY, 11101, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mathur</LastName>
                    <ForeName>Ruchi</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Prevention and Control Program, Bureau of Chronic Disease Prevention, New York City Department of Health and Mental Hygiene, Queens, NY, 11101, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiao</LastName>
                    <ForeName>Baozhen</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bureau of Cancer Epidemiology, New York State Department of Health, Albany, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Jennifer J</ForeName>
                    <Initials>JJ</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0001-6104-0573</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Cancer Prevention and Control Program, Bureau of Chronic Disease Prevention, New York City Department of Health and Mental Hygiene, Queens, NY, 11101, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <Agency>American Cancer Society</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Med</MedlineTA>
            <NlmUniqueID>101595310</NlmUniqueID>
            <ISSNLinking>2045-7634</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">New York City</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">breast cancer mortality rate</Keyword>
            <Keyword MajorTopicYN="N">breast cancer stage</Keyword>
            <Keyword MajorTopicYN="N">racial disparities</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>04</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>8</Hour>
                <Minute>36</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006431</ArticleId>
            <ArticleId IdType="doi">10.1002/cam4.3309</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Title>REFERENCES</Title>
            <Reference>
                <Citation>Division of Cancer Prevention and Control, Centers for Disease Control and Prevention. Breast cancer statistics. Available from https://www.cdc.gov/cancer/breast/statistics/. Accessed September 26, 2018.</Citation>
            </Reference>
            <Reference>
                <Citation>National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: female breast cancer. Available from https://seer.cancer.gov/statfacts/html/breast.html. Accessed January 9, 2018.</Citation>
            </Reference>
            <Reference>
                <Citation>Kim SJ, Glassgow AE, Watson KS, Molina Y, Calhoun EA. Gendered and racialized social expectations, barriers, and delayed breast cancer diagnosis. Cancer. 2018;124:4350-4357.</Citation>
            </Reference>
            <Reference>
                <Citation>Centers for Disease Control and Prevention. National breast and cervical cancer early detection program. Available from https://www.cdc.gov/cancer/nbccedp/about.htm. Accessed January 16, 2020.</Citation>
            </Reference>
            <Reference>
                <Citation>New York State Department of Health. New York state cancer services program. Available from https://www.health.ny.gov/diseases/cancer/services/. Accessed January 16, 2020.</Citation>
            </Reference>
            <Reference>
                <Citation>Deshpande AD, Jeffe DB, Gnerlich J, Iqbal AZ, Thummalakunta A, Margenthaler JA. Racial disparities in breast cancer survival: an analysis by age and stage. J Surg Res. 2009;153:105-113.</Citation>
            </Reference>
            <Reference>
                <Citation>Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313:165-173.</Citation>
            </Reference>
            <Reference>
                <Citation>Chen L, Li CI. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomarkers Prev. 2015;24:1666-1672.</Citation>
            </Reference>
            <Reference>
                <Citation>DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67:439-448.</Citation>
            </Reference>
            <Reference>
                <Citation>Miller JW, Smith JL, Ryerson AB, Tucker TC, Allemani C. Disparities in breast cancer survival in the United States (2001-2009): findings from the CONCORD-2 study. Cancer. 2017;123(Suppl 24):5100-5118.</Citation>
            </Reference>
            <Reference>
                <Citation>American Cancer Society. Breast Cancer Facts &amp; Figures 2017-2018. Atlanta: American Cancer Society Inc.; 2017.</Citation>
            </Reference>
            <Reference>
                <Citation>Hébert JR, Daguise VG, Hurley DM, et al. Mapping cancer mortality-to-incidence ratios to illustrate racial and sex disparities in a high-risk population. Cancer. 2009;115(11):2539-2552.</Citation>
            </Reference>
            <Reference>
                <Citation>Ben Ramadan AA, Jackson-Thompson J, Schmaltz CL. Estimated female breast cancer mortality-to-incidence ratio (MIR) of the counties and the senatorial districts grouped to county boundaries (SDGCs) in Missouri 2008-2012. J Health Disparities Res Practice. 2018;11(3):1-15.</Citation>
            </Reference>
            <Reference>
                <Citation>Ellis L, Belot A, Rachet B, Coleman MP. The mortality-to-incidence ratio is not a valid proxy for cancer survival. J Glob Oncol. 2019;5:1-9.</Citation>
            </Reference>
            <Reference>
                <Citation>Hunt BR, Whitman S, Hurlbert MS. Increasing Black: White disparities in breast cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol. 2014;38(2):118-123.</Citation>
            </Reference>
            <Reference>
                <Citation>Whitman S, Ansell D, Orsi J, Francois T. The racial disparity in breast cancer mortality. J Community Health. 2011;36:588-596.</Citation>
            </Reference>
            <Reference>
                <Citation>Whitman S, Orsi J, Hurlbert M. The racial disparity in breast cancer mortality in the 25 largest cities in the United States. Cancer Epidemiol. 2012;36:e147-e151.</Citation>
            </Reference>
            <Reference>
                <Citation>Hunt BR, Hurlbert MS. Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005-2014. Cancer Epidemiol. 2016;45:169-173.</Citation>
            </Reference>
            <Reference>
                <Citation>Sighoko D, Hunt BR, Irizarry B, Watson K, Ansell D, Murphy AM. Disparity in breast cancer mortality by age and geography in 10 racially diverse US cities. Cancer Epidemiol. 2018;53:178-183.</Citation>
            </Reference>
            <Reference>
                <Citation>Sighoko D, Murphy AM, Irizarry B, et al. Changes in the racial disparity in breast cancer mortality in the ten US cities with the largest African American populations from 1999 to 2013: the reduction in breast cancer mortality disparity in Chicago. Cancer Causes Control. 2017;28:563-568.</Citation>
            </Reference>
            <Reference>
                <Citation>NYC Department of Health and Mental Hygiene. NYC community health survey. Epiquery. Available from https://a816-healthpsi.nyc.gov/epiquery/. Accessed January 30, 2020.</Citation>
            </Reference>
            <Reference>
                <Citation>NYC Department of Health and Mental Hygiene. NYC community health survey methodology. Available from https://www1.nyc.gov/site/doh/data/data-sets/community-health-survey-methodology.page. Accessed January 30, 2020.</Citation>
            </Reference>
            <Reference>
                <Citation>NYC Department of Health and Mental Hygiene. NYC community health survey. Epiquery. Available from https://a816-healthpsi.nyc.gov/epiquery/. Accessed January 30, 2020.</Citation>
            </Reference>
            <Reference>
                <Citation>New York State Department of Health. NYS cancer registry and cancer statistics. Available from https://www.health.ny.gov/statistics/cancer/registry/. Accessed January 30, 2020.</Citation>
            </Reference>
            <Reference>
                <Citation>Asadzadeh Vostakolaei F, Karim-Kos HE, Janssen-Heijnen ML, Visser O, Verbeek AL, Kiemeney LA. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health. 2011;21:573-577.</Citation>
            </Reference>
            <Reference>
                <Citation>Choi E, Lee S, Nhung BC, et al. Cancer mortality-to-incidence ratio as an indicator of cancer management outcomes in Organization for Economic Cooperation and Development countries. Epidemiol Health. 2017;39:e2017006.</Citation>
            </Reference>
            <Reference>
                <Citation>Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-351.</Citation>
            </Reference>
            <Reference>
                <Citation>Howlader N, Altekruse SF, Li CI, et al. Incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106:dju055.</Citation>
            </Reference>
            <Reference>
                <Citation>Davis Lynn BC, Rosenberg PS, Anderson WF, Gierach GL. Black-white breast cancer incidence trends: effects of ethnicity. J Natl Cancer Inst. 2018;110:1270-1272.</Citation>
            </Reference>
            <Reference>
                <Citation>Islami F, Kahn AR, Bickell NA, Schymura MJ, Boffetta P. Disentangling the effects of race/ethnicity and socioeconomic status of neighborhood in cancer stage distribution in New York City. Cancer Causes Control. 2013;24:1069-1078.</Citation>
            </Reference>
            <Reference>
                <Citation>Smith-Bindman R, Miglioretti DL, Lurie N, et al. Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med. 2006;144:541-553.</Citation>
            </Reference>
            <Reference>
                <Citation>Hirschman J, Whitman S, Ansell D. The black:white disparity in breast cancer mortality: the example of Chicago. Cancer Causes Control. 2007;18:323-333.</Citation>
            </Reference>
            <Reference>
                <Citation>Daly B, Olopade OI. A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 2015;65:221-238.</Citation>
            </Reference>
            <Reference>
                <Citation>Griggs JJ, Culakova E, Sorbero MES, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007;25:2522-2527.</Citation>
            </Reference>
            <Reference>
                <Citation>Freedman RA, Virgo KS, He Y, et al. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011;117:180-189.</Citation>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006364</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1349-9157</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of radiation research</Title>
            </Journal>
            <ArticleTitle>Changes in peripheral immune cells after intraoperative radiation therapy in low-risk breast cancer.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">rraa083</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/jrr/rraa083</ELocationID>
            <Abstract>
                <AbstractText>A detailed understanding of the interactions and the best dose-fractionation scheme of radiation to maximize antitumor immunity have not been fully established. In this study, the effect on the host immune system of a single dose of 20 Gy through intraoperative radiation therapy (IORT) on the surgical bed in low-risk breast cancer patients undergoing conserving breast cancer has been assessed. Peripheral blood samples from 13 patients were collected preoperatively and at 48 h and 3 and 10 weeks after the administration of radiation. We performed a flow cytometry analysis for lymphocyte subpopulations, natural killer cells (NK), regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSCs). We observed that the subpopulation of NK CD56+high CD16+ increased significantly at 3 weeks after IORT (0.30-0.42%, P &lt; 0.001), while no changes were found in immunosuppressive profile, CD4+CD25+Foxp3+Helios+ Treg cells, granulocytic MDSCs (G-MDSCs) and monocytic MDSCs (Mo-MDSCs). A single dose of IORT may be an effective approach to improve antitumor immunity based on the increase in NK cells and the non-stimulation of immunosuppressive cells involved in immune escape. These findings support future combinations of IORT with immunotherapy, if they are confirmed in a large cohort of breast cancer patients.</AbstractText>
                <CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Linares-Galiana</LastName>
                    <ForeName>Isabel</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Department, Hospital Duran i Reynals, Institut Català d'Oncologia (ICO), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radiobiology and Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berenguer-Frances</LastName>
                    <ForeName>Miguel Angel</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Department, Hospital Duran i Reynals, Institut Català d'Oncologia (ICO), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radiobiology and Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cañas-Cortés</LastName>
                    <ForeName>Rut</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiobiology and Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pujol-Canadell</LastName>
                    <ForeName>Monica</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiobiology and Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Comas-Antón</LastName>
                    <ForeName>Silvia</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Department, Hospital Germans Trias i Pujol, Institut Català d'Oncologia (ICO), Carretera de Canyet, s/n, 08916 Badalona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martínez</LastName>
                    <ForeName>Evelyn</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Department, Hospital Duran i Reynals, Institut Català d'Oncologia (ICO), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Laplana</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Department, Hospital Duran i Reynals, Institut Català d'Oncologia (ICO), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pérez-Montero</LastName>
                    <ForeName>Héctor</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Department, Hospital Duran i Reynals, Institut Català d'Oncologia (ICO), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pla-Farnós</LastName>
                    <ForeName>María Jesús</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gynecology Department, Hospital Universitari de Bellvitge, Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Navarro-Martin</LastName>
                    <ForeName>Arturo</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Department, Hospital Duran i Reynals, Institut Català d'Oncologia (ICO), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radiobiology and Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nuñez</LastName>
                    <ForeName>Miriam</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Department, Hospital Duran i Reynals, Institut Català d'Oncologia (ICO), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radiobiology and Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Both</LastName>
                    <ForeName>Brigitte</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Affairs &amp; Professional Education, Business Sector Radiotherapy, Medical Technology Business Group, Carl Zeiss Meditec AG, ZEISS Group, Rudolf-Eber-Straße 11 Oberkochen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guedea</LastName>
                    <ForeName>Ferran</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiation Oncology Department, Hospital Duran i Reynals, Institut Català d'Oncologia (ICO), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radiobiology and Cancer Group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Avinguda de la Gran Via de l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08098 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Radiat Res</MedlineTA>
            <NlmUniqueID>0376611</NlmUniqueID>
            <ISSNLinking>0449-3060</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">flow cytometry</Keyword>
            <Keyword MajorTopicYN="N">immune system</Keyword>
            <Keyword MajorTopicYN="N">immunomodulation</Keyword>
            <Keyword MajorTopicYN="N">immunophenotyping</Keyword>
            <Keyword MajorTopicYN="N">intraoperative radiation therapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>8</Hour>
                <Minute>35</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006364</ArticleId>
            <ArticleId IdType="pii">5912577</ArticleId>
            <ArticleId IdType="doi">10.1093/jrr/rraa083</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006291</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2164-554X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human vaccines &amp; immunotherapeutics</Title>
            </Journal>
            <ArticleTitle>The co-presence of high-risk human papillomaviruses and Epstein-Barr virus is linked with tumor grade and stage in Qatari women with breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2020.1802977</ELocationID>
            <Abstract>
                <AbstractText>High-risk human papillomaviruses (HPV) can be present and cooperate with Epstein-Barr virus (EBV) to promote the onset and/or progression of various cancers including cervical, breast, head and neck as well as colorectal. In this investigation, we explored the co-prevalence of high-risk HPV and EBV in 74 breast cancer tissues from Qatari women using polymerase chain reaction. We found that high-risk HPV and EBV are present in 48/74 (65%) and 36/74 (49%) of the cases, respectively. While we noted that the presence of HPV presence is associated with triple-negative breast cancer (TNBC) (<i>p</i> = .008), however, the presence of EBV did not correlate with any breast cancer subgroup. Moreover, our data revealed that high-risk HPV and EBV are co-present in 35/74 (47%) of the samples and their co-presence is significantly associated with tumor grade (<i>p</i> = .04) and tumor stage (<i>p</i> = .04). These data indicate that HPV and EBV are commonly co-present in breast cancer and their association could be linked with a more aggressive tumor phenotype. Thus, further investigations are essential to understand the underlying mechanisms of HPV and EBV cooperation in breast carcinogenesis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gupta</LastName>
                    <ForeName>Ishita</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Medicine, QU Health, Qatar University , Doha, Qatar.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Research Centre, QU Health, Qatar University , Doha, Qatar.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jabeen</LastName>
                    <ForeName>Ayesha</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Medicine, QU Health, Qatar University , Doha, Qatar.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Research Centre, QU Health, Qatar University , Doha, Qatar.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Al-Sarraf</LastName>
                    <ForeName>Reem</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Hamad General Hospital , Doha, Qatar.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Farghaly</LastName>
                    <ForeName>Hanan</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Hamad General Hospital , Doha, Qatar.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vranic</LastName>
                    <ForeName>Semir</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Medicine, QU Health, Qatar University , Doha, Qatar.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sultan</LastName>
                    <ForeName>Ali A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbiology and Immunology, Weill Cornell Medicine - Qatar , Doha, Qatar.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Al Moustafa</LastName>
                    <ForeName>Ala-Eddin</ForeName>
                    <Initials>AE</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Medicine, QU Health, Qatar University , Doha, Qatar.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Research Centre, QU Health, Qatar University , Doha, Qatar.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Al-Thawadi</LastName>
                    <ForeName>Hamda</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Medicine, QU Health, Qatar University , Doha, Qatar.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hum Vaccin Immunother</MedlineTA>
            <NlmUniqueID>101572652</NlmUniqueID>
            <ISSNLinking>2164-5515</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EBV</Keyword>
            <Keyword MajorTopicYN="N">HPV</Keyword>
            <Keyword MajorTopicYN="N">Qatari population</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">tumor grade</Keyword>
            <Keyword MajorTopicYN="N">tumor stage</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>8</Hour>
                <Minute>35</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006291</ArticleId>
            <ArticleId IdType="doi">10.1080/21645515.2020.1802977</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006257</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0844</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of heart failure</Title>
            </Journal>
            <ArticleTitle>The role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and Cardio-Oncology Council of the European Society of Cardiology.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ejhf.2017</ELocationID>
            <Abstract>
                <AbstractText>Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio-Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two biomarkers troponin and natriuretic peptides are discussed, the link to the mechanisms of cardiovascular toxicity, and the evidence for their clinical use in surveillance during and after anthracycline chemotherapy, trastuzumab and HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy. Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio-oncology biomarker research are discussed.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Pudil</LastName>
                    <ForeName>Radek</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>1st Dept. Medicine - Cardioangiology, Charles University Prague, Medical Faculty and University Hospital Hradec Kralove, Czech Republic.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mueller</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Čelutkienė</LastName>
                    <ForeName>Jelena</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Santariškių 2, Vilnius, Lithuania.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>State Research Institute Centre For Innovative Medicine, Santariškių 5, Vilnius, Lithuania.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Henriksen</LastName>
                    <ForeName>Peter A</ForeName>
                    <Initials>PA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Edinburgh Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lenihan</LastName>
                    <ForeName>Dan</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardio-Oncology Center of Excellence, Washington University in St Louis, Missouri, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dent</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Duke Cancer Institute, Duke University, Durham, North, Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barac</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>MedStar Heart and Vascular Institute, Georgetown University, Washington, DC, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stanway</LastName>
                    <ForeName>Susanna</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Unit, Royal Marsden Hospital, Surrey, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moslehi</LastName>
                    <ForeName>Javid</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suter</LastName>
                    <ForeName>Thomas M</ForeName>
                    <Initials>TM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ky</LastName>
                    <ForeName>Bonnie</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Štěrba</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cardinale</LastName>
                    <ForeName>Daniela</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardioncology Unit, European Institute of Oncology, I.R.C.C, .S, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cohen-Solal</LastName>
                    <ForeName>Alain</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>UMR-S 942, Paris University, Cardiology Department, Lariboisiere Hospital, AP-, HP, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tocchetti</LastName>
                    <ForeName>Carlo Gabriele</ForeName>
                    <Initials>CG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University, Naples, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Farmakis</LastName>
                    <ForeName>Dimitrios</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Cyprus Medical School, Nicosia, Cyprus; Cardio-Oncology Clinic, Heart Failure Unit, &quot;Attikon&quot; University Hospital, Athens, Greece.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>National and Kapodistrian University of Athens Medical School, Athens, Greece.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bergler-Klein</LastName>
                    <ForeName>Jutta</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Med. University of Vienna, Dept. of Cardiology, Vienna, Austria.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anker</LastName>
                    <ForeName>Markus S</ForeName>
                    <Initials>MS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Von Haehling</LastName>
                    <ForeName>Stephan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology and Pneumology, University of Goettingen Medical Center, Goettingen, Germany and German Center for Cardiovascular Research (DZHK), partner site Goettingen, Goettingen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Belenkov</LastName>
                    <ForeName>Yury</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sechenov Medical University, Moscow, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iakobishvili</LastName>
                    <ForeName>Zaza</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Community Cardiology, Tel Aviv Jaffa District, Clalit Health Fund and Sackler Faculty of Medicine, Tel Aviv University, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maack</LastName>
                    <ForeName>Christoph</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Comprehensive Heart Failure Center, University Clinic Würzburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ciardiello</LastName>
                    <ForeName>Fortunato</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruschitzka</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coats</LastName>
                    <ForeName>Andrew J S</ForeName>
                    <Initials>AJS</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Warwick, UK and Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seferovic</LastName>
                    <ForeName>Petar</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Belgrade, Faculty of Medicine and Serbian Academy of Sciences and Arts, Belgrade, Serbia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lainscak</LastName>
                    <ForeName>Mitja</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Ljubljana, Ljubljana, Slovenia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Piepoli</LastName>
                    <ForeName>Massimo F</ForeName>
                    <Initials>MF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiac Department, Guglielmo da Saliceto Polichirurgico Hospital AUSL Piacenza, Piacenza, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chioncel</LastName>
                    <ForeName>Ovidiu</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Emergency Institute for Cardiovascular Diseases-&quot;Prof. C.C.Iliescu&quot;, Bucharest; University of Medicine Carol Davila, Bucharest, Romania.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bax</LastName>
                    <ForeName>Jereon</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hulot</LastName>
                    <ForeName>Jean-Sebastien</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Université de Paris, CIC1418, Paris Cardiovascular Research Center, INSERM, F-75015, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Skouri</LastName>
                    <ForeName>Hadi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiology Division-Internal Medicine Department at American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hägler-Laube</LastName>
                    <ForeName>Eva Simona</ForeName>
                    <Initials>ES</Initials>
                    <AffiliationInfo>
                        <Affiliation>Inselspital, University Hospital of Bern, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asteggiano</LastName>
                    <ForeName>Riccardo</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiologist in Practice, Corso Venezia, 10, Turin, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fernandez</LastName>
                    <ForeName>Teresa Lopez</ForeName>
                    <Initials>TL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiology Service, Cardio-Oncology Unit, La Paz University Hospital and IdiPAz Research Institute, Ciber CV, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Boer</LastName>
                    <ForeName>Rudolf A</ForeName>
                    <Initials>RA</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Lyon</LastName>
                    <ForeName>Alexander R</ForeName>
                    <Initials>AR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardio-Oncology Service, Royal Brompton Hospital and Imperial College London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Heart Fail</MedlineTA>
            <NlmUniqueID>100887595</NlmUniqueID>
            <ISSNLinking>1388-9842</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">B-type natriuretic peptides</Keyword>
            <Keyword MajorTopicYN="N">HER2-targeted therapies</Keyword>
            <Keyword MajorTopicYN="N">anthracyclines</Keyword>
            <Keyword MajorTopicYN="N">biomarkers</Keyword>
            <Keyword MajorTopicYN="N">cardiac troponin</Keyword>
            <Keyword MajorTopicYN="N">cardio-oncology</Keyword>
            <Keyword MajorTopicYN="N">cardiotoxicity</Keyword>
            <Keyword MajorTopicYN="N">heart failure</Keyword>
            <Keyword MajorTopicYN="N">immune checkpoint inhibitors</Keyword>
            <Keyword MajorTopicYN="N">myocarditis</Keyword>
            <Keyword MajorTopicYN="N">proteasome inhibitors</Keyword>
            <Keyword MajorTopicYN="N">radiotherapy</Keyword>
            <Keyword MajorTopicYN="N">vascular endothelial growth factor inhibitors</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>02</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>50</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006257</ArticleId>
            <ArticleId IdType="doi">10.1002/ejhf.2017</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006241</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2354</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of cancer care</Title>
            </Journal>
            <ArticleTitle>Cancer disclosure to friends: Survey on psychological distress and perceived social support provision.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e13332</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/ecc.13332</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the factors associated with the degree of distress experienced by patients with cancer before disclosing their cancer diagnosis to a friend and their perceptions of social support upon disclosure.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Adult patients with cancer participated in a cross-sectional Internet-based survey on their behaviour when disclosing their diagnosis to a selected friend, degree of distress before this disclosure and perceived social support upon disclosure.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 473 eligible respondents, around half were middle-aged (40-59 years) and around half were men. Having a younger age (20-39 years), being a woman and delaying disclosure were factors associated with greater pre-disclosure distress. Most participants perceived receiving emotional support upon disclosure. Telling a close friend or a female friend and early disclosure timing were associated with perceived social support, although this varied by social support type.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Younger patients and women may need more support in deciding to disclose their cancer diagnosis to friends. Selection of to whom to disclose this information and disclosure timing should be considered to achieve more desirable outcomes. In addition to selective disclosure-including planning and scheduling-communication skills may be required for effectively disclosing a cancer diagnosis and achieving favourable results following this disclosure.</AbstractText>
                <CopyrightInformation>© 2020 John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tsuchiya</LastName>
                    <ForeName>Miyako</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-4670-1702</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Survivorship Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adachi</LastName>
                    <ForeName>Keiichiro</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumagai</LastName>
                    <ForeName>Kaori</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Nursing and Social Service, Health Sciences University of Hokkaido, Ishikari-gun, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kondo</LastName>
                    <ForeName>Nami</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kimata</LastName>
                    <ForeName>Akiko</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Survivorship Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>JP16H05216</GrantID>
                    <Agency>JSPS KAKENHI</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>31-A-23</GrantID>
                    <Agency>the National Cancer Center Research and Development Fund</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Cancer Care (Engl)</MedlineTA>
            <NlmUniqueID>9301979</NlmUniqueID>
            <ISSNLinking>0961-5423</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>N</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>50</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006241</ArticleId>
            <ArticleId IdType="doi">10.1111/ecc.13332</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Title>References</Title>
            <Reference>
                <Citation>Adams, R. N., Winger, J. G., &amp; Mosher, C. E. (2015). A meta-analysis of the relationship between social constraintsand distress in cancer patients. Journal of Behavioral Medicine, 38, 294-305. https://doi.org/10.1007/s1086​5-014-9601-6</Citation>
            </Reference>
            <Reference>
                <Citation>Arora, N. K., Finney Rutten, L. J., Gustafson, D. H., Moser, R., &amp; Hawkins, R. P. (2007). Perceived helpfulness and impact of social support provided by family, friends, and health care providers to women newly diagnosed with breast cancer. Psycho-Oncology, 16, 474-486. https://doi.org/10.1002/pon.1084</Citation>
            </Reference>
            <Reference>
                <Citation>Arrey, A. E., Bilsen, J., Lacor, P., &amp; Deschepper, R. (2015). “It's my secret”: Fear of disclosure among sub-Saharan African migrant women living with HIV/AIDS in Belgium. PLoS One, 10, e0119653. https://doi.org/10.1371/journ​al.pone.0119653</Citation>
            </Reference>
            <Reference>
                <Citation>Belsley, D. A., Kuh, E., &amp; Welsch, R. E. (1980). Regression diagnostics: Identifying influential data and sources of collinearity. New York. NYJohn Wiley &amp; Son.</Citation>
            </Reference>
            <Reference>
                <Citation>Cabinet Office. (2018). International Survey of Youth Attitude 2018. Chapter 1. View on Life Retrieved from https://www8.cao.go.jp/youth/​engli​sh/surve​y/2018/pdf_index.html</Citation>
            </Reference>
            <Reference>
                <Citation>Cabinet Office (2019). Annual Report on the Aging Society. Retrieved from https://www8.cao.go.jp/koure​i/white​paper/​w-2019/html/zenbu​n/s1_1_3.html</Citation>
            </Reference>
            <Reference>
                <Citation>Cancer Registry and Statistics. (2020). Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan). Retrieved from https://ganjo​ho.jp/reg_stat/stati​stics/​dl/index.html#incid​ence4​pref</Citation>
            </Reference>
            <Reference>
                <Citation>Cantor, M. H. (1979). Neighours and friends: An overlooked resource in the informal support system. Research on Aging, 1, 434-463.</Citation>
            </Reference>
            <Reference>
                <Citation>Chaudoir, S. R., &amp; Fisher, J. D. (2010). The disclosure processes model: Understanding disclosure decision making and postdisclosure outcomes among people living with a concealable stigmatized identity. Psychological Bulletin, 136, 236-256. https://doi.org/10.1037/a0018193</Citation>
            </Reference>
            <Reference>
                <Citation>Choi, S. Y., Venetis, M. K., Greene, K., Magsamen-Conrad, K., Checton, M. G., &amp; Banerjee, S. C. (2016). Planning a stigmatized nonvisible disclosure: Applying the disclosure decision-making model. Journal of Psychology, 16, 1004-1025.</Citation>
            </Reference>
            <Reference>
                <Citation>Derlega, V. J., Maduro, R. S., Janda, L. H., Chen, I. A., &amp; Goodman, B. M. (2018). What motivates individuals with sickle cell disease to talk with others about their illness? Reasons for and against sickle cell disease disclosure. Journal of Health Psychology, 23, 103-113. https://doi.org/10.1177/13591​05316​649786</Citation>
            </Reference>
            <Reference>
                <Citation>Fukuoka, Y., &amp; Hashimoto, T. (1997). Stress-buffering effects of perceived social supports from family members and friends: A comparison of college students and middle-aged adults. The Japanese Journal of Psychology, 68, 403-409.</Citation>
            </Reference>
            <Reference>
                <Citation>Gonzalez, B. D., Jim, H. S., Cessna, J. M., Small, B. J., Sutton, S. K., &amp; Jacobsen, P. B. (2015). Concealment of lung cancer diagnosis: Prevalence and correlates. Psycho-Oncology, 24, 1774-1783. https://doi.org/10.1002/pon.3793</Citation>
            </Reference>
            <Reference>
                <Citation>Greene, K., Magsamen-Conrad, K., Venetis, M. K., Checton, M. G., Bagdasarov, Z., &amp; Banerjee, S. C. (2012). Assessing health diagnosis disclosure decisions in relationships: Testing the disclosure decision- making model. Health Communication, 27, 356-368. https://doi.org/10.1080/10410​236.2011.586988</Citation>
            </Reference>
            <Reference>
                <Citation>Harrison, J., Maguire, P., &amp; Pitceathly, C. (1995). Confiding in crisis: Gender differences in pattern of confiding among cancer patients. Social Science &amp; Medicine, 41, 1255-1260. https://doi.org/10.1016/0277-9536(94)00411​-L</Citation>
            </Reference>
            <Reference>
                <Citation>Hartup, W., &amp; Stevens, N. (1997). Friendships and adaptation in the life course. Psychological Bulletin, 121, 355-370. https://doi.org/10.1037/0033-2909.121.3.355</Citation>
            </Reference>
            <Reference>
                <Citation>Hastings, S. O. (2000). Self-disclosure and identity management by bereaved parents. Communication Studies, 51, 352-371. https://doi.org/10.1080/10510​97000​9388531</Citation>
            </Reference>
            <Reference>
                <Citation>Holtgraves, T. (1990). The language of self-disclosure. In H. Gilers, &amp; W. P. Robinson (Eds.), Handbook of language and social psychology (pp. 191-207). New York, NYJohn Wiley &amp; Sons.</Citation>
            </Reference>
            <Reference>
                <Citation>Hsu, B. Y., Chentsova Dutton, Y., Adams, I. F., Gomez, S. L., Allen, L., Huang, E., &amp; Wang, J. H. (2017). Talking about cancer: Explaining differences in social support among Chinese American and European American breast cancer survivors. Journal of Health Psychology, 25, 1043-1056. https://doi.org/10.1177/13591​05317​745967</Citation>
            </Reference>
            <Reference>
                <Citation>Jackson, T., Davis, K., Haisfield, L., Dowson, D., Lynch, J., Regan, J., … Taylor, K. (2010). Disclosure of diagnosis and treatment among early stage prostate cancer survivors. Patient Education and Counseling, 79, 239-244. https://doi.org/10.1016/j.pec.2009.08.004</Citation>
            </Reference>
            <Reference>
                <Citation>Janin, M. M. H., Ellis, S. J., Wakefield, C. E., &amp; Fardell, J. E. (2018). Talking about cancer among adolescent and young adult cancer patients and survivors: A systematic review. Journal of Adolescent and Young Adult Oncology, 7, 515-524. https://doi.org/10.1089/jayao.2017.0131</Citation>
            </Reference>
            <Reference>
                <Citation>Kim, H. S., Sherman, D. K., &amp; Taylor, S. E. (2008). Culture and social support. American Psychologist, 63, 518-526. https://doi.org/10.1037/0003-066X</Citation>
            </Reference>
            <Reference>
                <Citation>Kolokotroni, P., Anagnostopoulos, F., &amp; Hantzi, A. (2018). The role of optimism, social constraints, coping, and cognitive processing in psychosocial adjustment among breast cancer survivors. Journal of Clinical Psychology in Medical Settings, 25, 452-462. https://doi.org/10.1007/s1088​0-018-9555-x</Citation>
            </Reference>
            <Reference>
                <Citation>Lepore, S. J. (2001). A social-cognitive processing model of emotional adjustment to cancer. In A. Baum, &amp; B. L. Andersen (Eds.), Psychosocial Interventions for Cancer (pp. 99-116). Washington, DCAmerican Psychological Association.</Citation>
            </Reference>
            <Reference>
                <Citation>Litwak, E. (1985). Helping the elderly: The complementary roles of informal networks and formal systems. New York, NYGuilford Press.</Citation>
            </Reference>
            <Reference>
                <Citation>Petrak, J. A., Doyle, A. M., Smith, A., Skinner, C., &amp; Hedge, B. (2001). Factors associated with self-disclosure of HIV serostatus to significant others. British Journal of Health Psychology, 6, 69-79. https://doi.org/10.1348/13591​07011​69061</Citation>
            </Reference>
            <Reference>
                <Citation>Petronio, S. (2002). Boundaries of privacy: Dialectics of disclosure. Albany, NYState University of New York Press.</Citation>
            </Reference>
            <Reference>
                <Citation>Taniguchi, T., &amp; Wakasaki, A. (2016). The relationship between quality of life and perceived social support in the breast cancer patients in the adult life stage. Nursing Care Research [Japanese], 15, 1-9.</Citation>
            </Reference>
            <Reference>
                <Citation>Tsuchiya, M. (2011). Development of cancer stigma reduction program: community-approach. Yuumi Memorial Foundation for Home Health Care Research Report. Retrieved from http://zaita​kuiry​o-yuumi​zaidan.com/main/result</Citation>
            </Reference>
            <Reference>
                <Citation>Tsuchiya, M. (2019). Lay people’s psychological reactions and helping intention after friends' cancer disclosure: An exploratory analysis using vignettes. European Journal of Cancer Care, 28, e13150, https://doi.org/10.1111/ecc.13150</Citation>
            </Reference>
            <Reference>
                <Citation>Tsuchiya, M., Horn, S., &amp; Ingham, R. (2012). Development of the Psycho-social Discomfort Scale (PsDS): Investigation of psychometric properties among Japanese breast cancer survivor. Psycho-Oncology, 21, 161-167.</Citation>
            </Reference>
            <Reference>
                <Citation>Tsuchiya, M., Horn, S., &amp; Ingham, R. (2015). Social disclosure about lymphoedema symptoms: A qualitative study among Japanese breast cancer survivors. Psychology, Health &amp; Medicine, 20, 680-684. https://doi.org/10.1080/13548​506.2014.986140</Citation>
            </Reference>
            <Reference>
                <Citation>Wong, C. C. Y., Warmoth, K., Ivy, S., Cheung, B., &amp; Lu, Q. (2018). Relation of social constraints on disclosure to adjustment among Chinese American cancer survivors: A multiprocesses approach. Psycho-Oncology, 27, 977-982. https://doi.org/10.1002/pon.4604</Citation>
            </Reference>
            <Reference>
                <Citation>Yoo, G. J., Aviv, C., Levine, E. G., Ewing, C., &amp; Au, A. (2010). Emotion work: Disclosing cancer. Supportive Care in Cancer, 18, 205-215. https://doi.org/10.1007/s0052​0-009-0646-y</Citation>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006205</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1099-1611</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Psycho-oncology</Title>
            </Journal>
            <ArticleTitle>Young women's decision-making and experience of using tamoxifen to reduce BRCA1/2 breast cancer risk: a qualitative study.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/pon.5556</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Tamoxifen has been demonstrated to reduce breast cancer risk in high-risk, premenopausal women. Yet, very few young women with hereditary breast and ovarian cancer syndrome in Australia use tamoxifen despite this being a less invasive option compared to risk-reducing mastectomy. This study aims to examine young women's decision-making about and experience of taking tamoxifen to reduce their breast cancer risk.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Young women with a BRCA1/2 mutation participated in semi-structured qualitative interviews, recruited mainly from a metropolitan clinical genetics service. Data were analysed using an inductive, team-based approach to thematic analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty interviews with women aged 20-40 years with a BRCA1/2 mutation were conducted. Eleven women could not recall discussing tamoxifen with their healthcare provider or were too young to commence cancer risk management. Twenty-three women chose not to use tamoxifen because it is contraindicated for pregnancy or because it did not offer immediate and great enough risk reduction compared to bilateral risk-reducing mastectomy. Six women who were definite about not wanting to have children during the following five-year period chose to use tamoxifen, and most experienced none or transient side effects.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Decision-making about tamoxifen was nuanced and informed by considerations characteristic of young adulthood, especially childbearing. Therefore, clinical discussions about tamoxifen with young women with a BRCA1/2 mutation must include consideration of their reproductive plans.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Forrest</LastName>
                    <ForeName>Laura E</ForeName>
                    <Initials>LE</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-1126-4971</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shepherd</LastName>
                    <ForeName>Rowan Forbes</ForeName>
                    <Initials>RF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Young</LastName>
                    <ForeName>Mary-Anne</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, New South Wales, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Keogh</LastName>
                    <ForeName>Louise A</ForeName>
                    <Initials>LA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>James</LastName>
                    <ForeName>Paul A</ForeName>
                    <Initials>PA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>PF-14-009</GrantID>
                    <Agency>National Breast Cancer Foundation</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Psychooncology</MedlineTA>
            <NlmUniqueID>9214524</NlmUniqueID>
            <ISSNLinking>1057-9249</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA1</Keyword>
            <Keyword MajorTopicYN="N">BRCA2</Keyword>
            <Keyword MajorTopicYN="N">cancer</Keyword>
            <Keyword MajorTopicYN="N">chemoprevention</Keyword>
            <Keyword MajorTopicYN="N">female</Keyword>
            <Keyword MajorTopicYN="N">psycho-oncology</Keyword>
            <Keyword MajorTopicYN="N">risk management</Keyword>
            <Keyword MajorTopicYN="N">risk reduction</Keyword>
            <Keyword MajorTopicYN="N">tamoxifen</Keyword>
            <Keyword MajorTopicYN="N">young adult</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>49</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006205</ArticleId>
            <ArticleId IdType="doi">10.1002/pon.5556</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006013</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-4978</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular biology reports</Title>
            </Journal>
            <ArticleTitle>Chemotherapy resistance and stromal targets in breast cancer treatment: a review.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11033-020-05853-1</ELocationID>
            <Abstract>
                <AbstractText>Therapy resistance is a known problem in breast cancer and is associated with a variety of mechanisms. The role of the tumor microenvironment in cancer development and resistance mechanisms is becoming increasingly understood. Tumor-stroma is the main component of the tumor microenvironment. Stromal cells like cancer-associated fibroblasts (CAFs) are believed to contribute to chemotherapy resistance via the production of several secreted factors like cytokines and chemokines. CAFs are found to influence disease progression; patients with primary tumors with a high amount of tumor-stroma have a significantly worse outcome. Therefore the role of CAFs resistance mechanisms makes them a promising target in anti-cancer therapy. An overview of recent advances in strategies to target breast cancer stroma is given and the current literature regarding these stromal targets is discussed. CAF-specific proteins as well as secreted molecules involved in tumor-stroma interactions provide possibilities for stroma-specific therapy. The development of stroma-specific therapy is still in its infancy and the available literature is limited. Within the scope of personalized treatment, biomarkers based on the tumor-stroma have future potential for the improvement of treatment via image-guided surgery (IGS) and PET scanning.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van der Spek</LastName>
                    <ForeName>Y M</ForeName>
                    <Initials>YM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kroep</LastName>
                    <ForeName>J R</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tollenaar</LastName>
                    <ForeName>R A E M</ForeName>
                    <Initials>RAEM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mesker</LastName>
                    <ForeName>Wilma E</ForeName>
                    <Initials>WE</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5533-4778</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. W.E.Mesker@lumc.nl.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Mol Biol Rep</MedlineTA>
            <NlmUniqueID>0403234</NlmUniqueID>
            <ISSNLinking>0301-4851</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Chemotherapy resistance</Keyword>
            <Keyword MajorTopicYN="N">Review</Keyword>
            <Keyword MajorTopicYN="N">Stromal targets</Keyword>
            <Keyword MajorTopicYN="N">Tumor–stroma</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>47</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006013</ArticleId>
            <ArticleId IdType="doi">10.1007/s11033-020-05853-1</ArticleId>
            <ArticleId IdType="pii">10.1007/s11033-020-05853-1</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33006001</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
            </Journal>
            <ArticleTitle>Prospective surveillance model in the home for breast cancer-related lymphoedema: a feasibility study.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-020-05953-3</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The aim of this study was to assess the feasibility of delivering a prospective surveillance model in the home over 6 months for women at high risk of developing lymphoedema.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A single-group, intervention study recruited 20 women who had surgical and medical treatment for confirmed node-positive invasive breast cancer and therefore at high risk of developing arm lymphoedema. Participants received a package including Bioimpedance Spectroscopy (BIS) monitoring, lymphoedema education and support to promote self-management and physical activity.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants adhered to BIS monitoring 74% of the time, and felt extremely confident in using the device. By 6 months, mean BIS L-Dex scores had increased from 3.5 (SD 5.6) to 8.4 (SD 11.1); five women (25%) who experienced &gt;  + 6.5 increase in L-Dex score were fitted with a compression garment. Self-reported symptoms and distress decreased by 0.4 out of 10 (95% CI 0.1 to 0.7); number of self-management strategies used increased by 0.6 (95% CI 0.1 to 1.2); and planned exercise increased by 2.8 h/week (95% CI 0.4 to 5.2).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings indicate a prospective surveillance model of care in the home with BIS is feasible and associated with increased self-management. A Phase II randomised trial is warranted as well as research exploring the costs associated with implementing this model of care for high-risk individuals.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Koelmeyer</LastName>
                    <ForeName>Louise A</ForeName>
                    <Initials>LA</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2736-2330</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Australian Lymphoedema Education, Research and Treatment (ALERT) Program, Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia. Louise.koelmeyer@mq.edu.au.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moloney</LastName>
                    <ForeName>Emma</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Australian Lymphoedema Education, Research and Treatment (ALERT) Program, Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boyages</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Australian Lymphoedema Education, Research and Treatment (ALERT) Program, Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Icon Cancer Centre, Sydney, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sherman</LastName>
                    <ForeName>Kerry A</ForeName>
                    <Initials>KA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Emotional Health, Department of Psychology, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dean</LastName>
                    <ForeName>Catherine M</ForeName>
                    <Initials>CM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Professions, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bioimpedance spectroscopy (BIS)</Keyword>
            <Keyword MajorTopicYN="N">Breast cancer-related lymphoedema</Keyword>
            <Keyword MajorTopicYN="N">Feasibility</Keyword>
            <Keyword MajorTopicYN="N">Home monitoring</Keyword>
            <Keyword MajorTopicYN="N">Phase I trial</Keyword>
            <Keyword MajorTopicYN="N">Prospective surveillance model</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>47</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33006001</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-020-05953-3</ArticleId>
            <ArticleId IdType="pii">10.1007/s10549-020-05953-3</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33005979</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0843</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer chemotherapy and pharmacology</Title>
            </Journal>
            <ArticleTitle>Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00280-020-04156-3</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To assess efficacy and safety of trastuzumab biosimilars in comparison to the reference drug through a systematic review and meta-analysis of randomized controlled trials (RCTs).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive search was conducted using PubMed, Web of Science, Cochrane library, Open Grey and ClinicalTrials.gov databases. Dichotomous data for efficacy and safety outcomes were pooled to obtain the relative risk (RR) and 95% confidence intervals (CIs). Meta-analysis was performed with the Mantel-Haenszel method using Revman 5.3 software.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight phase III RCTs including a total of 3913 patients with HER2 + breast cancer were identified that met the inclusion criteria. The pooled results for the comparison of trastuzumab biosimilars to the reference drug showed no differences of objective response rate (ORR) (RR 1.05, 95% CI 0.98-1.12, P = 0.20) or overall survival (RR 0.82, 95% CI 0.61-1.09, P = 0.17) in the intention-to-treat population, as well as no difference of ORR (RR 1.03, 95% CI 0.97-1.10, P = 0.30) in the per-protocol population. Similarly, no significant difference was detected in any type of adverse event reported in at least three RCTs, including any serious treatment-emergent adverse effects (RR 0.97, 95% CI 0.76-1.25, P = 0.83), heart failure (RR 1.47, 95% CI 0.69-3.14, P = 0.32), neutropenia (RR 1.05, 95% CI 0.96-1.15, P = 0.26), and infusion-related reaction (RR 1.10, 95% CI 0.89-1.36, P = 0.38).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This meta-analysis provides compelling evidence of clinical comparability between trastuzumab biosimilars and the originator product in terms of both efficacy and safety for the treatment of HER2 + breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cargnin</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Jae Il</ForeName>
                    <Initials>JI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Genazzani</LastName>
                    <ForeName>Armando A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nottegar</LastName>
                    <ForeName>Alessia</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology Unit, Azienda Ospedaliera Universitaria Integrata (AOUI), 37134, Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Terrazzino</LastName>
                    <ForeName>Salvatore</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-4909-1121</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy. salvatore.terrazzino@uniupo.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Cancer Chemother Pharmacol</MedlineTA>
            <NlmUniqueID>7806519</NlmUniqueID>
            <ISSNLinking>0344-5704</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Biosimilars</Keyword>
            <Keyword MajorTopicYN="N">Efficacy</Keyword>
            <Keyword MajorTopicYN="N">Meta-analysis</Keyword>
            <Keyword MajorTopicYN="N">Randomized clinical trials</Keyword>
            <Keyword MajorTopicYN="N">Safety</Keyword>
            <Keyword MajorTopicYN="N">Trastuzumab</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>47</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005979</ArticleId>
            <ArticleId IdType="doi">10.1007/s00280-020-04156-3</ArticleId>
            <ArticleId IdType="pii">10.1007/s00280-020-04156-3</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33005960</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1541-8243</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>113</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Southern medical journal</Title>
            </Journal>
            <ArticleTitle>Improving Preventive Care for Women through a Provider Reminder Tool.</ArticleTitle>
            <Pagination>
                <MedlinePgn>475-481</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.14423/SMJ.0000000000001160</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the association of utilization of health maintenance tables (HMTs) as a provider reminder tool within the electronic medical record with the completion of women's preventive health services.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Guidelines from the US Preventive Services Task Force and the Advisory Committee on Immunization Practices were used to create the HMT. The study sample consisted of female patients between 18 and 74 years of age who visited the University of Florida Internal Medicine Clinic at Medical Plaza between February 15, 2016 and June 24, 2016. We determined whether a reminder system was used for each visit and whether the following preventive health services were up to date: breast cancer screening, cervical cancer screening, and human papillomavirus vaccination. χ<sup>2</sup> tests of independence were performed to compare the number of up-to-date preventive measures associated with each provider reminder type.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We divided the visits into four groups based on the type of provider reminder used: the HMT, the computer-generated reminder .HM, simple annotation, and no reminder. Compared with .HM, no reminder, and all non-HMT, HMT utilization had a statistically significant positive association with the completion of breast and cervical cancer screening and human papillomavirus vaccination. The difference between the HMT and simple annotation groups did not achieve statistical difference, however.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite well-established, evidence-based guidelines for screening tests and immunizations effective in reducing cancer-related morbidity and mortality, significant gaps in routine preventive care remain. The HMT may be a provider-friendly and cost-effective reminder tool to enhance the preventive health care of women.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Romero de Mello Sa</LastName>
                    <ForeName>Suellen A</ForeName>
                    <Initials>SA</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Medicine, Division of General Internal Medicine, University of Florida College of Medicine, Gainesville, and the Department of Biostatistics, University of Kansas Medical Center, Kansas City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mramba</LastName>
                    <ForeName>Lazarus K</ForeName>
                    <Initials>LK</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Medicine, Division of General Internal Medicine, University of Florida College of Medicine, Gainesville, and the Department of Biostatistics, University of Kansas Medical Center, Kansas City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sattari</LastName>
                    <ForeName>Maryam</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Medicine, Division of General Internal Medicine, University of Florida College of Medicine, Gainesville, and the Department of Biostatistics, University of Kansas Medical Center, Kansas City.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>South Med J</MedlineTA>
            <NlmUniqueID>0404522</NlmUniqueID>
            <ISSNLinking>0038-4348</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>47</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005960</ArticleId>
            <ArticleId IdType="doi">10.14423/SMJ.0000000000001160</ArticleId>
            <ArticleId IdType="pii">SMJ50846</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005833</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">2452-199X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2021</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Bioactive materials</Title>
            </Journal>
            <ArticleTitle>Inhibition of furin by bone targeting superparamagnetic iron oxide nanoparticles alleviated breast cancer bone metastasis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>712-720</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bioactmat.2020.09.006</ELocationID>
            <Abstract>
                <AbstractText>Breast cancer bone metastasis poses significant challenge for therapeutic strategies. Inside the metastatic environment, osteoclasts and tumor cells interact synergistically to promote cancer progression. In this study, the proprotein convertase furin is targeted due to its critical roles in both tumor cell invasion and osteoclast function. Importantly, the furin inhibitor is specifically delivered by bone targeting superparamagnetic iron oxide (SPIO) nanoparticles. Our <i>in vitro</i> and <i>in vivo</i> data demonstrate that this system can effectively inhibit both osteoclastic bone resorption and breast cancer invastion, leading to alleviated osteolysis. Therefore, the bone targeting &amp; furin inhibition nanoparticle system is a promising therapeutic and diagnostic strategy for breast cancer bone metastasis.</AbstractText>
                <CopyrightInformation>© 2020 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pang</LastName>
                    <ForeName>Yichuan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hongqiao International Institute of Medicine, Shanghai Jiaotong University School of Medicine, 201103, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Yao</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Chemistry of High-Performance &amp; Novel Materials, Department of Chemistry, Zhejiang University, Hangzhou, 310027, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Fan</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310027, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Chenxi</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hongqiao International Institute of Medicine, Shanghai Jiaotong University School of Medicine, 201103, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cao</LastName>
                    <ForeName>Xiankun</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Wenxin</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>Xueqian</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Chemistry of High-Performance &amp; Novel Materials, Department of Chemistry, Zhejiang University, Hangzhou, 310027, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Jiake</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, 6009, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qin</LastName>
                    <ForeName>An</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Bioact Mater</MedlineTA>
            <NlmUniqueID>101685294</NlmUniqueID>
            <ISSNLinking>2452-199X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bone targeting</Keyword>
            <Keyword MajorTopicYN="N">Breast cancer metastasis</Keyword>
            <Keyword MajorTopicYN="N">Furin</Keyword>
            <Keyword MajorTopicYN="N">Iron oxide nanoparticles</Keyword>
            <Keyword MajorTopicYN="N">Osteoclast</Keyword>
        </KeywordList>
        <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>46</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005833</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bioactmat.2020.09.006</ArticleId>
            <ArticleId IdType="pii">S2452-199X(20)30214-0</ArticleId>
            <ArticleId IdType="pmc">PMC7516174</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005774</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2405-8440</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Heliyon</Title>
            </Journal>
            <ArticleTitle>Iodine-131 labeled genistein as a potential radiotracer for breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e04780</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2020.e04780</ELocationID>
            <Abstract>
                <AbstractText Label="Objective" NlmCategory="UNASSIGNED">Genistein is an isoflavone compound that has been proven to have anticancer activity and is capable of binding to estrogen β receptors with Selective Estrogen Receptor Modulators (SERMs) properties, and has a strong affinity to inhibit the development of cancer cells. This study is to determine the optimum conditions of the reaction in the synthesis process of compounds labeled <sup>131</sup>I-genestein which can be potential for application of breast cancer diagnosis.</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">Synthesis of <sup>131</sup>I-Genistein compound labeling using the Chloramine-T iodination method. This method uses several parameter optimizations, including: pH conditions, the amount of chloramine-T oxidizer and sodium metabisulfite reducing agent. The radiochemical purity of the <sup>131</sup>I-Genistein compound was determined using thin layer chromatography TLC-SG F<sub>254</sub>, and measured by SCA (Single Channel Analyzer). The radiochemical purity of labeled compounds must fulfill the requirements of the United States of Pharmacopeia.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Optimization of the synthesis conditions of the <sup>131</sup>I-Genistein compound was obtained at pH 8, the amount of chloramine-T 0.225 mg, and the amount of Na-Metabisulfite 0.342 mg, with 30 min reaction time. This optimum condition produces radiochemical purity of 95.02 ± 0.76%.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Products labeled <sup>131</sup>I-Genistein meet radiochemical purity requirements according to USP requirements. The labeled compound is expected to be able to be used to detect breast cancer through a binding mechanism with estrogen receptors β.</AbstractText>
                <CopyrightInformation>© 2020 The Authors.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ramdhani</LastName>
                    <ForeName>Danni</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Padjadjaran University, Sumedang, West Java 45363, Indonesia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Radiation Protection and Safety Control, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Widyasari</LastName>
                    <ForeName>Eva Maria</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Applied Nuclear Science and Technology Center (PSTNT), National Nuclear Energy Agency of Indonesia (BATAN), Bandung, West Java 40116, Indonesia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sriyani</LastName>
                    <ForeName>Maula Eka</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>Applied Nuclear Science and Technology Center (PSTNT), National Nuclear Energy Agency of Indonesia (BATAN), Bandung, West Java 40116, Indonesia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arnanda</LastName>
                    <ForeName>Quinzheilla Putri</ForeName>
                    <Initials>QP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Padjadjaran University, Sumedang, West Java 45363, Indonesia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watabe</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Radiation Protection and Safety Control, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Heliyon</MedlineTA>
            <NlmUniqueID>101672560</NlmUniqueID>
            <ISSNLinking>2405-8440</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Estrogen receptors beta</Keyword>
            <Keyword MajorTopicYN="N">Genestein</Keyword>
            <Keyword MajorTopicYN="N">Iodine-131</Keyword>
            <Keyword MajorTopicYN="N">Pharmaceutical chemistry</Keyword>
            <Keyword MajorTopicYN="N">Radiotracer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>04</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>46</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005774</ArticleId>
            <ArticleId IdType="doi">10.1016/j.heliyon.2020.e04780</ArticleId>
            <ArticleId IdType="pii">S2405-8440(20)31623-6</ArticleId>
            <ArticleId IdType="pmc">PMC7509807</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005727</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2372-7705</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>18</Volume>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular therapy oncolytics</Title>
            </Journal>
            <ArticleTitle>A Screened GPR1 Peptide Exerts Antitumor Effects on Triple-Negative Breast Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>602-612</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omto.2020.08.013</ELocationID>
            <Abstract>
                <AbstractText>The adipokine chemerin has been considered an important regulator of tumor immune surveillance. Chemerin recruits leukocytes through the receptor CMKLR1 to improve clinical outcomes of tumors and overall patient survival, but the role of GPR1 in tumors has not been widely investigated. Here, we found that GPR1 expression is elevated in breast cancer-especially triple-negative breast cancer (TNBC) tissues and cell lines. Herein, we screened a phage display peptide library to identify LRH7-G5, a peptide antagonist that blocks chemerin/GPR1 signaling. This peptide performed as an anticancer agent to suppress the proliferation of the TNBC cell lines MDA-MB-231 and HCC1937 but has little effect on T47D cells. LRH7-G5 treatment significantly blocked tumor growth in a TNBC cell-bearing orthotopic mouse model. Last, our results showed that this peptide's antitumor role is mediated through the PI3K/AKT signaling pathway. In conclusion, these data collectively suggest that the chemerin receptor GPR1 is a novel target for controlling TNBC progression and establish peptide LRH7-G5 as a new therapeutic agent for suppressing TNBC tumor growth.</AbstractText>
                <CopyrightInformation>© 2020 The Author(s).</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Chen</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Energy Metabolism and Reproduction, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Pharmacy and Translational Medicine，School of Pharmacy and Biomedicine, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dai</LastName>
                    <ForeName>Xiao-Yong</ForeName>
                    <Initials>XY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Energy Metabolism and Reproduction, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cai</LastName>
                    <ForeName>Jia-Xuan</ForeName>
                    <Initials>JX</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peking University Shen Zhen Hospital, Shen Zhen, Guangdong, 518036, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Energy Metabolism and Reproduction, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Bao Bei</ForeName>
                    <Initials>BB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Energy Metabolism and Reproduction, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Wen</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Energy Metabolism and Reproduction, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Shenzhen College of Advanced Technology, University of Chinese Academy of Sciences, Shenzhen.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Esther</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biological Sciences Collegiate Division, University of Chicago, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peking University Shen Zhen Hospital, Shen Zhen, Guangdong, 518036, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jian V</ForeName>
                    <Initials>JV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Energy Metabolism and Reproduction, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Pharmacy and Translational Medicine，School of Pharmacy and Biomedicine, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Shenzhen College of Advanced Technology, University of Chinese Academy of Sciences, Shenzhen.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Ther Oncolytics</MedlineTA>
            <NlmUniqueID>101666776</NlmUniqueID>
            <ISSNLinking>2372-7705</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>02</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>46</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005727</ArticleId>
            <ArticleId IdType="doi">10.1016/j.omto.2020.08.013</ArticleId>
            <ArticleId IdType="pii">S2372-7705(20)30130-3</ArticleId>
            <ArticleId IdType="pmc">PMC7508919</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005627</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2296-889X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <PubDate>
                        <Year>2020</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in molecular biosciences</Title>
            </Journal>
            <ArticleTitle>Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>191</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fmolb.2020.00191</ELocationID>
            <Abstract>
                <AbstractText>Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze the addition of poly(ADP-ribose) (PAR) subunits onto themselves and other acceptor proteins. PARPs are known to function in a large range of cellular processes including DNA repair, DNA replication, transcription and modulation of chromatin structure. Inhibition of PARP holds great potential for therapy, especially in cancer. Several PARP1/2/3 inhibitors (PARPi) have had success in treating ovarian, breast and prostate tumors harboring defects in the homologous recombination (HR) DNA repair pathway, especially BRCA1/2 mutated tumors. However, treatment is limited to specific sub-groups of patients and resistance can occur, limiting the use of PARPi. Poly(ADP-ribose) glycohydrolase (PARG) reverses the action of PARP enzymes, hydrolysing the ribose-ribose bonds present in poly(ADP-ribose). Like PARPs, PARG is involved in DNA replication and repair and PARG depleted/inhibited cells show increased sensitivity to DNA damaging agents. They also display an accumulation of perturbed replication intermediates which can lead to synthetic lethality in certain contexts. In addition, PARG is thought to play an important role in preventing the accumulation of cytoplasmic PAR and therefore parthanatos, a caspase-independent PAR-mediated type of cell death. In contrast to PARP, the therapeutic potential of PARG has been largely ignored. However, several recent papers have demonstrated the exciting possibilities that inhibitors of this enzyme may have for cancer treatment, both as single agents and in combination with cytotoxic drugs and radiotherapy. This article discusses what is known about the functions of PARP and PARG and the potential future implications of pharmacological inhibition in anti-cancer therapy.</AbstractText>
                <CopyrightInformation>Copyright © 2020 Harrision, Gravells, Thompson and Bryant.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Harrision</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Academic Unit of Molecular Oncology, Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gravells</LastName>
                    <ForeName>Polly</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Academic Unit of Molecular Oncology, Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>Ruth</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Academic Unit of Molecular Oncology, Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bryant</LastName>
                    <ForeName>Helen E</ForeName>
                    <Initials>HE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Academic Unit of Molecular Oncology, Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Mol Biosci</MedlineTA>
            <NlmUniqueID>101653173</NlmUniqueID>
            <ISSNLinking>2296-889X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">cancer</Keyword>
            <Keyword MajorTopicYN="N">chemosensitization</Keyword>
            <Keyword MajorTopicYN="N">poly(ADP-ribose)glycohydrolase (PARG)</Keyword>
            <Keyword MajorTopicYN="N">poly(ADP-ribose)polymerase (PARP)</Keyword>
            <Keyword MajorTopicYN="N">radiosensitization</Keyword>
            <Keyword MajorTopicYN="N">synthetic lethality</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>46</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005627</ArticleId>
            <ArticleId IdType="doi">10.3389/fmolb.2020.00191</ArticleId>
            <ArticleId IdType="pmc">PMC7485115</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005588</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1976-8257</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>36</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicological research</Title>
            </Journal>
            <ArticleTitle>The effect of green tea catechins on breast cancer resistance protein activity and intestinal efflux of aflatoxin B<sub>1</sub> via breast cancer resistance protein in Caco-2 cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>293-300</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s43188-019-00032-2</ELocationID>
            <Abstract>
                <AbstractText>Aflatoxin B<sub>1</sub> (AFB<sub>1</sub>), a mycotoxin produced by <i>Aspergillus</i> spp., was proved as one of the major causes of human hepatocellular carcinoma (HCC) when chronically consumed. An efflux of AFB<sub>1</sub> was reported to be associated with breast cancer resistance protein (BCRP) whose activity could also be modulated by green tea catechins. The purpose of this study was, therefore, to examine the impacts of green tea catechins on BCRP activity in Caco-2 cells by H33342 (bis-benzamide, BCRP substrate) accumulation and AFB<sub>1</sub> efflux. Results showed a significant decrease (<i>p </i>&lt; 0.05) of AFB<sub>1</sub> in the efflux ratio following the incubation with Ko143, a specific BCRP inhibitor, and sodium fluoride, confirming the association of BCRP in AFB<sub>1</sub> efflux transport across the cells. Pre-incubation with green tea and gallate catechins (ECG and EGCG) significantly reduced the efflux ratio of AFB<sub>1</sub> (<i>p </i>&lt; 0.05) and significantly increased the intracellular H33342 substrate (<i>p </i>&lt; 0.05) in Caco-2 cells, clearly indicating the inhibitory effects of green tea and gallate catechins on BCRP function. Further study on H33342 accumulation revealed a dose-dependent increment of intracellular H33342 when co-administered with increasing concentrations of AFB<sub>1</sub>. This result implied a possible role of AFB<sub>1</sub> as a BCRP competitive inhibitor. The findings from this study concluded the roles of BCRP as an efflux transporter for AFB<sub>1</sub> and could be modulated by the exposure of green tea catechins. Owing to a reduction of its efflux, an inhibitory effect of BCRP when pre-exposed with green tea catechins could be crucial for AFB<sub>1</sub> cellular accumulation.</AbstractText>
                <CopyrightInformation>© Korean Society of Toxicology 2020.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tuntiteerawit</LastName>
                    <ForeName>Peeradon</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate Program in Toxicology, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, 40002 Thailand.</Affiliation>
                        <Identifier Source="GRID">grid.9786.0</Identifier>
                        <Identifier Source="ISNI">0000 0004 0470 0856</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jarukamjorn</LastName>
                    <ForeName>Kanokwan</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, 40002 Thailand.</Affiliation>
                        <Identifier Source="GRID">grid.9786.0</Identifier>
                        <Identifier Source="ISNI">0000 0004 0470 0856</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Research Group for Pharmaceutical Activities of Natural Products Using Pharmaceutical Biotechnology, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, 40002 Thailand.</Affiliation>
                        <Identifier Source="GRID">grid.9786.0</Identifier>
                        <Identifier Source="ISNI">0000 0004 0470 0856</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Porasuphatana</LastName>
                    <ForeName>Supatra</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate Program in Toxicology, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, 40002 Thailand.</Affiliation>
                        <Identifier Source="GRID">grid.9786.0</Identifier>
                        <Identifier Source="ISNI">0000 0004 0470 0856</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Pharmacognosy and Toxicology, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, 40002 Thailand.</Affiliation>
                        <Identifier Source="GRID">grid.9786.0</Identifier>
                        <Identifier Source="ISNI">0000 0004 0470 0856</Identifier>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>01</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Singapore</Country>
            <MedlineTA>Toxicol Res</MedlineTA>
            <NlmUniqueID>101483324</NlmUniqueID>
            <ISSNLinking>1976-8257</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Absorption</Keyword>
            <Keyword MajorTopicYN="N">Mycotoxins</Keyword>
            <Keyword MajorTopicYN="N">Polyphenols</Keyword>
            <Keyword MajorTopicYN="N">Transporter</Keyword>
        </KeywordList>
        <CoiStatement>Conflict of interestThe authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2021</Year>
                <Month>10</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>45</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005588</ArticleId>
            <ArticleId IdType="doi">10.1007/s43188-019-00032-2</ArticleId>
            <ArticleId IdType="pii">32</ArticleId>
            <ArticleId IdType="pmc">PMC7494721</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005563</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2212-1366</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>25</Volume>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of bone oncology</Title>
            </Journal>
            <ArticleTitle>Long non-coding RNA BLACAT1 expedites osteosarcoma cell proliferation, migration and invasion via up-regulating SOX12 through miR-608.</ArticleTitle>
            <Pagination>
                <MedlinePgn>100314</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbo.2020.100314</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Osteosarcoma is the most common type of bone malignancy. Increasing evidence indicated that long non-coding RNAs (lncRNAs) possess multiple functions in the development of cancer and can be used as indicators of prognosis and diagnosis. LncRNA BLACAT1 has been found to promote the proliferation of breast cancer cells. However, the role of BLACAT1 in osteosarcoma remains largely unknown.</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">QRT-PCR analysis was employed to evaluate mRNA expressions. Western blot was performed to measure relevant protein level. Colony formation and EdU assays were conducted to certify proliferative ability. TUNEL assay was finalized to assess apoptotic cells. Wound-healing and transwell assays were utilized for the exploration of migrating and invasive abilities. The subcellular distribution of BLACAT1 was studied by nucleus-cytoplasm separation assay. Relevant mechanical experiments were combined to elucidate molecular relationship between molecules.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">BLACAT1 was highly expressed in osteosarcoma. BLACAT1 promoted the proliferation and migration of osteosarcoma cells. BLACAT1 acted as a sponge for miR-608 to augment the expression of Sex determining region Y-box protein 12 (SOX12), the direct target of miR-608. Further, inhibiting miR-608 recovered the repressive effect of silenced BLACAT1 on the malignant behaviors of osteosarcoma cells.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">This study highlighted the contribution of BLACAT1/miR-608/SOX12 axis to the progression of osteosarcoma, suggesting novel targets for osteosarcoma therapy.</AbstractText>
                <CopyrightInformation>© 2020 The Authors.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Xiaotao</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Orthopedics, Qinghai Provincial People's Hospital, Xining City, Qinghai Province 810007, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cui</LastName>
                    <ForeName>Yubao</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Orthopadics, Hubei Aerospace Hospital, Xiaogan City, Hubei Province 432000, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Yanming</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Orthopedics, No. 2 Hospital of Yulin City, The South Road of Wenhua, Yuyang District, Yulin City, Shaanxi Province 719000, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Bone Oncol</MedlineTA>
            <NlmUniqueID>101610292</NlmUniqueID>
            <ISSNLinking>2212-1366</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ANOVA, analysis of variance</Keyword>
            <Keyword MajorTopicYN="N">ATCC, American type culture collection</Keyword>
            <Keyword MajorTopicYN="N">BLACAT1</Keyword>
            <Keyword MajorTopicYN="N">DMEM, Dulbecco’s modified Eagle’s medium</Keyword>
            <Keyword MajorTopicYN="N">FBS, fetal bovine serum</Keyword>
            <Keyword MajorTopicYN="N">FISH, Fluorescence in situ hybridization</Keyword>
            <Keyword MajorTopicYN="N">HRP, horseradish peroxidase</Keyword>
            <Keyword MajorTopicYN="N">Mut, mutant</Keyword>
            <Keyword MajorTopicYN="N">OS, osteosarcoma</Keyword>
            <Keyword MajorTopicYN="N">Osteosarcoma</Keyword>
            <Keyword MajorTopicYN="N">PVDF, polyvinylidene fluoride</Keyword>
            <Keyword MajorTopicYN="N">RIPA, radioimmunoprecipitation assay</Keyword>
            <Keyword MajorTopicYN="N">RT-qPCR, RNA extraction and quantitative real-time polymerase chain reaction</Keyword>
            <Keyword MajorTopicYN="N">SD, standard deviation</Keyword>
            <Keyword MajorTopicYN="N">SDS-PAGE, sulphate-polyacrylamide gel electrophoresis</Keyword>
            <Keyword MajorTopicYN="N">SOX, sex-determining region Y (SRY)-box</Keyword>
            <Keyword MajorTopicYN="N">SOX12</Keyword>
            <Keyword MajorTopicYN="N">SOX12, sex determining region Y-box protein 12</Keyword>
            <Keyword MajorTopicYN="N">WT, wild-type</Keyword>
            <Keyword MajorTopicYN="N">ceRNAs, competing endogenous RNAs</Keyword>
            <Keyword MajorTopicYN="N">lncRNAs, long non-coding RNAs</Keyword>
            <Keyword MajorTopicYN="N">mRNA, messenger RNA</Keyword>
            <Keyword MajorTopicYN="N">miR-608</Keyword>
            <Keyword MajorTopicYN="N">miRNAs, microRNAs</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>45</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005563</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jbo.2020.100314</ArticleId>
            <ArticleId IdType="pii">S2212-1374(20)30069-5</ArticleId>
            <ArticleId IdType="pmc">PMC7519359</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005492</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2167-8359</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <PubDate>
                        <Year>2020</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PeerJ</Title>
            </Journal>
            <ArticleTitle>Identification of NUF2 and FAM83D as potential biomarkers in triple-negative breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e9975</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.7717/peerj.9975</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Breast cancer is a heterogeneous disease. Compared with other subtypes of breast cancer, triple-negative breast cancer (TNBC) is easy to metastasize and has a short survival time, less choice of treatment options. Here, we aimed to identify the potential biomarkers to TNBC diagnosis and prognosis.</AbstractText>
                <AbstractText Label="Material/Methods" NlmCategory="UNASSIGNED">Three independent data sets (GSE45827, GSE38959, GSE65194) were downloaded from the Gene Expression Omnibus (GEO). The R software packages were used to integrate the gene profiles and identify differentially expressed genes (DEGs). A variety of bioinformatics tools were used to explore the hub genes, including the DAVID database, STRING database and Cytoscape software. Reverse transcription quantitative PCR (RT-qPCR) was used to verify the hub genes in 14 pairs of TNBC paired tissues.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">In this study, we screened out 161 DEGs between 222 non-TNBC and 126 TNBC samples, of which 105 genes were up-regulated and 56 were down-regulated. These DEGs were enriched for 27 GO terms and two pathways. GO analysis enriched mainly in &quot;cell division&quot;, &quot;chromosome, centromeric region&quot; and &quot;microtubule motor activity&quot;. KEGG pathway analysis enriched mostly in &quot;Cell cycle&quot; and &quot;Oocyte meiosis&quot;. PPI network was constructed and then 10 top hub genes were screened. According to the analysis results of the Kaplan-Meier survival curve, the expression levels of only NUF2, FAM83D and CENPH were associated with the recurrence-free survival in TNBC samples (<i>P</i> &lt; 0.05). RT-qPCR confirmed that the expression levels of NUF2 and FAM83D in TNBC tissues were indeed up-regulated significantly.</AbstractText>
                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">The comprehensive analysis showed that NUF2 and FAM83D could be used as potential biomarkers for diagnosis and prognosis of TNBC.</AbstractText>
                <CopyrightInformation>©2020 Zhai et al.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhai</LastName>
                    <ForeName>Xiuming</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Laboratory Medicine, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Zhaowei</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Thyroid, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Xiji</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Laboratory Medicine, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dong</LastName>
                    <ForeName>Zihe</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Laboratory Medicine, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Dandan</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Laboratory Medicine, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PeerJ</MedlineTA>
            <NlmUniqueID>101603425</NlmUniqueID>
            <ISSNLinking>2167-8359</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bioinformatics</Keyword>
            <Keyword MajorTopicYN="N">Biomarker</Keyword>
            <Keyword MajorTopicYN="N">RT-qPCR</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
        </KeywordList>
        <CoiStatement>The authors declare there are no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>45</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005492</ArticleId>
            <ArticleId IdType="doi">10.7717/peerj.9975</ArticleId>
            <ArticleId IdType="pii">9975</ArticleId>
            <ArticleId IdType="pmc">PMC7513746</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005415</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2050-0068</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2020</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical &amp; translational immunology</Title>
            </Journal>
            <ArticleTitle>Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e1177</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cti2.1177</ELocationID>
            <Abstract>
                <AbstractText Label="Objectives" NlmCategory="UNASSIGNED">Loss of tumor-inherent type I interferon (IFN) signalling has been closely linked to accelerated metastatic progression via decreased immunogenicity and antitumor immunity. Previous studies in murine models of triple-negative breast cancer (TNBC) demonstrate that systemic IFN inducers are effective antimetastatic agents, via sustained antitumor CD8<sup>+</sup> T-cell responses. Repeated systemic dosing with recombinant IFNs or IFN inducers is associated with significant toxicities; hence, the use of alternate intratumoral agents is an active area of investigation. It is critical to investigate the impact of intratumoral agents on subsequent metastatic spread to predict clinical impact.</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">In this study, the local and systemic impact of the intratumoral Toll-like receptor (TLR) 7/8 agonist 3M-052 alone or in combination with anti-PD1 was evaluated in metastatic TNBC models. The IFN-α receptor (IFNAR1) blocking antibody, MAR1-5A3, along with immune-deficient mice and <i>ex vivo</i> assays are utilised to examine the key targets of this agent that are critical for an antimetastatic response.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Single intratumoral administration of 3M-052 reduced mammary tumor growth, induced a T-cell-inflamed tumor microenvironment (TME) and reduced metastatic spread to lung. Metastasis suppression was reliant on IFN signalling and an antitumor immune response, in contrast to primary tumor growth inhibition, which was retained in NSG and CD8<sup>+</sup> T-cell-depleted mice. 3M-052 action was demonstrated via dendritic cell activation and production of type I IFN and other pro-inflammatory cytokines to initiate a T-cell-inflamed TME and promote tumor cell antigen presentation.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">This work supports neoadjuvant TLR agonist-based immunotherapeutics as realistic options for immune activation in the TME and long-term metastatic protection in TNBC.</AbstractText>
                <CopyrightInformation>© 2020 The Authors. Clinical &amp; Translational Immunology published by John Wiley &amp; Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zanker</LastName>
                    <ForeName>Damien J</ForeName>
                    <Initials>DJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology University of Melbourne Parkville VIC Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Immunology and Therapeutics Programs Peter MacCallum Cancer Centre Melbourne VIC Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spurling</LastName>
                    <ForeName>Alex J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Immunology and Therapeutics Programs Peter MacCallum Cancer Centre Melbourne VIC Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brockwell</LastName>
                    <ForeName>Natasha K</ForeName>
                    <Initials>NK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology University of Melbourne Parkville VIC Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Immunology and Therapeutics Programs Peter MacCallum Cancer Centre Melbourne VIC Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Owen</LastName>
                    <ForeName>Katie L</ForeName>
                    <Initials>KL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology University of Melbourne Parkville VIC Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Immunology and Therapeutics Programs Peter MacCallum Cancer Centre Melbourne VIC Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zakhour</LastName>
                    <ForeName>Jasmine M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics La Trobe Institute for Molecular Science La Trobe University Melbourne VIC Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robinson</LastName>
                    <ForeName>Tina</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics La Trobe Institute for Molecular Science La Trobe University Melbourne VIC Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duivenvoorden</LastName>
                    <ForeName>Hendrika M</ForeName>
                    <Initials>HM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics La Trobe Institute for Molecular Science La Trobe University Melbourne VIC Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Biological Sciences Monash University Clayton VIC Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hertzog</LastName>
                    <ForeName>Paul J</ForeName>
                    <Initials>PJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Innate Immunity and Infectious Diseases Hudson Institute of Medical Research Clayton VIC Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mullins</LastName>
                    <ForeName>Stefanie R</ForeName>
                    <Initials>SR</Initials>
                    <AffiliationInfo>
                        <Affiliation>R&amp;D Oncology AstraZeneca Ltd Cambridge UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilkinson</LastName>
                    <ForeName>Robert W</ForeName>
                    <Initials>RW</Initials>
                    <AffiliationInfo>
                        <Affiliation>R&amp;D Oncology AstraZeneca Ltd Cambridge UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parker</LastName>
                    <ForeName>Belinda S</ForeName>
                    <Initials>BS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology University of Melbourne Parkville VIC Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Immunology and Therapeutics Programs Peter MacCallum Cancer Centre Melbourne VIC Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics La Trobe Institute for Molecular Science La Trobe University Melbourne VIC Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Australia</Country>
            <MedlineTA>Clin Transl Immunology</MedlineTA>
            <NlmUniqueID>101638268</NlmUniqueID>
            <ISSNLinking>2050-0068</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CD8+ T cell</Keyword>
            <Keyword MajorTopicYN="N">TLR agonist</Keyword>
            <Keyword MajorTopicYN="N">immunotherapy</Keyword>
            <Keyword MajorTopicYN="N">interferon</Keyword>
            <Keyword MajorTopicYN="N">metastasis</Keyword>
            <Keyword MajorTopicYN="N">triple‐negative breast cancer</Keyword>
        </KeywordList>
        <CoiStatement>Financial support and reagents were provided by AstraZeneca. SRM and RWW are employed by AstraZeneca Ltd.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>45</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005415</ArticleId>
            <ArticleId IdType="doi">10.1002/cti2.1177</ArticleId>
            <ArticleId IdType="pii">CTI21177</ArticleId>
            <ArticleId IdType="pmc">PMC7520806</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005409</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2049-9450</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular and clinical oncology</Title>
            </Journal>
            <ArticleTitle>Asymptomatic solitary metastasis to the stomach from breast cancer: A case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>75</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3892/mco.2020.2145</ELocationID>
            <Abstract>
                <AbstractText>Distant metastases from breast cancer are frequently found in bones, lungs and the liver. Metastasis to the stomach is rare, and its clinical presentation remains unclear. The present report describes a case of isolated gastric metastasis from breast cancer identified by contrast-enhanced computed tomography (CT). A 45-year-old female patient underwent right mastectomy and axillary lymph node dissection after preoperative chemotherapy for right invasive lobular breast carcinoma T4bN2M0, stage IIIB. Postoperative radiotherapy and endocrine therapy with tamoxifen for 5 years were performed. CT for postoperative follow-up at 52 years old revealed thickening of the stomach wall. Although the patient was asymptomatic, erosive mucosa was observed on the gastric body during gastroscopy. The gastric lesion was immunohistochemically diagnosed as metastatic luminal disease from the breast cancer. Positron emission tomography/CT revealed no abnormal accumulation suggesting metastasis to other organs. Palbociclib and fulvestrant treatment were initiated for gastric metastasis. Invasive lobular breast carcinoma results in gastrointestinal metastasis, including the stomach, more frequently than invasive ductal breast carcinoma. However, most gastric metastases occur simultaneously with systemic metastases. Solitary metastasis to the stomach without symptoms as in this case has rarely been reported. The possibility of gastric metastasis should be considered among the differential diagnoses, even in the absence of symptoms, when gastrointestinal abnormalities are seen on CT in patients with a history of breast cancer.</AbstractText>
                <CopyrightInformation>Copyright: © Kaneko et al.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kaneko</LastName>
                    <ForeName>Yuki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738-8503, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koi</LastName>
                    <ForeName>Yumiko</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738-8503, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kajitani</LastName>
                    <ForeName>Keiko</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738-8503, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ohara</LastName>
                    <ForeName>Masahiro</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738-8503, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Daimaru</LastName>
                    <ForeName>Yutaka</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Pathological Research and Laboratory, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738-8503, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Mol Clin Oncol</MedlineTA>
            <NlmUniqueID>101613422</NlmUniqueID>
            <ISSNLinking>2049-9450</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">computed tomography</Keyword>
            <Keyword MajorTopicYN="N">gastric metastasis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>45</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005409</ArticleId>
            <ArticleId IdType="doi">10.3892/mco.2020.2145</ArticleId>
            <ArticleId IdType="pii">MCO-0-0-02145</ArticleId>
            <ArticleId IdType="pmc">PMC7523290</ArticleId>
        </ArticleIdList>
        <?pmcsd?>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005404</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2049-9450</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular and clinical oncology</Title>
            </Journal>
            <ArticleTitle>HER2-positive breast cancer that resists therapeutic drugs and ionizing radiation releases sphingomyelin-based molecules to circulating blood serum.</ArticleTitle>
            <Pagination>
                <MedlinePgn>70</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3892/mco.2020.2140</ELocationID>
            <Abstract>
                <AbstractText>Breast cancer is the second most common cancer in the world based on incidence, reaching more than 2 million new cases in 2018, while continuing to increase. Invasive ductal carcinoma is the most common type of this cancer, making up approximately 70-80% of all breast cancer diagnoses. In particular, the type of breast cancer overexpressing human epidermal growth factor receptor 2 (HER2) has potential of strong proliferation, migration and invasion and early treatment is necessary. The authors identified and studied a single patient displaying complete therapeutic resistance to monoclonal anti-HER2 antibody therapy, chemotherapy and radiotherapy. A patient who exhibited resistance to postoperative adjuvant therapy after mastectomy was selected from HER2-positive breast cancer, and this patient had the grade of T<sub>4b</sub>N<sub>2a</sub>M<sub>0</sub>, Stage IIIB. The patient samples, blood serum and cancer tissue, were analyzed by metabolome and immunostaining technique, respectively. The characteristics of peripheral blood serum and solid tumor were investigated, aiming to find new serum biomarker(s) using the metabolomics technique. A correlation between the appearance of HER2-positive cancer tissue and serum concentration of the sphingomyelin family was found. In addition, HER2-positive tumor tissue in both the primary and recurrent cancer express the sphingomyelinase. These results suggest that sphingomyelins from this cancer tissue leads to therapy resistance, induction of invasion and strong proliferation.</AbstractText>
                <CopyrightInformation>Copyright: © Monzen et al.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Monzen</LastName>
                    <ForeName>Satoru</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036-8564, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tatara</LastName>
                    <ForeName>Yota</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Glycotechnology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mariya</LastName>
                    <ForeName>Yasushi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Mutsu General Hospital, Mutsu, Aomori 035-0071, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chiba</LastName>
                    <ForeName>Mitsuru</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Bioscience and Laboratory Medicine, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036-8564, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wojcik</LastName>
                    <ForeName>Andrzej</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Radiation Protection Research, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 114 18 Stockholm, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lundholm</LastName>
                    <ForeName>Lovisa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Radiation Protection Research, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 114 18 Stockholm, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Mol Clin Oncol</MedlineTA>
            <NlmUniqueID>101613422</NlmUniqueID>
            <ISSNLinking>2049-9450</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">HER2-positive breast cancer</Keyword>
            <Keyword MajorTopicYN="N">metabolomics analysis</Keyword>
            <Keyword MajorTopicYN="N">postoperative adjuvant therapy</Keyword>
            <Keyword MajorTopicYN="N">resistant</Keyword>
            <Keyword MajorTopicYN="N">sphingomyeline</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>02</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>45</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005404</ArticleId>
            <ArticleId IdType="doi">10.3892/mco.2020.2140</ArticleId>
            <ArticleId IdType="pii">MCO-0-0-02140</ArticleId>
            <ArticleId IdType="pmc">PMC7523270</ArticleId>
        </ArticleIdList>
        <?pmcsd?>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005399</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2049-0801</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>59</Volume>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of medicine and surgery (2012)</Title>
            </Journal>
            <ArticleTitle>Future perspectives of surgical treatment of breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>93-95</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amsu.2020.09.021</ELocationID>
            <Abstract>
                <AbstractText>Breast cancer is a heterogenous disease which requires updates on scientific research to offer patients the best possible and personalized treatment. Modern surgical treatment of breast cancer is recently been reviewed and it is clearly a field of continuous change and improvement. The change in treatment strategies is a challenge given that prognosis is already acceptable. The collaboration between specialties across different countries is needed to exchange experience and improve international guidelines. Multidisciplinary teams are mandatory for the patient to be provided with all treatment options and to make an informed decision on their treatment. The major trend in surgical treatment of breast cancer is de-escalating surgery and more focus on tumor biology. A &quot;one-size-fits all&quot; approach does not apply in treatment of breast cancer today. There are two major questions in future aspects of breast cancer treatment; Can surgery in the breast be omitted in patients with a pathological complete response after neoadjuvant therapy? And can some patients be spared axillary surgery? The timing of surgery is also debatable. These are major questions that need to be answered and through randomized controlled trials. This commentary gives an insight on thoughts and scientific research with focus on future aspects of breast cancer treatment.</AbstractText>
                <CopyrightInformation>© 2020 The Author.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Riis</LastName>
                    <ForeName>Margit</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Section of Breast- and Endocrine Surgery, Oslo University Hospital, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Ann Med Surg (Lond)</MedlineTA>
            <NlmUniqueID>101616869</NlmUniqueID>
            <ISSNLinking>2049-0801</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>45</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005399</ArticleId>
            <ArticleId IdType="doi">10.1016/j.amsu.2020.09.021</ArticleId>
            <ArticleId IdType="pii">S2049-0801(20)30325-3</ArticleId>
            <ArticleId IdType="pmc">PMC7509585</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005315</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2001-0370</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>18</Volume>
                    <PubDate>
                        <Year>2020</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Computational and structural biotechnology journal</Title>
            </Journal>
            <ArticleTitle>TGIF1-Twist1 axis in pancreatic ductal adenocarcinoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2568-2572</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.csbj.2020.09.023</ELocationID>
            <Abstract>
                <AbstractText>TG-interacting factor 1 (TGIF1) exerts inhibitory effects on transforming growth factor-beta (TGF-β) signaling by suppressing Smad signaling pathway at multiple levels. TGIF1 activity is important for normal embryogenesis and organogenesis, yet its dysregulation can culminate in tumorigenesis. For instance, increased expression of TGIF1 correlates with poor prognosis in triple-negative breast cancer patients, and enforced expression of TGIF1 facilitates Wnt-driven mammary tumorigenesis, suggesting that TGIF1 might function as an oncoprotein. Quite surprisingly, TGIF1 has recently been shown to function as a tumor suppressor in pancreatic ductal adenocarcinoma (PDAC), possibly owing to its ability to antagonize the pro-malignant transcription factor Twist1. In this article, we will briefly elaborate on the biological and clinical significance of the unique tumor-suppressive function of TGIF1 and its functional interaction with Twist1 in the context of PDAC pathogenesis and progression.</AbstractText>
                <CopyrightInformation>© 2020 The Author(s).</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Razzaque</LastName>
                    <ForeName>Mohammed S</ForeName>
                    <Initials>MS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Lake Erie College of Osteopathic Medicine, Erie, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Atfi</LastName>
                    <ForeName>Azeddine</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Comput Struct Biotechnol J</MedlineTA>
            <NlmUniqueID>101585369</NlmUniqueID>
            <ISSNLinking>2001-0370</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Pancreatic ductal adenocarcinoma</Keyword>
            <Keyword MajorTopicYN="N">TGF-β</Keyword>
            <Keyword MajorTopicYN="N">TGIF1</Keyword>
            <Keyword MajorTopicYN="N">Tumor suppressor</Keyword>
            <Keyword MajorTopicYN="N">Twist1</Keyword>
        </KeywordList>
        <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>44</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005315</ArticleId>
            <ArticleId IdType="doi">10.1016/j.csbj.2020.09.023</ArticleId>
            <ArticleId IdType="pii">S2001-0370(20)30407-4</ArticleId>
            <ArticleId IdType="pmc">PMC7520386</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005300</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1948-5204</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>12</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>World journal of gastrointestinal oncology</Title>
            </Journal>
            <ArticleTitle>Colorectal cancer metastatic to the breast: A case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1073-1079</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4251/wjgo.v12.i9.1073</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Breast metastases from colorectal cancer (CRC) are very uncommon. There is no unanimous consensus regarding the best treatment for this rare condition, and management is, especially in elderly patients, limited to diagnosis and palliative care. Capecitabine, an oral fluoropyrimidine derivative, might be helpful in controlling the disease and may be a treatment option for patients unable to receive more aggressive chemotherapy.</AbstractText>
                <AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">We report a case of synchronous massive breast metastasis from CRC in an 85 year old patient who came to the hospital presenting a huge mass originating from the axillary extension of the right breast. A whole body computed tomography also showed a mass in the right colon. The patient underwent a simple right mastectomy along with right hemicolectomy. The resected breast showed massive metastasis from CRC with intense and homogeneous nuclear CDX2 staining, while the colon specimen revealed poorly differentiated adenocarcinoma stage pT4a pN0 pM1 (breast) (Tumor Node Metastasis 2017). Three months later she developed a subcutaneous mass at the site of the previous mastectomy. An ultrasound guided biopsy was carried out again and revealed a metastasis from CRC. The patient then started treatment with capecitabine plus bevacizumab, obtaining stable disease (RECIST criteria) and a clinical benefit after 3 mo of therapy.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In our experience, capecitabine and bevacizumab may be a useful treatment option for breast metastases from primary CRC in elderly patients.</AbstractText>
                <CopyrightInformation>©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Taccogna</LastName>
                    <ForeName>Silvia</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Regina Apostolorum, Albano 00041, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gozzi</LastName>
                    <ForeName>Elisa</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>UOC of Oncology, Sapienza University of Rome, Aprilia 04011, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rossi</LastName>
                    <ForeName>Luigi</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>UOC of Oncology, Sapienza University of Rome, Aprilia 04011, Rome, Italy. dr.rossi@ymail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caruso</LastName>
                    <ForeName>Davide</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, Regina Apostolorum Hospital, Albano 00041, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Conte</LastName>
                    <ForeName>Davide</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, Regina Apostolorum Hospital, Albano 00041, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trenta</LastName>
                    <ForeName>Patrizia</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, Regina Apostolorum Hospital, Albano 00041, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leoni</LastName>
                    <ForeName>Valentina</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, Regina Apostolorum Hospital, Albano 00041, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomao</LastName>
                    <ForeName>Silverio</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology A, Sapienza University of Rome, Albano 00161, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Raimondi</LastName>
                    <ForeName>Lucrezia</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>UOC of Oncology, Sapienza University of Rome, Aprilia 04011, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Angelini</LastName>
                    <ForeName>Francesco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit, Regina Apostolorum Hospital, Albano 00041, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>World J Gastrointest Oncol</MedlineTA>
            <NlmUniqueID>101532470</NlmUniqueID>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bevacizumab</Keyword>
            <Keyword MajorTopicYN="N">Breast metastases</Keyword>
            <Keyword MajorTopicYN="N">Capecitabine</Keyword>
            <Keyword MajorTopicYN="N">Case report</Keyword>
            <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>
            <Keyword MajorTopicYN="N">Elderly patient</Keyword>
        </KeywordList>
        <CoiStatement>Conflict-of-interest statement: The authors declare no potential financial interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>04</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>04</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>44</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005300</ArticleId>
            <ArticleId IdType="doi">10.4251/wjgo.v12.i9.1073</ArticleId>
            <ArticleId IdType="pmc">PMC7509995</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005283</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1930-0433</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>15</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Radiology case reports</Title>
            </Journal>
            <ArticleTitle>Disappearing grouped breast calcifications: An ominous sign.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2453-2458</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.radcr.2020.08.062</ELocationID>
            <Abstract>
                <AbstractText>Spontaneous disappearing breast calcifications is a rarely-reported phenomenon and the relatively small number of studies that have been done mostly associated the resolution of benign-appearing breast calcifications with benign processes. We present a case of a postmenopausal woman who had spontaneously resolving grouped, coarse heterogenous calcifications in the setting a new soft tissue mass which was pathologically proven to be invasive ductal carcinoma. A handful of studies have shown the resolution of indeterminant calcifications to be associated with malignancy, and interestingly, all of these cases also demonstrated a new parenchymal abnormality which is akin to the present case. Overall, the majority of benign-appearing spontaneous resolving microcalcifications likely are related to benign processes; however, radiologists should be aware of the association of disappearing grouped, indeterminant calcifications with the resulting development of malignancy, especially in the presence of a nearby, newly-forming soft tissue mass.</AbstractText>
                <CopyrightInformation>© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Paolini</LastName>
                    <ForeName>Brielle</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Medical University of South Carolina, 169 Ashley Ave, Charleston, SC 29425, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leddy</LastName>
                    <ForeName>Rebecca</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Medical University of South Carolina, 169 Ashley Ave, Charleston, SC 29425, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Irshad</LastName>
                    <ForeName>Abid</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Medical University of South Carolina, 169 Ashley Ave, Charleston, SC 29425, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Radiol Case Rep</MedlineTA>
            <NlmUniqueID>101467888</NlmUniqueID>
            <ISSNLinking>1930-0433</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Disappearing calcifications</Keyword>
            <Keyword MajorTopicYN="N">Malignancy, Mammography</Keyword>
            <Keyword MajorTopicYN="N">Resolving calcifications</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>44</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005283</ArticleId>
            <ArticleId IdType="doi">10.1016/j.radcr.2020.08.062</ArticleId>
            <ArticleId IdType="pii">S1930-0433(20)30452-0</ArticleId>
            <ArticleId IdType="pmc">PMC7519265</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005267</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1895-5770</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>15</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2020</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Przeglad gastroenterologiczny</Title>
            </Journal>
            <ArticleTitle>Incidence of genes encoding vanA/vanB vancomycin resistance in rectal swabs of patients with diagnosed cancer, on the day of admission to hospital, in a non-epidemic period.</ArticleTitle>
            <Pagination>
                <MedlinePgn>220-224</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.5114/pg.2020.98537</ELocationID>
            <Abstract>
                <AbstractText Label="Introduction" NlmCategory="UNASSIGNED">Rapid diagnosis is important for preventing infections due to vancomycin-resistant enterococci.</AbstractText>
                <AbstractText Label="Aim" NlmCategory="UNASSIGNED">To evaluate the status of gastrointestinal colonisation with strains containing vanA/vanB genes in oncological patients.</AbstractText>
                <AbstractText Label="Material and methods" NlmCategory="UNASSIGNED">A total of 167 samples of rectal swabs taken from 161 patients (mean age: 63, range: 29-93 years) were examined, including 113 patients from surgical wards (70.2%) and 48 patients from non-surgical wards (29.8%), with diagnosed cancer. The tests were carried out within 24 h of admitting the patient to the department, using the Cepheid Xpert vanA/vanB test, with a CE marked GeneXpert<sup>®</sup> Instrument Systems analyser. Samples with positive vanB gene results were additionally seeded on chromogenic media.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">The presence of the vanA gene was found in 2.7% and 6.3% of the examined patients, respectively, from the surgical and non-surgical departments, which accounted for 3.7% of all the patients examined. The presence of the vanB gene was detected in 21.1% of the patients, but in no case was there any growth of vancomycin-resistant enterococci on the chromogenic medium.</AbstractText>
                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Patients admitted to non-surgical wards were more often colonised with vanA/vanB genes than were patients admitted to surgical wards, but the differences were not statistically significant.</AbstractText>
                <CopyrightInformation>Copyright © 2020 Termedia.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Szymankiewicz</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbiology, Prof. F. Łukaszczyk Centre of Oncology, Bydgoszcz, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wróblewska</LastName>
                    <ForeName>Joanna</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbiology, Prof. F. Łukaszczyk Centre of Oncology, Bydgoszcz, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nowikiewicz</LastName>
                    <ForeName>Tomasz</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Chair and Clinic of Oncological Surgery, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Clinical Department of Breast Cancer and Reconstructive Surgery, Prof. F. Łukaszczyk Centre of Oncology, Bydgoszcz, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Poland</Country>
            <MedlineTA>Prz Gastroenterol</MedlineTA>
            <NlmUniqueID>101280380</NlmUniqueID>
            <ISSNLinking>1895-5770</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">colonisation</Keyword>
            <Keyword MajorTopicYN="N">oncological patients</Keyword>
            <Keyword MajorTopicYN="N">vanA/vanB enterococci</Keyword>
        </KeywordList>
        <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>44</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005267</ArticleId>
            <ArticleId IdType="doi">10.5114/pg.2020.98537</ArticleId>
            <ArticleId IdType="pii">41689</ArticleId>
            <ArticleId IdType="pmc">PMC7509899</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005177</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1664-8021</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <PubDate>
                        <Year>2020</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in genetics</Title>
            </Journal>
            <ArticleTitle>The Association Between Breast Cancer and Blood-Based Methylation of <i>
                    <i>S100P</i>
                </i> and <i>
                    <i>HYAL2</i>
                </i> in the Chinese Population.</ArticleTitle>
            <Pagination>
                <MedlinePgn>977</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fgene.2020.00977</ELocationID>
            <Abstract>
                <AbstractText>Previous work has shown that DNA methylation in peripheral blood may be associated with malignancy; however, these studies have mainly been conducted within Caucasian populations. Here, we investigated the association between blood-based methylation of S100 calcium-binding protein P gene (<i>S100P</i>) and hyaluronoglucosaminidase 2 gene (<i>HYAL2</i>) and breast cancer (BC) via mass spectrometry in two independent case-control studies of the Chinese population with a total of 351 BC cases and 427 cancer-free female controls. In Study I, in which subjects had an average of 45 years, hypomethylation of <i>S100P</i> showed a protective effect for women ≤45 years (six out of nine CpG sites, <i>p</i> &lt; 0.05) but not for women &gt;45 years. In contrast, hypomethylation of <i>HAYL2</i> was not correlated with BC in women ≤45 years but was a risk factor for women &gt;45 years (three out of four CpG sites, <i>p</i> &lt; 0.05). We proposed an age-dependent correlation between BC and methylation of <i>S100P</i> and <i>HYAL2</i> and performed further validation in Study II with older subjects (average age = 52.5 years), where hypomethylation of both <i>S100P</i> and <i>HYAL2</i> was a risk factor for BC (<i>p</i> &lt; 0.05 for 10 CpG sites) as reported in Caucasians who develop BC around 55 years old. Together with the observation that Chinese cancer-free females having variant basal methylation levels comparing to Caucasians, we assumed that blood-based methylation might be modified by ethnic background, hormone status, and lifestyle. Here, we highlighted that the epigenetic biomarkers warrant validations when its application in variant ethnic groups is considered.</AbstractText>
                <CopyrightInformation>Copyright © 2020 Yin, Yang, Li, Xu, Zhou, Gu, Ma and Yang.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yin</LastName>
                    <ForeName>Qiming</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Xiaoqin</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Lixi</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Tian</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Wenjie</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Chengdu Shang Jin Nan Fu Hospital, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gu</LastName>
                    <ForeName>Wanjian</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Rongxi</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Genet</MedlineTA>
            <NlmUniqueID>101560621</NlmUniqueID>
            <ISSNLinking>1664-8021</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">DNA methylation</Keyword>
            <Keyword MajorTopicYN="N">S100 calcium-binding protein P gene</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">epigenomics</Keyword>
            <Keyword MajorTopicYN="N">hyaluronoglucosaminidase 2 gene</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>44</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005177</ArticleId>
            <ArticleId IdType="doi">10.3389/fgene.2020.00977</ArticleId>
            <ArticleId IdType="pmc">PMC7485126</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33005101</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1475-2867</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>20</Volume>
                    <PubDate>
                        <Year>2020</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer cell international</Title>
            </Journal>
            <ArticleTitle>SOX4 promotes the growth and metastasis of breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>468</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12935-020-01568-2</ELocationID>
            <Abstract>
                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">Increasing evidence has shown that the transcription factor SOX4 is closely associated with the development and progression of many malignant tumors. However, the effect of SOX4 on breast cancer is unclear. In this study, we purposed to investigate the role of SOX4 in the growth and metastasis in breast cancer and the underlying mechanism. Moreover, the effect of SOX4 on cancer cell resistance to chemotherapeutic agents was also evaluated in vitro and in vivo.</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">We used lentivirus technique to ectopically express SOX4 in MDA-MB-231 and SUM149 cells or knockdown SOX4 in BT474 cells, and examined the effect of these changes on various cellular functions. MTT assay was used to determine the cell viability as well as resistance to chemotherapeutic agents. The regulation of SOX4 on epithelial-mesenchymal transition (EMT)-related genes was analyzed using qRT-PCR. The binding of SOX4 to the CXCR7 gene was demonstrated using chromatin immunoprecipitation assay and dual-luciferase reporter activity assay. The effect of SOX4/CXCR7 axis on metastasis was examined using Transwell migration and Matrigel invasion assays. The expression of SOX4/CXCR7 in primary tumors and metastatic foci in lymph nodes was assessed using immunohistochemistry. Cellular morphology was investigated under phase contrast microscope and transmission electron microscopy. Moreover, the effect of SOX4 on tumor growth, metastasis, and resistance to chemotherapy was also studied in vivo by using bioluminescent imaging.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">SOX4 increased breast cancer cell viability, migration, and invasion in vitro and enhanced tumor growth and metastasis in vivo. It regulated EMT-related genes and bound to CXCR7 promoter to upregulate CXCR7 transcription. Both SOX4 and CXCR7 were highly expressed in human primary tumors and metastatic foci in lymph nodes. Treatment of breast cancer cells with the CXCR7 inhibitor CCX771 reversed the SOX4 effect on cell migration and invasion. Ectopic expression of SOX4 increased the susceptibility of cells to paclitaxel.</AbstractText>
                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">SOX4 plays an important role in the growth and metastasis of breast cancer. SOX4/CXCR7 may serve as potential therapeutic targets for the treatment. Paclitaxel may be a good therapeutic option if the expression level of SOX4 is high.</AbstractText>
                <CopyrightInformation>© The Author(s) 2020.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang 310003 People's Republic of China.</Affiliation>
                        <Identifier Source="GRID">grid.13402.34</Identifier>
                        <Identifier Source="ISNI">0000 0004 1759 700X</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA.</Affiliation>
                        <Identifier Source="GRID">grid.240145.6</Identifier>
                        <Identifier Source="ISNI">0000 0001 2291 4776</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xiao</LastName>
                    <ForeName>Chunhua</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA.</Affiliation>
                        <Identifier Source="GRID">grid.240145.6</Identifier>
                        <Identifier Source="ISNI">0000 0001 2291 4776</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>First Department of Breast Cancer, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, 1 Huan-Hu Xi Road, Ti-Yuan Bei, He Xi, Tianjin, 300060 People's Republic of China.</Affiliation>
                        <Identifier Source="GRID">grid.411918.4</Identifier>
                        <Identifier Source="ISNI">0000 0004 1798 6427</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Zhenbo</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA.</Affiliation>
                        <Identifier Source="GRID">grid.240145.6</Identifier>
                        <Identifier Source="ISNI">0000 0001 2291 4776</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, No.6 Shuangyong Road, Nanning, Guangxi 530021 People's Republic of China.</Affiliation>
                        <Identifier Source="GRID">grid.412594.f</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gong</LastName>
                    <ForeName>Yun</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA.</Affiliation>
                        <Identifier Source="GRID">grid.240145.6</Identifier>
                        <Identifier Source="ISNI">0000 0001 2291 4776</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Baohua</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA.</Affiliation>
                        <Identifier Source="GRID">grid.240145.6</Identifier>
                        <Identifier Source="ISNI">0000 0001 2291 4776</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Zhongqi</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang 310003 People's Republic of China.</Affiliation>
                        <Identifier Source="GRID">grid.13402.34</Identifier>
                        <Identifier Source="ISNI">0000 0004 1759 700X</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Yimin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang 310003 People's Republic of China.</Affiliation>
                        <Identifier Source="GRID">grid.13402.34</Identifier>
                        <Identifier Source="ISNI">0000 0004 1759 700X</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fei</LastName>
                    <ForeName>Xiaojie</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang 310003 People's Republic of China.</Affiliation>
                        <Identifier Source="GRID">grid.13402.34</Identifier>
                        <Identifier Source="ISNI">0000 0004 1759 700X</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Weizhu</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Thyroid Surgery, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, Zhejiang 315000 People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Xiaoping</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA.</Affiliation>
                        <Identifier Source="GRID">grid.240145.6</Identifier>
                        <Identifier Source="ISNI">0000 0001 2291 4776</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teng</LastName>
                    <ForeName>Lisong</ForeName>
                    <Initials>L</Initials>
                    <Identifier Source="ORCID">0000-0001-6470-9017</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang 310003 People's Republic of China.</Affiliation>
                        <Identifier Source="GRID">grid.13402.34</Identifier>
                        <Identifier Source="ISNI">0000 0004 1759 700X</Identifier>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Cancer Cell Int</MedlineTA>
            <NlmUniqueID>101139795</NlmUniqueID>
            <ISSNLinking>1475-2867</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">CXCR7</Keyword>
            <Keyword MajorTopicYN="N">Growth</Keyword>
            <Keyword MajorTopicYN="N">Metastasis</Keyword>
            <Keyword MajorTopicYN="N">SOX4</Keyword>
        </KeywordList>
        <CoiStatement>Competing interestsAll authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>43</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005101</ArticleId>
            <ArticleId IdType="doi">10.1186/s12935-020-01568-2</ArticleId>
            <ArticleId IdType="pii">1568</ArticleId>
            <ArticleId IdType="pmc">PMC7523060</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33005030</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-4679</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature cell biology</Title>
            </Journal>
            <ArticleTitle>LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1276-1285</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41556-020-00586-6</ELocationID>
            <Abstract>
                <AbstractText>Breast cancer brain metastasis (BCBM) is a devastating disease. Radiation therapy remains the mainstay for treatment of this disease. Unfortunately, its efficacy is limited by the dose that can be safely applied. One promising approach to overcoming this limitation is to sensitize BCBMs to radiation by inhibiting their ability to repair DNA damage. Here, we report a DNA repair suppressor, leucine-rich repeat-containing protein 31 (LRRC31), that was identified through a genome-wide CRISPR screen. We found that overexpression of LRRC31 suppresses DNA repair and sensitizes BCBMs to radiation. Mechanistically, LRRC31 interacts with Ku70/Ku80 and the ataxia telangiectasia mutated and RAD3-related (ATR) at the protein level, resulting in inhibition of DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) recruitment and activation, and disruption of the MutS homologue 2 (MSH2)-ATR module. We demonstrate that targeted delivery of the LRRC31 gene via nanoparticles improves the survival of tumour-bearing mice after irradiation. Collectively, our study suggests LRRC31 as a major DNA repair suppressor that can be targeted for cancer radiosensitizing therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Yanke</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cell Biology and Genetics, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Ting</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cell Biology and Genetics, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Hongyi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbiology and Immunology, School of Medicine, Jinan University, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gou</LastName>
                    <ForeName>Xingchun</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Shaanxi Key Laboratory of Brain Disorders &amp; Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Cong</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cell Biology and Genetics, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jianhui</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Ann T</ForeName>
                    <Initials>AT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Engineering, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology in the First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Zeming</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jing</LastName>
                    <ForeName>Xintao</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cell Biology and Genetics, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lei</LastName>
                    <ForeName>Hong</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shaanxi Key Laboratory of Brain Disorders &amp; Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Zhenzhen</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cell Biology and Genetics, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bao</LastName>
                    <ForeName>Youmei</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baqri</LastName>
                    <ForeName>Mehdi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Public Health, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bindra</LastName>
                    <ForeName>Ranjit S</ForeName>
                    <Initials>RS</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3255-0467</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Therapeutic Radiology, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hansen</LastName>
                    <ForeName>James E</ForeName>
                    <Initials>JE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Therapeutic Radiology, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dou</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Chen</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2407-9716</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Cell Biology and Genetics, Xi'an Jiaotong University, Xi'an, Shaanxi, China. hchen@mail.xjtu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Xi'an, Shaanxi, China. hchen@mail.xjtu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Jiangbing</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1201-5360</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Yale University, New Haven, CT, USA. jiangbing.zhou@yale.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Engineering, Yale University, New Haven, CT, USA. jiangbing.zhou@yale.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>2017KW-059</GrantID>
                    <Agency>Natural Science Foundation of Shaanxi Province (Shaanxi Province Natural Science Foundation)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>NS095817</GrantID>
                    <Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Cell Biol</MedlineTA>
            <NlmUniqueID>100890575</NlmUniqueID>
            <ISSNLinking>1465-7392</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>42</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33005030</ArticleId>
            <ArticleId IdType="doi">10.1038/s41556-020-00586-6</ArticleId>
            <ArticleId IdType="pii">10.1038/s41556-020-00586-6</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33004987</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-2322</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Scientific reports</Title>
            </Journal>
            <ArticleTitle>Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years prior to diagnosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>16275</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-73451-z</ELocationID>
            <Abstract>
                <AbstractText>We analyzed 1196 proteins in longitudinal plasma samples from participants in a commercial wellness program, including samples collected pre-diagnosis from ten cancer patients and 69 controls. For three individuals ultimately diagnosed with metastatic breast, lung, or pancreatic cancer, CEACAM5 was a persistent longitudinal outlier as early as 26.5 months pre-diagnosis. CALCA, a biomarker for medullary thyroid cancer, was hypersecreted in metastatic pancreatic cancer at least 16.5 months pre-diagnosis. ERBB2 levels spiked in metastatic breast cancer between 10.0 and 4.0 months pre-diagnosis. Our results support the value of deep phenotyping seemingly healthy individuals in prospectively inferring disease transitions.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Magis</LastName>
                    <ForeName>Andrew T</ForeName>
                    <Initials>AT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Systems Biology, 401 Terry Ave N, Seattle, WA, 98109, USA. andrew.magis@isbscience.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rappaport</LastName>
                    <ForeName>Noa</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Systems Biology, 401 Terry Ave N, Seattle, WA, 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Conomos</LastName>
                    <ForeName>Matthew P</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, University of Washington, Seattle, WA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Omenn</LastName>
                    <ForeName>Gilbert S</ForeName>
                    <Initials>GS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Systems Biology, 401 Terry Ave N, Seattle, WA, 98109, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Departments of Computational Medicine &amp; Bioinformatics, Internal Medicine, Human Genetics, and School of Public Health, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lovejoy</LastName>
                    <ForeName>Jennifer C</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Systems Biology, 401 Terry Ave N, Seattle, WA, 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hood</LastName>
                    <ForeName>Leroy</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Systems Biology, 401 Terry Ave N, Seattle, WA, 98109, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Providence St. Joseph Health, Seattle, WA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Price</LastName>
                    <ForeName>Nathan D</ForeName>
                    <Initials>ND</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Systems Biology, 401 Terry Ave N, Seattle, WA, 98109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30ES017885-01A1</GrantID>
                    <Acronym>NH</Acronym>
                    <Agency>NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>BRK_201801-05</GrantID>
                    <Agency>Andy Hill Cancer Research Endowment Fund</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Sci Rep</MedlineTA>
            <NlmUniqueID>101563288</NlmUniqueID>
            <ISSNLinking>2045-2322</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>41</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33004987</ArticleId>
            <ArticleId IdType="doi">10.1038/s41598-020-73451-z</ArticleId>
            <ArticleId IdType="pii">10.1038/s41598-020-73451-z</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">33004749</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1998-4138</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>16</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cancer research and therapeutics</Title>
            </Journal>
            <ArticleTitle>A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1069-1076</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4103/jcrt.JCRT_792_19</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Previous studies have shown that vinorelbine/capecitabine (NX) and docetaxel/capecitabine (TX) chemotherapy has a certain effect in advanced breast cancer. However, there are few clinical studies directly comparing TX and NX regimen chemotherapy, especially in patients with advanced breast cancer previously treated with anthracycline and taxane. The purpose of this Phase II study was to compare survival and side effects between patients with anthracycline- and taxane-resistant advanced breast cancer treated with NX and those treated with TX chemotherapy.</AbstractText>
                <AbstractText Label="Patients and Methods" NlmCategory="UNASSIGNED">From February 2012 to March 2014, a total number of 97 patients were randomly assigned to NX (n = 55) or TX (n = 42). Baseline characteristics were relatively well-balanced in the two treatment arms. The clinical trial registration number (clincaltrials.gov) is NCT01635465.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">After a median follow-up of 46.0 months, there was no significant difference between the NX and TX arms in objective response rate (17.9% vs. 21.1%; P = 0.686) and progression-free survival (6 months vs. 7 months; P = 0.560). The overall survival period of the TX arm was longer than that of the NX arm (32 months vs. 27 months) but without statistical significance. Both regimens were well-tolerated. The main toxicities were neutropenia, leukopenia, and anemia. In the TX arm, hand-foot syndrome occurred more frequently than in the NX arm (P &lt; 0.01), but frequencies of other minor adverse effects were similar between the two arms.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">NX and TX regimens are both alternative treatments for patients with anthracycline- and taxane-resistant advanced breast cancer, but the safety profile was more favorable and manageable with the NX regimen.</AbstractText>
                <AbstractText Label="Trial Registrations" NlmCategory="UNASSIGNED">ClinicalTrials.gov NCT01635465. Registered 09 July 2012.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Shufen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, Cancer Hospital of Tianjin, Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meng</LastName>
                    <ForeName>Wenjing</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, Cancer Hospital of Tianjin, Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jibo</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Hebei Province Xingtai People's Hospital, Hebei Medical University Affiliated Hospital, Xingtai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Xiaojuan</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Xiamen No. 2 Hospital, Xiamen, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hao</LastName>
                    <ForeName>Chunfang</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, Cancer Hospital of Tianjin, Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Yongsheng</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, Cancer Hospital of Tianjin, Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tong</LastName>
                    <ForeName>Zhongsheng</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, Cancer Hospital of Tianjin, Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01635465</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>J Cancer Res Ther</MedlineTA>
            <NlmUniqueID>101249598</NlmUniqueID>
            <ISSNLinking>1998-4138</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anthracycline-pretreated</Keyword>
            <Keyword MajorTopicYN="N">capecitabine</Keyword>
            <Keyword MajorTopicYN="N">docetaxel</Keyword>
            <Keyword MajorTopicYN="N">metastatic breast cancer</Keyword>
            <Keyword MajorTopicYN="N">vinorelbine</Keyword>
        </KeywordList>
        <CoiStatement>None</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>37</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33004749</ArticleId>
            <ArticleId IdType="pii">JCanResTher_2020_16_5_1069_296446</ArticleId>
            <ArticleId IdType="doi">10.4103/jcrt.JCRT_792_19</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33004410</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1756-1833</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>371</Volume>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMJ (Clinical research ed.)</Title>
            </Journal>
            <ArticleTitle>Pause in breast cancer screening is opportunity to re-evaluate programme, says critic.</ArticleTitle>
            <Pagination>
                <MedlinePgn>m3810</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.m3810</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Griffin</LastName>
                    <ForeName>Shaun</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMJ</MedlineTA>
            <NlmUniqueID>8900488</NlmUniqueID>
            <ISSNLinking>0959-8138</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>35</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33004410</ArticleId>
            <ArticleId IdType="doi">10.1136/bmj.m3810</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33004378</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-Print">
            <Journal>
                <ISSN IssnType="Electronic">1478-5242</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>70</Volume>
                    <Issue>699</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The British journal of general practice : the journal of the Royal College of General Practitioners</Title>
            </Journal>
            <ArticleTitle>Update on breast cancer diagnosis and management: new topics for primary care.</ArticleTitle>
            <Pagination>
                <MedlinePgn>515-516</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3399/bjgp20X712985</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cox</LastName>
                    <ForeName>Julie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>South Tyneside and Sunderland NHS Foundation Trust, Sunderland Royal Hospital; University of Sunderland, Faculty of Health Sciences and Wellbeing, Sunderland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bhatti</LastName>
                    <ForeName>Amir</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>County Durham and Darlington NHS Foundation Trust, Department of Surgery, Durham.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Graham</LastName>
                    <ForeName>Yitka</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Sunderland, Faculty of Health Sciences and Wellbeing, Sunderland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Daniela</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Northern Centre for Cancer Care, Newcastle Hospitals Foundation Trust, Freeman Hospital, Newcastle upon Tyne.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Gen Pract</MedlineTA>
            <NlmUniqueID>9005323</NlmUniqueID>
            <ISSNLinking>0960-1643</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>03</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>03</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>34</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33004378</ArticleId>
            <ArticleId IdType="pii">70/699/515</ArticleId>
            <ArticleId IdType="doi">10.3399/bjgp20X712985</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33004351</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1538-7445</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer research</Title>
            </Journal>
            <ArticleTitle>A functional genomic screen identifies the deubiquitinase USP11 as a novel transcriptional regulator of ERα in breast cancer.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">canres.0214.2020</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-20-0214</ELocationID>
            <Abstract>
                <AbstractText>Approximately 70% of breast cancers express estrogen receptor α (ERα) and depend on this key transcriptional regulator for proliferation and differentiation. While patients with this disease can be treated with targeted anti-endocrine agents, drug resistance remains a significant issue, with almost half of patients ultimately relapsing. Elucidating the mechanisms that control ERα function may further our understanding of breast carcinogenesis and reveal new therapeutic opportunities. Here we investigated the role of deubiquitinases (DUB) in regulating ERα in breast cancer. An RNAi loss-of-function screen in breast cancer cells targeting all DUB identified USP11 as a regulator of ERα transcriptional activity, which was further validated by assessment of direct transcriptional targets of ERα. USP11 expression was induced by estradiol (E2), an effect that was blocked by tamoxifen and not observed in ERα-negative cells. Mass spectrometry revealed a significant change to the proteome and ubiquitinome in USP11 knockdown cells in the presence of E2. RNA sequencing in LCC1 USP11 knockdown cells revealed significant suppression of cell cycle-associated and ERα target genes, phenotypes that were not observed in LCC9 USP11 knockdown, anti-endocrine resistant cells. In a breast cancer patient cohort coupled with in silico analysis of publicly available cohorts, high expression of USP11 was significantly associated with poor survival in ERα-positive patients. Overall, this study highlights a novel role for USP11 in the regulation of ERα activity, where USP11 may represent a prognostic marker in ERα-positive breast cancer.</AbstractText>
                <CopyrightInformation>Copyright ©2020, American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dwane</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Connor</LastName>
                    <ForeName>Aisling E</ForeName>
                    <Initials>AE</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Das</LastName>
                    <ForeName>Sudipto</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moran</LastName>
                    <ForeName>Bruce</ForeName>
                    <Initials>B</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-7266-0265</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Dept. of Pathology, St. Vincent's University Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mulrane</LastName>
                    <ForeName>Laoighse</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>UCD School of Biomolecular and Biomedical Science, University College Dublin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pinto-Fernandez</LastName>
                    <ForeName>Adan</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Oxford.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ward</LastName>
                    <ForeName>Elspeth</ForeName>
                    <Initials>E</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-7530-2279</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Molecular oncology research, Royal College of Surgeons in Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blümel</LastName>
                    <ForeName>Anna M</ForeName>
                    <Initials>AM</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-9461-6185</Identifier>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy &amp; Biomolecular Sciences, Royal College of Surgeons in Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cavanagh</LastName>
                    <ForeName>Brenton L</ForeName>
                    <Initials>BL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cellular and Molecular Imaging Core, Royal College of Surgeons in Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mooney</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy &amp; Biomolecular Sciences, Royal College of Surgeons in Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dirac</LastName>
                    <ForeName>Annette M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Molecular Carcinogenesis, Netherlands Cancer Institute.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jirström</LastName>
                    <ForeName>Karin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Sciences,, Lund University.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kessler</LastName>
                    <ForeName>Benedikt M</ForeName>
                    <Initials>BM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Medicine, University of Oxford.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ní Chonghaile</LastName>
                    <ForeName>Tríona</ForeName>
                    <Initials>T</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-3041-4031</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernards</LastName>
                    <ForeName>René</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Molecular Carcinogenesis, The Netherlands Cancer Institute.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gallagher</LastName>
                    <ForeName>William M</ForeName>
                    <Initials>WM</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-4307-5999</Identifier>
                    <AffiliationInfo>
                        <Affiliation>School of Biomolecular and Biomedical Science, University College Dublin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Connor</LastName>
                    <ForeName>Darran P</ForeName>
                    <Initials>DP</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-8835-1547</Identifier>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy &amp; Biomolecular Sciences, Royal College of Surgeons in Ireland darranoconnor@rcsi.ie.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Res</MedlineTA>
            <NlmUniqueID>2984705R</NlmUniqueID>
            <ISSNLinking>0008-5472</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>01</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>34</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33004351</ArticleId>
            <ArticleId IdType="pii">0008-5472.CAN-20-0214</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-20-0214</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33004253</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1569-8041</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
            </Journal>
            <ArticleTitle>ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0923-7534(20)42164-7</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.annonc.2020.08.2102</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is associated with sensitivity to PARP inhibitor (PARPi) therapy. HRD testing provides an opportunity to optimise PARPi use in HGSC but methodologies are diverse and clinical application remains controversial.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">To define best practice for HRD testing in HGSC the ESMO Translational Research and Precision Medicine Working Group launched a collaborative project that incorporated a systematic review approach. The main aims were to (i) define the term 'HRD test'; (ii) provide an overview of the biological rationale and the level of evidence supporting currently available HRD tests; (iii) provide recommendations on the clinical utility of HRD tests in clinical management of HGSC.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A broad range of repair genes, genomic scars, mutational signatures and functional assays are associated with a history of HRD. Currently, the clinical validity of HRD tests in ovarian cancer is best assessed, not in terms of biological HRD status per se, but in terms of PARPi benefit. Clinical trials evidence supports the use of BRCA mutation testing and two commercially available assays that also incorporate genomic instability for identifying subgroups of HGSCs that derive different magnitudes of benefit from PARPi therapy, albeit with some variation by clinical scenario. These tests can be used to inform treatment selection and scheduling but their use is limited by a failure to consistently identify a subgroup of patients who derive no benefit from PARPis in most studies. Existing tests lack negative predictive value and inadequately address the complex and dynamic nature of the HRD phenotype.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Currently available HRD tests are useful for predicting likely magnitude of benefit from PARPis but better biomarkers are urgently needed to better identify current homologous recombination proficiency status and stratify HGSC management.</AbstractText>
                <CopyrightInformation>Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>R E</ForeName>
                    <Initials>RE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, University College London, London, UK; Department of Medical Oncology, St Bartholomew's Hospital, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leary</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and INSERM U981, Gustave Roussy Cancer Center, Université Paris-Saclay, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scott</LastName>
                    <ForeName>C L</ForeName>
                    <Initials>CL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia; The University of Melbourne, Melbourne, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serra</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Experimental Therapeutics Group Vall d'Hebron Institute of Oncology, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lord</LastName>
                    <ForeName>C J</ForeName>
                    <Initials>CJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bowtell</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia; The University of Melbourne, Melbourne, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>D K</ForeName>
                    <Initials>DK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Glasgow Precision Oncology Laboratory, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garsed</LastName>
                    <ForeName>D W</ForeName>
                    <Initials>DW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia; The University of Melbourne, Melbourne, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jonkers</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ledermann</LastName>
                    <ForeName>J A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>UCL Cancer Institute, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nik-Zainal</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, Cambridge, UK; MRC Cancer Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ray-Coquard</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre Leon Berard, Lyon, France; University Claude Bernard Groupe University of Lyon, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shah</LastName>
                    <ForeName>S P</ForeName>
                    <Initials>SP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matias-Guiu</LastName>
                    <ForeName>X</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Pathology, Hospital U Arnau de Vilanova and Hospital U de Bellvitge, Universities of Lleida and Barcelona, Irblleida, Idibell, Ciberonc, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swisher</LastName>
                    <ForeName>E M</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yates</LastName>
                    <ForeName>L R</ForeName>
                    <Initials>LR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge; Guy's Cancer Centre, Guys and St Thomas' NHS Foundation Trust, London, UK. Electronic address: education@esmo.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017065">Practice Guideline</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Ann Oncol</MedlineTA>
            <NlmUniqueID>9007735</NlmUniqueID>
            <ISSNLinking>0923-7534</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA</Keyword>
            <Keyword MajorTopicYN="N">genomic scar assays</Keyword>
            <Keyword MajorTopicYN="N">homologous recombination deficiency (HRD)</Keyword>
            <Keyword MajorTopicYN="N">poly-ADP ribose inhibitors (PARPi)</Keyword>
        </KeywordList>
        <CoiStatement>Disclosures REM receives consultancy fees from Merck, TESARO-GSK and Clovis Oncology, speaker bureau from Roche and TESARO and travel grants from AstraZeneca and TESARO. LRY receives research funding from the Wellcome Trust (Clinical Career Development Fellowship 214584/Z/18/Z). AL receives consultancy fees from Ability, Astra Zeneca, Clovis, GamaMabs, GSK, MSD, Merck Serono, and TESARO, research funding from Merus, GamaMabs, Inivata, and Sanofi Investigator and fees for trials with Ability, Agenus, AstraZeneca, BMS, Boehringer. IRC is the principal investigator of PAOLA1 trial; receives honoraria from AstraZeneca, Clovis, TESARO and Pharma Mar; consulting/advisory board fees from AstraZeneca, Roche, Clovis, TESARO, Genmab, Pharma Mar, MSD and Pfizer; research funding from MSD; travel expenses from AstraZeneca, GSK and Roche. JAL received fees for Advisory Boards and Lectures for AstraZeneca; Clovis Oncology; GSK. Advisory Boards from MSD/Merck; Eisai; Artios; Amgen; Regeneron. Grants AstraZeneca; MSD/Merck. SPS is a founder and shareholder of Canexia Health Inc. VS developed EP3502700A1: methods based on the detection of rad51 foci in tumour cells and developed EP3502700A1: methods based on the detection of rad51 foci in tumour cells and receives research funding from AstraZeneca and Tesaro; received consultancy, SAB membership or honoraria payments from Abbvie. CJL receives research funding from AstraZeneca, Merck KGaA, and Artios; received consultancy, SAB membership or honoraria payments from Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma, and Artios. CJL has stock in Tango and OVIBIO and is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from the development as part of the ICR ‘Rewards to Inventors’ scheme. JJ is an advisory board member of Artios Pharma. DKC received research funding from Cancer Research UK (C51058/A25407), Celgene and Astra Zeneca, and speaker bureau from Celgene. DB receives research grant funding from Astra Zeneca, Genentech/Roche, Beigene, and paid consultancy from Exo Therapeutics. SNZ holds multiple patents on mutational-signature-based clinical algorithms and is a current or past recipient of honoraria from Astra Zeneca, Artios Pharma and the Scottish Genomics Partnership. JJ is an advisory board member of Artios Pharma and receives research funding from Artios Pharma, Cancer Research UK, Dutch Cancer Society and Oncode Institute. All remaining authors have declared no conflicts of interest. CLS acts in an honorary advisory capacity for AstraZeneca, Clovis Oncology, Roche, Eisai Inc, Sierra Oncology, Takeda, MSD.; receives grant/research support from Clovis Oncology, Eisai Inc, Sierra Oncology, Roche, Beigene; travel support from AstraZeneca.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>33</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33004253</ArticleId>
            <ArticleId IdType="pii">S0923-7534(20)42164-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.annonc.2020.08.2102</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33004231</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-1983</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical nutrition (Edinburgh, Scotland)</Title>
            </Journal>
            <ArticleTitle>Long-term consumption of non-fermented and fermented dairy products and risk of breast cancer by estrogen receptor status - Population-based prospective cohort study.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0261-5614(20)30469-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clnu.2020.09.013</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">The impact of dairy consumption on breast cancer development is unclear. We sought to examine associations between long-term consumption of milk and fermented dairy products and risk of breast cancer by estrogen (ER) and progesterone receptor (PR) status and assess whether these associations varied by body weight.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The population-based Swedish Mammography Cohort included 33,780 women (88.2% postmenopausal), with no history of cancer or diabetes at baseline (1997). Long-term consumption of dairy products was assessed using a self-administered food-frequency questionnaire in 1987 and 1997. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">During 16.6 years of follow-up (559,286 person-years), 1870 total breast cancer cases were diagnosed (1162 ER+/PR+; 195 ER-/PR-). High long-term non-fermented milk consumption was associated with increased ER+/PR+ breast cancer incidence, HR = 1.30, 95%CI:1.02-1.65 for the average of 1987 and 1997 intake ≥2 vs. 0 servings/day and this increased risk was limited to women with BMI&lt;25 kg/m<sup>2</sup> HR = 1.55, 95%CI:1.08-2.21, while no significant associations with milk consumption were observed with ER-/PR- breast cancer. In contrast, consumption of fermented dairy products was inversely associated with ER-/PR- breast cancer (for consistently high intake ≥3 vs. &lt;1 servings/day HR = 0.28, 95%CI:0.10-0.78), but not clear association was observed for ER+/PR+ (HR = 0.89, 95%CI:0.69-1.14).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this cohort of mainly postmenopausal women, high long-term consumption of milk was associated with increased risk of ER+/PR+ breast cancer. In contrast, high long-term consumption of fermented dairy products was associated with decreased risk of ER-/PR- breast cancer.</AbstractText>
                <CopyrightInformation>Copyright © 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kaluza</LastName>
                    <ForeName>Joanna</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Nutrition Research Laboratory, Department of Human Nutrition, Warsaw University of Life Sciences-SGGW, Warsaw, Poland. Electronic address: joanna_kaluza@sggw.edu.pl.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Komatsu</LastName>
                    <ForeName>Shoko</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health and Welfare Science, Faculty of Sport Science, Sendai University, Japan. Electronic address: sk-komatsu@sendai-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lauriola</LastName>
                    <ForeName>Mara</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: lauriolamary@hotmail.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harris</LastName>
                    <ForeName>Holly R</ForeName>
                    <Initials>HR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA. Electronic address: hharris@fredhutch.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bergkvist</LastName>
                    <ForeName>Leif</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Clinical Research, Uppsala University, Västmanland County Hospital, Västerås, Sweden. Electronic address: leif.bergkvist@regionvastmanland.se.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michaëlsson</LastName>
                    <ForeName>Karl</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. Electronic address: karl.michaelsson@surgsci.uu.se.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wolk</LastName>
                    <ForeName>Alicja</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. Electronic address: alicja.wolk@ki.se.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Clin Nutr</MedlineTA>
            <NlmUniqueID>8309603</NlmUniqueID>
            <ISSNLinking>0261-5614</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Diet</Keyword>
            <Keyword MajorTopicYN="N">Epidemiology</Keyword>
            <Keyword MajorTopicYN="N">Estrogen receptor</Keyword>
            <Keyword MajorTopicYN="N">Milk</Keyword>
            <Keyword MajorTopicYN="N">Prospective cohort study</Keyword>
        </KeywordList>
        <CoiStatement>Conflicts of interest None.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>33</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33004231</ArticleId>
            <ArticleId IdType="pii">S0261-5614(20)30469-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clnu.2020.09.013</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33004179</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1769-6917</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Bulletin du cancer</Title>
            </Journal>
            <ArticleTitle>[PARP inhibitors in breast cancer: Current clinical development and perspectives].</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0007-4551(20)30355-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bulcan.2020.07.011</ELocationID>
            <Abstract>
                <AbstractText>The association of a germline mutation in the BRCA1/2 genes in breast cancer leads to a higher genomic instability and, thus, a potential higher sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. In this review, we will summarize the different DNA-repair pathways including PARP-dependent mechanisms that support the use of PARP inhibitors. We will present clinical trials evaluating PARP inhibitors alone or in combination in early or advanced stage breast cancer. We will then discuss the different mechanisms involved in the resistance to PARP inhibitors. We will also introduce the concept of BRCAness by which the use of PARP inhibitors could be extended to BRCA1/2-wild type patients. Finally, we will describe the new channels implemented for the theranostic genetic screening.</AbstractText>
                <CopyrightInformation>Copyright © 2020. Published by Elsevier Masson SAS.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Robbe</LastName>
                    <ForeName>Julie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Paoli-Calmettes, département d'oncologie médicale, 232, boulevard Sainte-Marguerite, BP 156, 13273 Marseille cedex 9, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moretta</LastName>
                    <ForeName>Jessica</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Paoli-Calmettes, département d'anticipation et de suivi des cancers - oncogénétique clinique, 232, boulevard Sainte-Marguerite, BP 156, 13273 Marseille cedex 9, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vicier</LastName>
                    <ForeName>Cécile</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Aix-Marseille Université, Institut Paoli-Calmettes, CNRS, département d'Oncologie Médicale, CRCM, Inserm, 232, boulevard Sainte-Marguerite, BP 156, 13273 Marseille cedex 9, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sabatier</LastName>
                    <ForeName>Renaud</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Aix-Marseille Université, Institut Paoli-Calmettes, CNRS, département d'Oncologie Médicale, CRCM, Inserm, 232, boulevard Sainte-Marguerite, BP 156, 13273 Marseille cedex 9, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Noguès</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Paoli-Calmettes, département d'anticipation et de suivi des cancers - oncogénétique clinique, 232, boulevard Sainte-Marguerite, BP 156, 13273 Marseille cedex 9, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gonçalves</LastName>
                    <ForeName>Anthony</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Aix-Marseille Université, Institut Paoli-Calmettes, CNRS, département d'Oncologie Médicale, CRCM, Inserm, 232, boulevard Sainte-Marguerite, BP 156, 13273 Marseille cedex 9, France. Electronic address: goncalvesa@ipc.unicancer.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>fre</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Inhibiteurs de PARP dans les cancers du sein : développement clinique actuel et perspectives.</VernacularTitle>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Bull Cancer</MedlineTA>
            <NlmUniqueID>0072416</NlmUniqueID>
            <ISSNLinking>0007-4551</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA</Keyword>
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Cancer du sein</Keyword>
            <Keyword MajorTopicYN="N">Inhibiteurs de PARP</Keyword>
            <Keyword MajorTopicYN="N">PARP inhibitors</Keyword>
            <Keyword MajorTopicYN="N">Poly(ADP)-ribose polymerase</Keyword>
            <Keyword MajorTopicYN="N">Poly(ADP)-ribose polymérase</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>02</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>32</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33004179</ArticleId>
            <ArticleId IdType="pii">S0007-4551(20)30355-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bulcan.2020.07.011</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33004039</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1465-542X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research : BCR</Title>
            </Journal>
            <ArticleTitle>Association between indicators of systemic inflammation biomarkers during puberty with breast density and onset of menarche.</ArticleTitle>
            <Pagination>
                <MedlinePgn>104</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13058-020-01338-y</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Systemic inflammation may play a role in shaping breast composition, one of the strongest risk factors for breast cancer. Pubertal development presents a critical window of breast tissue susceptibility to exogenous and endogenous factors, including pro-inflammatory markers. However, little is known about the role of systemic inflammation on adolescent breast composition and pubertal development among girls.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We investigated associations between circulating levels of inflammatory markers (e.g., interleukin-6 (IL-6), tumor necrosis factor receptor 2 (TNFR2), and C-reactive protein (CRP)) at Tanner stages 2 and 4 and breast composition at Tanner stage 4 in a cohort of 397 adolescent girls in Santiago, Chile (Growth and Obesity Cohort Study, 2006-2018). Multivariable linear models were used to examine the association between breast composition and each inflammatory marker, stratifying by Tanner stage at inflammatory marker measurement. Accelerated failure time models were used to evaluate the association between inflammatory markers concentrations at each Tanner stage and time to menarche.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In age-adjusted linear regression models, a doubling of TNFR2 at Tanner 2 was associated with a 26% (95% CI 7-48%) increase in total breast volume at Tanner 4 and a 22% (95% CI 10-32%) decrease of fibroglandular volume at Tanner 4. In multivariable models further adjusted for body fatness and other covariates, these associations were attenuated to the null. The time to menarche was 3% (95% CI 1-5%) shorter among those in the highest quartile of IL-6 at Tanner 2 relative to those in the lowest quartile in fully adjusted models. Compared to those in the lowest quartile of CRP at Tanner 4, those in the highest quartile experienced 2% (95% CI 0-3%) longer time to menarche in multivariable models.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Systemic inflammation during puberty was not associated with breast volume or breast density at the conclusion of breast development among pubertal girls after adjusting for body fatness; however, these circulating inflammation biomarkers, specifically CRP and IL-6, may affect the timing of menarche onset.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Michels</LastName>
                    <ForeName>Karin B</ForeName>
                    <Initials>KB</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5137-5505</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, Fielding School of Public Health, University of California, 650 Charles Young Drive South, Room 71-264 CHS, Los Angeles, CA, 90095, USA. k.michels@ucla.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute for Prevention and Cancer Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg im Breisgau, Germany. k.michels@ucla.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Keller</LastName>
                    <ForeName>Kristen</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pereira</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Claire E</ForeName>
                    <Initials>CE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, Fielding School of Public Health, University of California, 650 Charles Young Drive South, Room 71-264 CHS, Los Angeles, CA, 90095, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santos</LastName>
                    <ForeName>José L</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shepherd</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Population Sciences in the Pacific Program (Cancer Epidemiology), University of Hawai'i Cancer Center, University of Hawai'i, Honolulu, HI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Corvalan</LastName>
                    <ForeName>Camila</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Binder</LastName>
                    <ForeName>Alexandra M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, Fielding School of Public Health, University of California, 650 Charles Young Drive South, Room 71-264 CHS, Los Angeles, CA, 90095, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Population Sciences in the Pacific Program (Cancer Epidemiology), University of Hawai'i Cancer Center, University of Hawai'i, Honolulu, HI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01CA158313</GrantID>
                    <Agency>Division of Cancer Prevention, National Cancer Institute</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>K07CA225856</GrantID>
                    <Agency>Foundation for the National Institutes of Health (US)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>11170670</GrantID>
                    <Agency>FONDECYT</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>REDI170060</GrantID>
                    <Agency>PCI Proyecto</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>2010/245</GrantID>
                    <Agency>World Cancer Research Fund</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Breast Cancer Res</MedlineTA>
            <NlmUniqueID>100927353</NlmUniqueID>
            <ISSNLinking>1465-5411</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adiposity</Keyword>
            <Keyword MajorTopicYN="N">Breast Cancer</Keyword>
            <Keyword MajorTopicYN="N">Breast density</Keyword>
            <Keyword MajorTopicYN="N">C-reactive protein</Keyword>
            <Keyword MajorTopicYN="N">Interleukin-6</Keyword>
            <Keyword MajorTopicYN="N">Menarche</Keyword>
            <Keyword MajorTopicYN="N">Puberty</Keyword>
            <Keyword MajorTopicYN="N">Systemic inflammation</Keyword>
            <Keyword MajorTopicYN="N">Tumor necrosis factor receptor 2</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>02</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>28</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33004039</ArticleId>
            <ArticleId IdType="doi">10.1186/s13058-020-01338-y</ArticleId>
            <ArticleId IdType="pii">10.1186/s13058-020-01338-y</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">33004032</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2407</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC cancer</Title>
            </Journal>
            <ArticleTitle>Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>946</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-020-07462-4</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer. Although UC has been considered a highly aggressive malignancy, no clinical studies have addressed the efficacy of chemotherapy for unresectable UC. Therefore, we conducted multicenter retrospective study to investigate the efficacy of chemotherapy in patients with UC of the pancreas.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This multicenter retrospective cohort study was conducted at 17 institutions in Japan between January 2007 and December 2017. A total of 50 patients treated with chemotherapy were analyzed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The median overall survival (OS) in UC patients treated with chemotherapy was 4.08 months. The details of first-line chemotherapy were as follows: gemcitabine (n = 24), S-1 (n = 12), gemcitabine plus nab-paclitaxel (n = 6), and other treatment (n = 8). The median progression-free survival (PFS) was 1.61 months in the gemcitabine group, 2.96 months in the S-1 group, and 4.60 months in the gemcitabine plus nab-paclitaxel group. Gemcitabine plus nab-paclitaxel significantly improved PFS compared with gemcitabine (p = 0.014). The objective response rate (ORR) was 4.2% in the gemcitabine group, 0.0% in the S-1 group, and 33.3% in the gemcitabine plus nab-paclitaxel group. Gemcitabine plus nab-paclitaxel also showed a significantly higher ORR compared with both gemcitabine and S-1 (gemcitabine plus nab-paclitaxel vs. gemcitabine: p = 0.033; gemcitabine plus nab-paclitaxel vs. S-1: p = 0.034). A paclitaxel-containing first-line regimen significantly improved OS compared with a non-paclitaxel-containing regimen (6.94 months vs. 3.75 months, respectively; p = 0.041). After adjustment, use of a paclitaxel-containing regimen in any line was still an independent predictor of OS (hazard ratio for OS, 0.221; 95% confidence interval, 0.076-0.647; p = 0.006) in multiple imputation by chained equation.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of the present study indicate that a paclitaxel-containing regimen would offer relatively longer survival, and it is considered a reasonable option for treating patients with unresectable UC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Imaoka</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0584-0095</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. hiroshi.imaoka.md@me.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ikeda</LastName>
                    <ForeName>Masafumi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maehara</LastName>
                    <ForeName>Kosuke</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Umemoto</LastName>
                    <ForeName>Kumiko</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Oncology, St.Marianna University School of Medicine, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ozaka</LastName>
                    <ForeName>Masato</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Medicine, Cancer Institute Hospital Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kobayashi</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Terashima</LastName>
                    <ForeName>Takeshi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inoue</LastName>
                    <ForeName>Hiroto</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakaguchi</LastName>
                    <ForeName>Chihiro</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Shikoku Cancer Center, Matsuyama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsuji</LastName>
                    <ForeName>Kunihiro</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shioji</LastName>
                    <ForeName>Kazuhiko</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okamura</LastName>
                    <ForeName>Keiya</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pancreato-Biliary Section, Department of Gastroenterology, JA Sapporo Kohsei Hospital, Sapporo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawamoto</LastName>
                    <ForeName>Yasuyuki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>Rei</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shirakawa</LastName>
                    <ForeName>Hirofumi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center, Utsunomiya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nagano</LastName>
                    <ForeName>Hiroaki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ueno</LastName>
                    <ForeName>Makoto</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morizane</LastName>
                    <ForeName>Chigusa</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Furuse</LastName>
                    <ForeName>Junji</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>29-A-3</GrantID>
                    <Agency>National Cancer Center Research and Development Fund</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Cancer</MedlineTA>
            <NlmUniqueID>100967800</NlmUniqueID>
            <ISSNLinking>1471-2407</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anaplastic carcinoma</Keyword>
            <Keyword MajorTopicYN="N">Chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">Gemcitabine</Keyword>
            <Keyword MajorTopicYN="N">Osteoclast-like giant cells</Keyword>
            <Keyword MajorTopicYN="N">Paclitaxel</Keyword>
            <Keyword MajorTopicYN="N">Pancreatic cancer</Keyword>
            <Keyword MajorTopicYN="N">Predictor</Keyword>
            <Keyword MajorTopicYN="N">Undifferentiated carcinoma</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>28</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33004032</ArticleId>
            <ArticleId IdType="doi">10.1186/s12885-020-07462-4</ArticleId>
            <ArticleId IdType="pii">10.1186/s12885-020-07462-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">33004031</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2407</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC cancer</Title>
            </Journal>
            <ArticleTitle>Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.</ArticleTitle>
            <Pagination>
                <MedlinePgn>944</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-020-07432-w</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Next-generation sequencing (NGS) has shown that recurrent/metastatic breast cancer lesions may have additional genetic changes compared with the primary tumor. These additional changes may be related to tumor progression and/or drug resistance. However, breast cancer-targeted NGS is not still widely used in clinical practice to compare the genomic profiles of primary breast cancer and recurrent/metastatic lesions.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Triplet samples of genomic DNA were extracted from each patient's normal breast tissue, primary breast cancer, and recurrent/metastatic lesion(s). A DNA library was constructed using the QIAseq Human Breast Cancer Panel (93 genes, Qiagen) and then sequenced using MiSeq (Illumina). The Qiagen web portal was utilized for data analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Successful results for three or four samples (normal breast tissue, primary tumor, and at least one metastatic/recurrent lesion) were obtained for 11 of 35 breast cancer patients with recurrence/metastases (36 samples). We detected shared somatic mutations in all but one patient, who had a germline mutation in TP53. Additional mutations that were detected in recurrent/metastatic lesions compared with primary tumor were in genes including TP53 (three patients) and one case each of ATR, BLM, CBFB, EP300, ERBB2, MUC16, PBRM1, and PIK3CA. Actionable mutations and/or copy number variations (CNVs) were detected in 73% (8/11) of recurrent/metastatic breast cancer lesions.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The QIAseq Human Breast Cancer Panel assay showed that recurrent/metastatic breast cancers sometimes acquired additional mutations and CNV. Such additional genomic changes could provide therapeutic target.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Akahane</LastName>
                    <ForeName>Toshiaki</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Hokuto Hospital, Obihiro, Hokkaido, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanomata</LastName>
                    <ForeName>Naoki</ForeName>
                    <Initials>N</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0172-4524</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, St. Luke's International Hospital, Akashi-cho 9-1, Chuoku, Tokyo, 104-8560, Japan. kanomnao@luke.ac.jp.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kawasaki Medical School, Kurashiki, Japan. kanomnao@luke.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harada</LastName>
                    <ForeName>Oi</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Hokuto Hospital, Obihiro, Hokkaido, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamashita</LastName>
                    <ForeName>Tetsumasa</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kurebayashi</LastName>
                    <ForeName>Junichi</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanimoto</LastName>
                    <ForeName>Akihide</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moriya</LastName>
                    <ForeName>Takuya</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kawasaki Medical School, Kurashiki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>17K08750</GrantID>
                    <Agency>Japan Society for the Promotion of Science</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>30-026</GrantID>
                    <Agency>Kawasaki Medical School</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Cancer</MedlineTA>
            <NlmUniqueID>100967800</NlmUniqueID>
            <ISSNLinking>1471-2407</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Metastasis</Keyword>
            <Keyword MajorTopicYN="N">Next-generation sequencing</Keyword>
            <Keyword MajorTopicYN="N">Recurrence</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>28</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33004031</ArticleId>
            <ArticleId IdType="doi">10.1186/s12885-020-07432-w</ArticleId>
            <ArticleId IdType="pii">10.1186/s12885-020-07432-w</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33003585</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">2072-6694</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>12</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancers</Title>
            </Journal>
            <ArticleTitle>Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E2809</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers12102809</ELocationID>
            <Abstract>
                <AbstractText>Chromosomal instability (CIN) is an emerging hallmark of cancer and its role in therapeutic responses has been increasingly attracting the attention of the research community. To target the vulnerability of tumors with high CIN, it is important to identify the genes and mechanisms involved in the maintenance of CIN. In our work, we recognize the tumor suppressor gene Phosphatase and Tensin homolog (<i>PTEN)</i> as a potential gene causing CIN in triple-negative breast cancer (TNBC) and show that TNBC with low expression levels of PTEN can be sensitized for the treatment with poly-(ADP-ribose)-polymerase 1 (PARP1) inhibitors, independent of Breast Cancer (BRCA) mutations or a BRCA-like phenotype. In silico analysis of mRNA expression data from 200 TNBC patients revealed low expression of PTEN in tumors with a high CIN70 score. Western blot analysis of TNBC cell lines confirm lower protein expression of PTEN compared to non TNBC cell lines. Further, PTEN-deficient cell lines showed cellular sensitivity towards PARP1 inhibition treatment. DNA fiber assays and examination of chromatin bound protein fractions indicate a protective role of PTEN at stalled replication forks. In this study, we recognize <i>PTEN</i> as a potential CIN-causing gene in TNBC and identify its important role in the replication processes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rieckhoff</LastName>
                    <ForeName>Johanna</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Radiobiology &amp; Experimental Radio Oncology, Centre of Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meyer</LastName>
                    <ForeName>Felix</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Radiobiology &amp; Experimental Radio Oncology, Centre of Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Classen</LastName>
                    <ForeName>Sandra</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Radiobiology &amp; Experimental Radio Oncology, Centre of Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zielinski</LastName>
                    <ForeName>Alexandra</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Radiobiology &amp; Experimental Radio Oncology, Centre of Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Riepen</LastName>
                    <ForeName>Britta</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Radiobiology &amp; Experimental Radio Oncology, Centre of Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wikman</LastName>
                    <ForeName>Harriet</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Tumor Biology, Center of Experimental Medicine, University Medical Center, Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Petersen</LastName>
                    <ForeName>Cordula</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiotherapy and Radio Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rothkamm</LastName>
                    <ForeName>Kai</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Radiobiology &amp; Experimental Radio Oncology, Centre of Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Borgmann</LastName>
                    <ForeName>Kerstin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Radiobiology &amp; Experimental Radio Oncology, Centre of Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parplys</LastName>
                    <ForeName>Ann Christin</ForeName>
                    <Initials>AC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Radiobiology &amp; Experimental Radio Oncology, Centre of Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>undefined</GrantID>
                    <Agency>Pro Exzellenzia</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>undefined</GrantID>
                    <Agency>Werner Otto Stiftung</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Cancers (Basel)</MedlineTA>
            <NlmUniqueID>101526829</NlmUniqueID>
            <ISSNLinking>2072-6694</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CIN</Keyword>
            <Keyword MajorTopicYN="N">PARP1 inhibition</Keyword>
            <Keyword MajorTopicYN="N">PTEN</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">replication fork instability</Keyword>
            <Keyword MajorTopicYN="N">replication stress</Keyword>
        </KeywordList>
        <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>1</Hour>
                <Minute>2</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003585</ArticleId>
            <ArticleId IdType="pii">cancers12102809</ArticleId>
            <ArticleId IdType="doi">10.3390/cancers12102809</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33003551</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">2072-6694</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>12</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancers</Title>
            </Journal>
            <ArticleTitle>Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E2804</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers12102804</ELocationID>
            <Abstract>
                <AbstractText>The prostate cancer (PCa) field lacks clinically relevant, syngeneic mouse models which retain the tumour microenvironment observed in PCa patients. This study establishes a cell line from prostate tumour tissue derived from the <i>Pten<sup>-/-</sup>/trp53<sup>-/-</sup></i> mouse, termed DVL3 which when subcutaneously implanted in immunocompetent C57BL/6 mice, forms tumours with distinct glandular morphology, strong cytokeratin 8 and androgen receptor expression, recapitulating high-risk localised human PCa. Compared to the commonly used TRAMP C1 model, generated with SV40 large T-antigen, DVL3 tumours are immunologically cold, with a lower proportion of CD8+ T-cells, and high proportion of immunosuppressive myeloid derived suppressor cells (MDSCs), thus resembling high-risk PCa. Furthermore, DVL3 tumours are responsive to fractionated RT, a standard treatment for localised and metastatic PCa, compared to the TRAMP C1 model. RNA-sequencing of irradiated DVL3 tumours identified upregulation of type-1 interferon and STING pathways, as well as transcripts associated with MDSCs. Upregulation of STING expression in tumour epithelium and the recruitment of MDSCs following irradiation was confirmed by immunohistochemistry. The DVL3 syngeneic model represents substantial progress in preclinical PCa modelling, displaying pathological, micro-environmental and treatment responses observed in molecular high-risk disease. Our study supports using this model for development and validation of treatments targeting PCa, especially novel immune therapeutic agents.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Haughey</LastName>
                    <ForeName>Charles M</ForeName>
                    <Initials>CM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast BT9 7AE, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mukherjee</LastName>
                    <ForeName>Debayan</ForeName>
                    <Initials>D</Initials>
                    <Identifier Source="ORCID">0000-0002-6356-0684</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Steele</LastName>
                    <ForeName>Rebecca E</ForeName>
                    <Initials>RE</Initials>
                    <Identifier Source="ORCID">0000-0003-4746-7348</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast BT9 7AE, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London SM2 5NG, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Popple</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dura-Perez</LastName>
                    <ForeName>Lara</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast BT9 7AE, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pickard</LastName>
                    <ForeName>Adam</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">0000-0001-9757-143X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast BT9 7AE, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Wellcome Centre for Cell Matrix Research, University of Manchester, Manchester M13 9PL, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Mehjabin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>Suneil</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast BT9 7AE, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mullan</LastName>
                    <ForeName>Paul B</ForeName>
                    <Initials>PB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast BT9 7AE, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Williams</LastName>
                    <ForeName>Rich</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast BT9 7AE, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oliveira</LastName>
                    <ForeName>Pedro</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Christie Hospital Foundation Trust, Manchester M20 4BX, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buckley</LastName>
                    <ForeName>Niamh E</ForeName>
                    <Initials>NE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast BT9 7AE, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Honeychurch</LastName>
                    <ForeName>Jamie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>S McDade</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">0000-0002-3024-4773</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast BT9 7AE, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Illidge</LastName>
                    <ForeName>Timothy</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PL, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Christie Hospital Foundation Trust, Manchester M20 4BX, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mills</LastName>
                    <ForeName>Ian G</ForeName>
                    <Initials>IG</Initials>
                    <Identifier Source="ORCID">0000-0001-5347-5083</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast BT9 7AE, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eddie</LastName>
                    <ForeName>Sharon L</ForeName>
                    <Initials>SL</Initials>
                    <Identifier Source="ORCID">0000-0002-6119-0480</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast BT9 7AE, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>MA-CE018-002</GrantID>
                    <Agency>Movember Foundation</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>PCUK PG13-021</GrantID>
                    <Acronym>PCUK_</Acronym>
                    <Agency>Prostate Cancer UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>studentship</GrantID>
                    <Agency>Gracey Foundation</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>2012MAYSF122</GrantID>
                    <Acronym>BBC_</Acronym>
                    <Agency>Breast Cancer Now</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>A17737</GrantID>
                    <Acronym>CRUK_</Acronym>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>C431/A28280</GrantID>
                    <Acronym>CRUK_</Acronym>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>NIHR-BRC-1215_20007</GrantID>
                    <Agency>NIHR Manchester BRC</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Cancers (Basel)</MedlineTA>
            <NlmUniqueID>101526829</NlmUniqueID>
            <ISSNLinking>2072-6694</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">myeloid-derived suppressor cells</Keyword>
            <Keyword MajorTopicYN="N">preclinical modelling</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">radiotherapy</Keyword>
            <Keyword MajorTopicYN="N">syngeneic model</Keyword>
            <Keyword MajorTopicYN="N">tumour microenvironment</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>1</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003551</ArticleId>
            <ArticleId IdType="pii">cancers12102804</ArticleId>
            <ArticleId IdType="doi">10.3390/cancers12102804</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33003540</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2073-4409</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cells</Title>
            </Journal>
            <ArticleTitle>Notch Signaling in Breast Cancer: A Role in Drug Resistance.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E2204</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/cells9102204</ELocationID>
            <Abstract>
                <AbstractText>Breast cancer is a heterogeneous disease that can be subdivided into unique molecular subtypes based on protein expression of the Estrogen Receptor, Progesterone Receptor, and/or the Human Epidermal Growth Factor Receptor 2. Therapeutic approaches are designed to inhibit these overexpressed receptors either by endocrine therapy, targeted therapies, or combinations with cytotoxic chemotherapy. However, a significant percentage of breast cancers are inherently resistant or acquire resistance to therapies, and mechanisms that promote resistance remain poorly understood. Notch signaling is an evolutionarily conserved signaling pathway that regulates cell fate, including survival and self-renewal of stem cells, proliferation, or differentiation. Deregulation of Notch signaling promotes resistance to targeted or cytotoxic therapies by enriching of a small population of resistant cells, referred to as breast cancer stem cells, within the bulk tumor; enhancing stem-like features during the process of de-differentiation of tumor cells; or promoting epithelial to mesenchymal transition. Preclinical studies have shown that targeting the Notch pathway can prevent or reverse resistance through reduction or elimination of breast cancer stem cells. However, Notch inhibitors have yet to be clinically approved for the treatment of breast cancer, mainly due to dose-limiting gastrointestinal toxicity. In this review, we discuss potential mechanisms of Notch-mediated resistance in breast cancer cells and breast cancer stem cells, and various methods of targeting Notch through γ-secretase inhibitors, Notch signaling biologics, or transcriptional inhibitors. We also discuss future plans for identification of novel Notch-targeted therapies, in order to reduce toxicity and improve outcomes for women with resistant breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>BeLow</LastName>
                    <ForeName>McKenna</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">0000-0002-2656-5187</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Integrated Cell Biology Program, Loyola University Chicago, Maywood, IL 60513, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osipo</LastName>
                    <ForeName>Clodia</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">0000-0003-1979-8465</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Integrated Cell Biology Program, Loyola University Chicago, Maywood, IL 60513, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Biology, Loyola University Chicago, Maywood, IL 60513, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL 60513, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AA013527</GrantID>
                    <Acronym>NH</Acronym>
                    <Agency>NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>2019-2020</GrantID>
                    <Agency>Breast Cancer Research Foundation</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Cells</MedlineTA>
            <NlmUniqueID>101600052</NlmUniqueID>
            <ISSNLinking>2073-4409</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Notch</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">cancer stem cells</Keyword>
            <Keyword MajorTopicYN="N">resistance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>1</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003540</ArticleId>
            <ArticleId IdType="pii">cells9102204</ArticleId>
            <ArticleId IdType="doi">10.3390/cells9102204</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33003486</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">2072-6694</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>12</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancers</Title>
            </Journal>
            <ArticleTitle>Cx43 and Associated Cell Signaling Pathways Regulate Tunneling Nanotubes in Breast Cancer Cells.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E2798</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers12102798</ELocationID>
            <Abstract>
                <AbstractText>Connexin 43 (Cx43) forms gap junctions that mediate the direct intercellular diffusion of ions and small molecules between adjacent cells. Cx43 displays both pro- and anti-tumorigenic properties, but the mechanisms underlying these characteristics are not fully understood. Tunneling nanotubes (TNTs) are long and thin membrane projections that connect cells, facilitating the exchange of not only small molecules, but also larger proteins, organelles, bacteria, and viruses. Typically, TNTs exhibit increased formation under conditions of cellular stress and are more prominent in cancer cells, where they are generally thought to be pro-metastatic and to provide growth and survival advantages. Cx43 has been described in TNTs, where it is thought to regulate small molecule diffusion through gap junctions. Here, we developed a high-fidelity CRISPR/Cas9 system to knockout (KO) Cx43. We found that the loss of Cx43 expression was associated with significantly reduced TNT length and number in breast cancer cell lines. Notably, secreted factors present in conditioned medium stimulated TNTs more potently when derived from Cx43-expressing cells than from KO cells. Moreover, TNT formation was significantly induced by the inhibition of several key cancer signaling pathways that both regulate Cx43 and are regulated by Cx43, including RhoA kinase (ROCK), protein kinase A (PKA), focal adhesion kinase (FAK), and p38. Intriguingly, the drug-induced stimulation of TNTs was more potent in Cx43 KO cells than in wild-type (WT) cells. In conclusion, this work describes a novel non-canonical role for Cx43 in regulating TNTs, identifies key cancer signaling pathways that regulate TNTs in this setting, and provides mechanistic insight into a pro-tumorigenic role of Cx43 in cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tishchenko</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patologia Molecular Translacional, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Azorín</LastName>
                    <ForeName>Daniel D</ForeName>
                    <Initials>DD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patologia Molecular Translacional, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vidal-Brime</LastName>
                    <ForeName>Laia</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patologia Molecular Translacional, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muñoz</LastName>
                    <ForeName>María José</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patologia Molecular Translacional, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arenas</LastName>
                    <ForeName>Pol Jiménez</ForeName>
                    <Initials>PJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patologia Molecular Translacional, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pearce</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patologia Molecular Translacional, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Girao</LastName>
                    <ForeName>Henrique</ForeName>
                    <Initials>H</Initials>
                    <Identifier Source="ORCID">0000-0002-5786-8447</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, Celas, 3000-548 Coimbra, Portugal.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Innovative Biomedicine and Biotechnology, University of Coimbra, 3000-548 Coimbra, Portugal.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Clinical Academic Centre of Coimbra, CACC, 3000-548 Coimbra, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramón Y Cajal</LastName>
                    <ForeName>Santiago</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Patologia Molecular Translacional, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Anatomía Patológica, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CIBER de Cáncer (CIBERONC), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 3-5, 28029 Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aasen</LastName>
                    <ForeName>Trond</ForeName>
                    <Initials>T</Initials>
                    <Identifier Source="ORCID">0000-0003-0763-2695</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Patologia Molecular Translacional, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CIBER de Cáncer (CIBERONC), Instituto de Salud Carlos III, Avenida de Monforte de Lemos 3-5, 28029 Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>PI16/00772; CPII16/00042</GrantID>
                    <Agency>European Regional Development Fund</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>PI16/00772; CPII16/00042</GrantID>
                    <Agency>Instituto de Salud Carlos III</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>Ideas Semillas 2020</GrantID>
                    <Agency>Fundación Científica Asociación Española Contra el Cáncer</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Cancers (Basel)</MedlineTA>
            <NlmUniqueID>101526829</NlmUniqueID>
            <ISSNLinking>2072-6694</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">cancer</Keyword>
            <Keyword MajorTopicYN="N">cell signaling</Keyword>
            <Keyword MajorTopicYN="N">cell–cell communication</Keyword>
            <Keyword MajorTopicYN="N">connexin 43</Keyword>
            <Keyword MajorTopicYN="N">gap junctions</Keyword>
            <Keyword MajorTopicYN="N">intercellular communication</Keyword>
            <Keyword MajorTopicYN="N">tumor microtubes</Keyword>
            <Keyword MajorTopicYN="N">tunneling nanotubes</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>1</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003486</ArticleId>
            <ArticleId IdType="pii">cancers12102798</ArticleId>
            <ArticleId IdType="doi">10.3390/cancers12102798</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33003468</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">1999-4923</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>12</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmaceutics</Title>
            </Journal>
            <ArticleTitle>Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E929</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics12100929</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) is one of the most aggressive types of breast cancer. Owing to the absenteeism of hormonal receptors expressed at the cancerous breast cells, hormonal therapies and other medications targeting human epidermal growth factor receptor 2 (HER2) are ineffective in TNBC patients, making traditional chemotherapeutic agents the only current appropriate regimen. Patients' predisposition to relapse and metastasis, chemotherapeutics' cytotoxicity and resistance and poor prognosis of TNBC necessitates researchers to investigate different novel-targeted therapeutics. The role of small interfering RNA (siRNA) in silencing the genes/proteins that are aberrantly overexpressed in carcinoma cells showed great potential as part of TNBC therapeutic regimen. However, targeting specificity, siRNA stability, and delivery efficiency cause challenges in the progression of this application clinically. Nanotechnology was highlighted as a promising approach for encapsulating and transporting siRNA with high efficiency-low toxicity profile. Advances in preclinical and clinical studies utilizing engineered siRNA-loaded nanotherapeutics for treatment of TNBC were discussed. Specific and selective targeting of diverse signaling molecules/pathways at the level of tumor proliferation and cell cycle, tumor invasion and metastasis, angiogenesis and tumor microenvironment, and chemotherapeutics' resistance demonstrated greater activity via integration of siRNA-complexed nanoparticles.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hattab</LastName>
                    <ForeName>Dima</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, University of Jordan, Queen Rania Street, 11942 Amman, Jordan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bakhtiar</LastName>
                    <ForeName>Athirah</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">0000-0003-2752-9783</Identifier>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Monash University Malaysia, Bandar Sunway, 47500 Selangor, Malaysia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Pharmaceutics</MedlineTA>
            <NlmUniqueID>101534003</NlmUniqueID>
            <ISSNLinking>1999-4923</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">RNA interference</Keyword>
            <Keyword MajorTopicYN="N">gene silencing</Keyword>
            <Keyword MajorTopicYN="N">small interfering RNA (siRNA), nanotechnology</Keyword>
            <Keyword MajorTopicYN="N">triple negative breast cancer (TNBC)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>1</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003468</ArticleId>
            <ArticleId IdType="pii">pharmaceutics12100929</ArticleId>
            <ArticleId IdType="doi">10.3390/pharmaceutics12100929</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33003428</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">2077-0383</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical medicine</Title>
            </Journal>
            <ArticleTitle>Expression of MTDH and IL-10 Is an Independent Predictor of Worse Prognosis in ER-Negative or PR-Negative Breast Cancer Patients.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E3153</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm9103153</ELocationID>
            <Abstract>
                <AbstractText>(1) Background: Tumor hypoxia leads to metastasis and certain immune responses, and interferes with normal biological functions. It also affects glucose intake, down-regulates oxidative phosphorylation, and inhibits fatty-acid desaturation regulated by hypoxia-inducible factor 1α (HIF-1α). Although tumor hypoxia has been found to promote tumor metastasis, the roles of HIF-1α-regulated genes and their application are not completely integrated in clinical practice. (2) Methods: We examined the correlation between HIF-1α, metadherin (MTDH), and interleukin (IL)-10 mRNA expression, as well as their expression patterns in the prognosis of breast cancer using the Gene Expression Profiling Interactive Analysis (GEPIA) databases via a web interface; tissue microarrays (TMAs) were stained for MTDH and IL-10 protein expression using immunohistochemistry. (3) Results: HIF-1α, MTDH, and IL-10 mRNA expression are highly correlated and strongly associated with poor prognosis. MTDH and IL-10 protein expression of breast cancer patients usually harbored negative estrogen receptor (ER) or progesterone receptor (PR) status, and late-stage tumors have higher IL-10 expression. With regard to MTDH and IL-10 protein expression status for using univariate and multivariate analysis, the results showed that the protein expression of MTDH and IL-10 in ER-negative or PR-negative breast cancer patients have the worse prognosis. (4) Conclusions: we propose a new insight into hypoxia tumors in the metabolism and immune evidence for breast cancer therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chu</LastName>
                    <ForeName>Pei-Yi</ForeName>
                    <Initials>PY</Initials>
                    <Identifier Source="ORCID">0000-0001-7336-2465</Identifier>
                    <AffiliationInfo>
                        <Affiliation>School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei 242, Taiwan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Show Chwan Memorial Hospital, Changhua 500, Taiwan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Food, Chung Chou University of Science and Technology, Changhua 510, Taiwan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>National Institute of Cancer Research, National Health Research Institute, Tainan 704, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Shin-Mae</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery, Show Chwan Memorial Hospital, Changhua 500, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Po-Ming</ForeName>
                    <Initials>PM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Assistant Center, Show Chwan Memorial Hospital, Changhua 500, Taiwan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Food Science and Biotechnology, National Chung Hsing University, Taichung 40402, Taiwan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Innovation and Development Center of Sustainable Agriculture (IDCSA), National Chung Hsing University, Taichung 402, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Feng-Yao</ForeName>
                    <Initials>FY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Science Laboratory, Department of Nutrition, China Medical University, Taichung 40402, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chiang</LastName>
                    <ForeName>En-Pei Isabel</ForeName>
                    <Initials>EI</Initials>
                    <Identifier Source="ORCID">0000-0002-0158-0962</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Food Science and Biotechnology, National Chung Hsing University, Taichung 40402, Taiwan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Innovation and Development Center of Sustainable Agriculture (IDCSA), National Chung Hsing University, Taichung 402, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>J Clin Med</MedlineTA>
            <NlmUniqueID>101606588</NlmUniqueID>
            <ISSNLinking>2077-0383</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">IL-10</Keyword>
            <Keyword MajorTopicYN="N">MTDH</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">hypoxia</Keyword>
            <Keyword MajorTopicYN="N">survival</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>1</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003428</ArticleId>
            <ArticleId IdType="pii">jcm9103153</ArticleId>
            <ArticleId IdType="doi">10.3390/jcm9103153</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33003415</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">1424-8247</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmaceuticals (Basel, Switzerland)</Title>
            </Journal>
            <ArticleTitle>Pharmacological Modulation of Blood-Brain Barrier Permeability by Kinin Analogs in Normal and Pathologic Conditions.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E279</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/ph13100279</ELocationID>
            <Abstract>
                <AbstractText>The blood-brain barrier (BBB) is a major obstacle to the development of effective diagnostics and therapeutics for brain cancers and other central nervous system diseases. Peptide agonist analogs of kinin B1 and B2 receptors, acting as BBB permeabilizers, have been utilized to overcome this barrier. The purpose of the study was to provide new insights for the potential utility of kinin analogs as brain drug delivery adjuvants. In vivo imaging studies were conducted in various animal models (primary/secondary brain cancers, late radiation-induced brain injury) to quantify BBB permeability in response to kinin agonist administrations. Results showed that kinin B1 (B1R) and B2 receptors (B2R) agonists increase the BBB penetration of chemotherapeutic doxorubicin to glioma sites, with additive effects when applied in combination. B2R agonist also enabled extravasation of high-molecular-weight fluorescent dextrans (155 kDa and 2 MDa) in brains of normal mice. Moreover, a systemic single dose of B2R agonist did not increase the incidence of metastatic brain tumors originating from circulating breast cancer cells. Lastly, B2R agonist promoted the selective delivery of co-injected diagnostic MRI agent Magnevist in irradiated brain areas, depicting increased vascular B2R expression. Altogether, our findings suggest additional evidence for using kinin analogs to facilitate specific access of drugs to the brain.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sikpa</LastName>
                    <ForeName>Dina</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine &amp; Radiobiology, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Whittingstall</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine &amp; Radiobiology, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Savard</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology &amp; Physiology, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lebel</LastName>
                    <ForeName>Réjean</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine &amp; Radiobiology, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Côté</LastName>
                    <ForeName>Jérôme</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology &amp; Physiology, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McManus</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology &amp; Physiology, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chemtob</LastName>
                    <ForeName>Sylvain</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology &amp; Physiology, Université de Montréal, Montréal, QC H2X 0A9, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fortin</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lepage</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nuclear Medicine &amp; Radiobiology, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gobeil</LastName>
                    <ForeName>Fernand</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology &amp; Physiology, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>MOP-273995</GrantID>
                    <Acronym>CAPMC</Acronym>
                    <Agency> CIHR</Agency>
                    <Country>Canada</Country>
                </Grant>
                <Grant>
                    <GrantID>N/A</GrantID>
                    <Agency>Drug Research Quebec Network (RQRM)</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Pharmaceuticals (Basel)</MedlineTA>
            <NlmUniqueID>101238453</NlmUniqueID>
            <ISSNLinking>1424-8247</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CNS diseases</Keyword>
            <Keyword MajorTopicYN="N">G protein-coupled receptors</Keyword>
            <Keyword MajorTopicYN="N">blood–brain barrier permeability</Keyword>
            <Keyword MajorTopicYN="N">chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">kinin analogs</Keyword>
            <Keyword MajorTopicYN="N">radiotherapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>1</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003415</ArticleId>
            <ArticleId IdType="pii">ph13100279</ArticleId>
            <ArticleId IdType="doi">10.3390/ph13100279</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">33003386</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">2072-6694</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>12</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancers</Title>
            </Journal>
            <ArticleTitle>Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E2795</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers12102795</ELocationID>
            <Abstract>
                <AbstractText>The multifunctional protein Y-box binding protein-1 (YB-1) regulates all the so far described cancer hallmarks including cell proliferation and survival. The MAPK/ERK and PI3K/Akt pathways are also the major pathways involved in cell growth, proliferation, and survival, and are the frequently hyperactivated pathways in human cancers. A gain of function mutation in <i>KRAS</i> mainly leads to the constitutive activation of the MAPK pathway, while the activation of the PI3K/Akt pathway occurs either through the loss of PTEN or a gain of function mutation of the catalytic subunit alpha of PI3K (<i>PIK3CA</i>). In this study, we investigated the underlying signaling pathway involved in YB-1 phosphorylation at serine 102 (S102) in <i>KRAS(G13D)</i>-mutated triple-negative breast cancer (TNBC) MDA-MB-231 cells versus <i>PIK3CA(H1047R)</i>/<i>PTEN(E307K)</i> mutated TNBC MDA-MB-453 cells. Our data demonstrate that S102 phosphorylation of YB-1 in <i>KRAS</i>-mutated cells is mainly dependent on the MAPK/ERK pathway, while in <i>PIK3CA</i>/<i>PTEN</i>-mutated cells, YB-1 S102 phosphorylation is entirely dependent on the PI3K/Akt pathway. Independent of the individual dominant pathway regulating YB-1 phosphorylation, dual targeting of MEK and PI3K efficiently inhibited YB-1 phosphorylation and blocked cell proliferation. This represents functional crosstalk between the two pathways. Our data obtained from the experiments, applying pharmacological inhibitors and genetic approaches, shows that YB-1 is a key player in cell proliferation, clonogenic activity, and tumor growth of TNBC cells through the MAPK and PI3K pathways. Therefore, dual inhibition of these two pathways or single targeting of YB-1 may be an effective strategy to treat TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tiwari</LastName>
                    <ForeName>Aadhya</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Radiobiology and Molecular Environmental Research, Department of Radiation Oncology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>German Cancer Consortium (DKTK), Partner Site Tuebingen and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iida</LastName>
                    <ForeName>Mari</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">0000-0001-7168-8680</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kosnopfel</LastName>
                    <ForeName>Corinna</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">0000-0002-0910-838X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Dermatology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abbariki</LastName>
                    <ForeName>Mahyar</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Menegakis</LastName>
                    <ForeName>Apostolos</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>German Cancer Consortium (DKTK), Partner Site Tuebingen and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fehrenbacher</LastName>
                    <ForeName>Birgit</ForeName>
                    <Initials>B</Initials>
                    <Identifier Source="ORCID">0000-0003-3022-7567</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Dermatology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maier</LastName>
                    <ForeName>Julia</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Natural and Medical Sciences Institute, University of Tuebingen, 72770 Reutlingen, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Pharmaceutical Biotechnology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schaller</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Dermatology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brucker</LastName>
                    <ForeName>Sara Y</ForeName>
                    <Initials>SY</Initials>
                    <Identifier Source="ORCID">0000-0001-5162-1542</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Women's Health, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wheeler</LastName>
                    <ForeName>Deric L</ForeName>
                    <Initials>DL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harari</LastName>
                    <ForeName>Paul M</ForeName>
                    <Initials>PM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rothbauer</LastName>
                    <ForeName>Ulrich</ForeName>
                    <Initials>U</Initials>
                    <Identifier Source="ORCID">0000-0001-5923-8986</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Natural and Medical Sciences Institute, University of Tuebingen, 72770 Reutlingen, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Pharmaceutical Biotechnology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schittek</LastName>
                    <ForeName>Birgit</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Dermatology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zips</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Radiobiology and Molecular Environmental Research, Department of Radiation Oncology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>German Cancer Consortium (DKTK), Partner Site Tuebingen and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Toulany</LastName>
                    <ForeName>Mahmoud</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Radiobiology and Molecular Environmental Research, Department of Radiation Oncology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Tuebingen, 72076 Tuebingen, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>German Cancer Consortium (DKTK), Partner Site Tuebingen and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DFG TO 685/2-1</GrantID>
                    <Agency>Deutsche Forschungsgemeinschaft</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Cancers (Basel)</MedlineTA>
            <NlmUniqueID>101526829</NlmUniqueID>
            <ISSNLinking>2072-6694</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">KRAS</Keyword>
            <Keyword MajorTopicYN="N">MAPK/ERK</Keyword>
            <Keyword MajorTopicYN="N">PI3K/Akt</Keyword>
            <Keyword MajorTopicYN="N">PIK3CA</Keyword>
            <Keyword MajorTopicYN="N">PTEN</Keyword>
            <Keyword MajorTopicYN="N">YB-1</Keyword>
            <Keyword MajorTopicYN="N">triple negative breast cancer cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>1</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003386</ArticleId>
            <ArticleId IdType="pii">cancers12102795</ArticleId>
            <ArticleId IdType="doi">10.3390/cancers12102795</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33003314</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2073-4425</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Genes</Title>
            </Journal>
            <ArticleTitle>Comprehensive Analysis of <i>ABCG2</i> Genetic Variation in the Polish Population and Its Inter-Population Comparison.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E1144</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/genes11101144</ELocationID>
            <Abstract>
                <AbstractText>ATP-binding cassette sub-family G member 2 (ABCG2), also known as breast cancer resistance protein (BCRP), is one of the key efflux ATP-binding cassette (ABC) transporters of xenobiotics, their metabolites and endogenous compounds such as urate. Some of its genetic variants have been found to influence protein functioning, resulting in serious clinical implications concerning chemotherapy response, as well as gout or blood group phenotype Jr(a-). Previous reports have suggested that the frequencies of certain crucial polymorphisms, such as c.34G&gt;A (p.Val12Met) and c.421C&gt;A (p.Gln141Lys) differ significantly between the Polish population and other Caucasian populations. Thus, to clarify this issue, the present study performs a complete analysis of the genetic variation of <i>ABCG2</i> coding sequence in the Polish population. The genetic variation in 14 out of 15 coding exons of the <i>ABCG2</i> gene, as well as their flanking intron sequences, were examined among 190 healthy representatives of the Polish population using scanning with High Resolution Melting (HRM). HRM scanning revealed 17 polymorphisms: eight in the exons (including five missense variants and one point-nonsense mutation) and nine in the intron sequences (eight single nucleotide polymorphisms (SNPs) and one deletion variant). These included variants correlating with the presence of gout and phenotype Jr(a-). Linkage disequilibrium, haplotype blocks and haplotype analyses were also performed. The frequencies of the most common polymorphisms in the Polish population did not differ significantly to those observed for other Caucasian populations, but demonstrated divergence from non-Caucasian populations. We hope that our findings may be helpful for other researchers and clinicians, evaluating the pharmacogenetic role of <i>ABCG2</i>.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Słomka</LastName>
                    <ForeName>Marcin</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">0000-0002-7906-5549</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Biobank Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, Pilarskiego 14/16, 90-231 Łódź, Poland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>BBMRI.pl Consortium, 54-066 Wrocław, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sobalska-Kwapis</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biobank Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, Pilarskiego 14/16, 90-231 Łódź, Poland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>BBMRI.pl Consortium, 54-066 Wrocław, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Korycka-Machała</LastName>
                    <ForeName>Małgorzata</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Biology, Polish Academy of Sciences, Lodowa 106, 93-232 Łódź, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dziadek</LastName>
                    <ForeName>Jarosław</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">0000-0003-1427-884X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Biology, Polish Academy of Sciences, Lodowa 106, 93-232 Łódź, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bartosz</LastName>
                    <ForeName>Grzegorz</ForeName>
                    <Initials>G</Initials>
                    <Identifier Source="ORCID">0000-0002-0347-0740</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, Pomorska 141/143, 90-236 Łódź, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strapagiel</LastName>
                    <ForeName>Dominik</ForeName>
                    <Initials>D</Initials>
                    <Identifier Source="ORCID">0000-0001-9752-4270</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Biobank Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, Pilarskiego 14/16, 90-231 Łódź, Poland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>BBMRI.pl Consortium, 54-066 Wrocław, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>01.01.02-10-005/08 TESTOPLEK</GrantID>
                    <Agency>European Regional Development Fund</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Genes (Basel)</MedlineTA>
            <NlmUniqueID>101551097</NlmUniqueID>
            <ISSNLinking>2073-4425</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ABCG2</Keyword>
            <Keyword MajorTopicYN="N">BCRP</Keyword>
            <Keyword MajorTopicYN="N">High Resolution Melting</Keyword>
            <Keyword MajorTopicYN="N">Polish population</Keyword>
            <Keyword MajorTopicYN="N">gene scanning</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>1</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003314</ArticleId>
            <ArticleId IdType="pii">genes11101144</ArticleId>
            <ArticleId IdType="doi">10.3390/genes11101144</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">33003293</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1422-0067</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <Issue>19</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of molecular sciences</Title>
            </Journal>
            <ArticleTitle>Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E7178</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21197178</ELocationID>
            <Abstract>
                <AbstractText>Interferons are crucial for adaptive immunity and play an important role in the immune landscape of breast cancer. Using microarray-based gene expression analysis, we examined the subtype-specific prognostic significance of interferon-γ (IFN-γ) as a single gene as well as an IFN-γ signature covering the signaling pathway in 461 breast cancer patients. Prognostic significance of IFN-γ, as well as the IFN-γ signature for metastasis-free survival (MFS), were examined using Kaplan-Meier as well as univariate and multivariate Cox regression analyses in the whole cohort and in different molecular subtypes. The independent prognostic significance of IFN-γ as a single gene was limited to basal-like breast cancer (hazard ratio (HR) 2.779, 95% confidence interval (95% CI) 1.117-6.919, <i>p</i> = 0.028). In contrast, the IFN-γ-associated gene signature was an independent prognostic factor in the whole cohort (HR 2.287, 95% CI 1.410-3.633, <i>p</i> &lt; 0.001) as well as in the basal-like (HR 3.458, 95% CI 1.154-10.359, <i>p</i> = 0.027) and luminal B (HR 2.690, 95% CI 1.416-5.112, <i>p</i> = 0.003) molecular subtypes. These results underline the subtype-dependent prognostic influence of the immune system in early breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Heimes</LastName>
                    <ForeName>Anne-Sophie</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University Medical Center Mainz, 55131 Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Härtner</LastName>
                    <ForeName>Franziska</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center Mainz, 55131 Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Almstedt</LastName>
                    <ForeName>Katrin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University Medical Center Mainz, 55131 Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krajnak</LastName>
                    <ForeName>Slavomir</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University Medical Center Mainz, 55131 Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lebrecht</LastName>
                    <ForeName>Antje</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University Medical Center Mainz, 55131 Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Battista</LastName>
                    <ForeName>Marco J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University Medical Center Mainz, 55131 Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Edlund</LastName>
                    <ForeName>Karolina</ForeName>
                    <Initials>K</Initials>
                    <Identifier Source="ORCID">0000-0002-0276-2143</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Leibniz-Research Centre for Working Environment and Human Factors at the TU Dortmund (IfADo), 44139 Dortmund, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brenner</LastName>
                    <ForeName>Walburgis</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University Medical Center Mainz, 55131 Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hasenburg</LastName>
                    <ForeName>Annette</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">0000-0002-1547-4968</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University Medical Center Mainz, 55131 Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sahin</LastName>
                    <ForeName>Ugur</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>TRON-Translational Oncology at the University Medical Center Mainz, 55131 Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gehrmann</LastName>
                    <ForeName>Mathias</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bayer AG, 42113 Wuppertal, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hengstler</LastName>
                    <ForeName>Jan G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Leibniz-Research Centre for Working Environment and Human Factors at the TU Dortmund (IfADo), 44139 Dortmund, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmidt</LastName>
                    <ForeName>Marcus</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">0000-0003-1365-2414</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University Medical Center Mainz, 55131 Mainz, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>no. 01GR0816</GrantID>
                    <Agency>Federal Ministry of Education and 394 Research</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Int J Mol Sci</MedlineTA>
            <NlmUniqueID>101092791</NlmUniqueID>
            <ISSNLinking>1422-0067</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">interferon</Keyword>
            <Keyword MajorTopicYN="N">molecular subtypes</Keyword>
            <Keyword MajorTopicYN="N">prognosis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>1</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003293</ArticleId>
            <ArticleId IdType="pii">ijms21197178</ArticleId>
            <ArticleId IdType="doi">10.3390/ijms21197178</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33003262</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-685X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>159</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of thoracic and cardiovascular surgery</Title>
            </Journal>
            <ArticleTitle>Perioperative outcomes among chronic opioid users who receive lobectomy for non-small cell lung cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>691-702.e5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0022-5223(19)32058-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtcvs.2019.09.059</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We sought to identify whether chronic opioid users are at increased risk for complications or hospital readmission following lobectomy for non-small cell lung cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The National Cancer Institute Surveillance, Epidemiology, and End Results-Medicare database was queried to identify patients older than age 65 years who received a lobectomy for non-small cell lung cancer. Chronic opioid users were identified through Medicare Part D records and were defined as those with &gt;120 cumulative days of opioid supply for the year before surgery. A systematic 1:2 propensity matching was performed among chronic opioid users.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Six thousand four hundred thirty-seven patients were identified, among whom 3627 (56%) were opioid naïve, 1866 (29%) were intermittent opioid users, and 944 (15%) were chronic opioid users. After propensity matching, 30-day mortality and 90-day mortality were nearly 2-fold higher among chronic opioid users compared with nonchronic users. In addition, length of stay and hospital charges were increased among chronic opioid users (median, 6 vs 7 days and mean increase, $12,526, respectively). Multivariable analysis revealed that intermittent opioid users and chronic opioid users were associated with an increased risk of 90-day hospital readmission compared with opioid-naïve patients (odds ratio, 1.35; 95% confidence interval, 1.07-1.71 and odds ratio, 1.72; 95% confidence interval, 1.40-2.12, respectively), predominantly burdened by infectious, renal, and pulmonary causes.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients who chronically use opioids before lobectomy represent high-risk patients. The risk of 30- and 90-day mortality, length of stay, hospital charges, and 90-day readmission after lobectomy among chronic opioid users are substantially elevated.</AbstractText>
                <CopyrightInformation>Copyright © 2019 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>David B</ForeName>
                    <Initials>DB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Niu</LastName>
                    <ForeName>Jiangong</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Tex.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mitchell</LastName>
                    <ForeName>Kyle G</ForeName>
                    <Initials>KG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Antonoff</LastName>
                    <ForeName>Mara B</ForeName>
                    <Initials>MB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giordano</LastName>
                    <ForeName>Sharon H</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Tex; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hofstetter</LastName>
                    <ForeName>Wayne L</ForeName>
                    <Initials>WL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vaporciyan</LastName>
                    <ForeName>Ara A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sepesi</LastName>
                    <ForeName>Boris</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mehran</LastName>
                    <ForeName>Reza J</ForeName>
                    <Initials>RJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rice</LastName>
                    <ForeName>David C</ForeName>
                    <Initials>DC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex. Electronic address: drice@mdanderson.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Thorac Cardiovasc Surg</MedlineTA>
            <NlmUniqueID>0376343</NlmUniqueID>
            <ISSNLinking>0022-5223</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">lobectomy</Keyword>
            <Keyword MajorTopicYN="N">lung cancer</Keyword>
            <Keyword MajorTopicYN="N">opioid dependency</Keyword>
            <Keyword MajorTopicYN="N">perioperative morbidity</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>1</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003262</ArticleId>
            <ArticleId IdType="pii">S0022-5223(19)32058-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jtcvs.2019.09.059</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33003135</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1530-0374</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Menopause (New York, N.Y.)</Title>
            </Journal>
            <ArticleTitle>Vasomotor symptoms, cognition, and breast cancer: another important piece of the puzzle.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/GME.0000000000001660</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Soares</LastName>
                    <ForeName>Claudio N</ForeName>
                    <Initials>CN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, Queen's University School of Medicine, Kingston, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Menopause</MedlineTA>
            <NlmUniqueID>9433353</NlmUniqueID>
            <ISSNLinking>1072-3714</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>20</Hour>
                <Minute>23</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003135</ArticleId>
            <ArticleId IdType="doi">10.1097/GME.0000000000001660</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33003122</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1538-9804</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer nursing</Title>
            </Journal>
            <ArticleTitle>Quality of Life and Prolonged Symptoms in Korean Breast Cancer Survivors.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/NCC.0000000000000894</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A culture of serious overwork in South Korea, more than other developed countries, may impact symptoms and quality of life (QOL) experienced by Korean breast cancer survivors (BCS).</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to examine health-related QOL and influencing factors in BCS in Seoul, Korea, who have recovered from treatment for at least 1 year and returned to normal life and work.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In a cross-sectional study, 199 BCS completed a self-administered questionnaire in Seoul, Korea.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean QOL scores were lower than expected, with 49% of the variance explained by depressive symptoms, physical fatigability, cognitive impairment, and social support. Psychological distress was high (67.8%), along with anxiety (47.2%) and depressive symptoms (36.7%). Participants reported a high prevalence of physical fatigability (71.1%), sleeping an average of only 6 hours per night, with 58.9% reporting poor quality sleep.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Quality of life was lower in Korean BCS than comparable studies in the United States, although participants received care at a premiere medical center. Depressive symptoms and anxiety were common and did not taper off over the 5 years after diagnosis, unlike BCS elsewhere. Korean survivors experienced significant physical fatigability, much higher than reported in a US study of mixed male and female cancer survivors. Overwork was not a significant predictor of QOL, although 30% of employed women reported working 45 to 90 hours weekly.</AbstractText>
                <AbstractText Label="IMPLICATIONS FOR PRACTICE" NlmCategory="CONCLUSIONS">Findings demonstrate the importance of continued efforts to mitigate these symptoms in clinical survivorship care, as well as future research, to provide avenues for improving QOL for BCS, particularly in Korea.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jang</LastName>
                    <ForeName>Min Kyeong</ForeName>
                    <Initials>MK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Author Affiliations: Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago (Drs Jang, Park, Collins, Quinn, and Ferrans); University of Illinois Cancer Center, Chicago (Dr Jang); and College of Nursing, Yonsei University, Seoul, Korea (Dr Kim).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Sue</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Chang Gi</ForeName>
                    <Initials>CG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Collins</LastName>
                    <ForeName>Eileen G</ForeName>
                    <Initials>EG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quinn</LastName>
                    <ForeName>Lauretta T</ForeName>
                    <Initials>LT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferrans</LastName>
                    <ForeName>Carol Estwing</ForeName>
                    <Initials>CE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Nurs</MedlineTA>
            <NlmUniqueID>7805358</NlmUniqueID>
            <ISSNLinking>0162-220X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CitationSubset>N</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>20</Hour>
                <Minute>22</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33003122</ArticleId>
            <ArticleId IdType="doi">10.1097/NCC.0000000000000894</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33002949</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1531-6963</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Current opinion in rheumatology</Title>
            </Journal>
            <ArticleTitle>Cancer and scleroderma: recent insights.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/BOR.0000000000000755</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">As survival in systemic sclerosis (SSc) improves, research interest has shifted to the leading cause of non-SSc related death, namely cancer, which accounts for over a third of non-SSc related deaths. This review will provide an overview of the recent insights into the evolving relationship between SSc and cancer.</AbstractText>
                <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Recent studies confirm the increased risk of cancer in SSc compared with the general population [standardised incidence ratio 1.9-2.2] in particular the risk of breast, lung and skin cancer. This increased cancer risk, particularly occurring in close proximity to SSc onset, raises the novel concept of autoimmunity occurring as a direct immune response to the cancerous cells. We highlight the important role that SSc-specific autoantibodies may have in identifying these at-risk patients, prognostication and triaging those who may require tight surveillance and further cancer screening.</AbstractText>
                <AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">This knowledge will allow the development of future prospective studies evaluating clinically relevant and targeted cancer screening strategies for newly diagnosed SSc patients in order to optimise cancer detection while minimising harms and costs from over-screening.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Morrisroe</LastName>
                    <ForeName>Kathleen</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, The University of Melbourne at St Vincent's Hospital (Melbourne), 41 Victoria Parade, Fitzroy 3065, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Rheumatology St Vincent's Hospital (Melbourne), 41 Victoria Parade, Fitzroy 3065, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nikpour</LastName>
                    <ForeName>Mandana</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, The University of Melbourne at St Vincent's Hospital (Melbourne), 41 Victoria Parade, Fitzroy 3065, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Rheumatology St Vincent's Hospital (Melbourne), 41 Victoria Parade, Fitzroy 3065, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Curr Opin Rheumatol</MedlineTA>
            <NlmUniqueID>9000851</NlmUniqueID>
            <ISSNLinking>1040-8711</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>20</Hour>
                <Minute>22</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002949</ArticleId>
            <ArticleId IdType="doi">10.1097/BOR.0000000000000755</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33002501</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2422</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental cell research</Title>
            </Journal>
            <ArticleTitle>Noncanonical pS727 post translational modification dictates major STAT3 activation and downstream functions in breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>112313</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0014-4827(20)30562-0</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexcr.2020.112313</ELocationID>
            <Abstract>
                <AbstractText>Activation of STAT3 via Y705-phosphorylation is well documented across multiple cancer types and thus forms the basis of canonical pathway to judge STAT3 activation. Recently, important roles of two other post-translational modification (PTM) sites, i.e. S727-phosphorylation and K685-acetylation, leading to STAT3 activation are reported. However, their critical mode of function in controlling STAT3 dimerization and signaling, independent of canonical activation remains elusive. Therefore, to understand the functional relevance of each STAT3 PTMs in breast cancer (BC), cell models are developed by stable overexpression of PTM-site specific point mutants, i.e. Y705F, S727A or K685R, in a 3'UTR-STAT3 knockdown BC cell background. Results using this model system reveal novel findings showing that phosphorylation at S727 can lead to STAT3 activation independent of phosphoY705. We also demonstrate that loss of pS727 or K685ac significantly affects functional phenotypes such as cell survival and proliferation as well as downstream transcriptional activity (Twist 1, Socs3, c-Myc, Bcl-1 and Mcl-1) of STAT3. Thereafter, by utilizing a BRET biosensor for measuring STAT3 phosphorylation in live cells, a crucial role of pS727 in dictating STAT3 activation and homodimerization formation is uncovered. Further by performing retrospective IHC analysis of total and phospho-forms of STAT3 in a cohort of 76 triple negative breast cancer (TNBC) patient samples, a significant dominant expression of phosphoS727 over phosphoY705 PTM (p &lt; 0.001) is found in STAT3 positive cases. We also focus on validating known STAT3 inhibitor molecules for their action against both pY705 and pS727 activation. This study for the first time demonstrates that an anti-helminth drug compound, Niclosamide, is capable of inactivating both phospho-PTM sites on STAT3 and exhibits excellent anticancer efficacy in preclinical TNBC tumour model.</AbstractText>
                <CopyrightInformation>Copyright © 2020. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dimri</LastName>
                    <ForeName>Shalini</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Functional Imaging Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India; Homi Bhabha National Institute, Mumbai, India. Electronic address: yashree.dimri@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malhotra</LastName>
                    <ForeName>Renu</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Functional Imaging Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India. Electronic address: renu_d16@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shet</LastName>
                    <ForeName>Tanuja</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tata Memorial Hospital, Mumbai, India; Homi Bhabha National Institute, Mumbai, India. Electronic address: tanujashet5@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mokal</LastName>
                    <ForeName>Smruti</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tata Memorial Hospital, Mumbai, India; Homi Bhabha National Institute, Mumbai, India. Electronic address: smruti272mokal@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gupta</LastName>
                    <ForeName>Sudeep</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tata Memorial Hospital, Mumbai, India; Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India; Homi Bhabha National Institute, Mumbai, India. Electronic address: sudeepgupta04@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De</LastName>
                    <ForeName>Abhijit</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Functional Imaging Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India; Homi Bhabha National Institute, Mumbai, India. Electronic address: ade@actrec.gov.in.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Exp Cell Res</MedlineTA>
            <NlmUniqueID>0373226</NlmUniqueID>
            <ISSNLinking>0014-4827</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">)</Keyword>
            <Keyword MajorTopicYN="N">Bioluminescence resonance energy transfer (BRET)</Keyword>
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Niclosamide</Keyword>
            <Keyword MajorTopicYN="N">Post translational modification (PTM</Keyword>
            <Keyword MajorTopicYN="N">STAT3</Keyword>
            <Keyword MajorTopicYN="N">Triple negative breast cancer (TNBC)</Keyword>
        </KeywordList>
        <CoiStatement>Declaration of competing interest All the authors declare that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>04</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>20</Hour>
                <Minute>11</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002501</ArticleId>
            <ArticleId IdType="pii">S0014-4827(20)30562-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yexcr.2020.112313</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33002445</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1474-5488</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Lancet. Oncology</Title>
            </Journal>
            <ArticleTitle>Stewart-Treves syndrome: a rapidly fatal complication of breast cancer treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e495</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1470-2045(20)30274-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(20)30274-6</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hsu</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology/Oncology, Warren Alpert Medical School at Brown University, Providence, RI, USA. Electronic address: andrew_hsu1@brown.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matera</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Warren Alpert Medical School at Brown University, Providence, RI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dizon</LastName>
                    <ForeName>Don S</ForeName>
                    <Initials>DS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology/Oncology, Warren Alpert Medical School at Brown University, Providence, RI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Lancet Oncol</MedlineTA>
            <NlmUniqueID>100957246</NlmUniqueID>
            <ISSNLinking>1470-2045</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>04</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>04</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>04</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>20</Hour>
                <Minute>10</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002445</ArticleId>
            <ArticleId IdType="pii">S1470-2045(20)30274-6</ArticleId>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30274-6</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33002444</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1474-5488</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Lancet. Oncology</Title>
            </Journal>
            <ArticleTitle>Demystifying the estimand framework: a case study using patient-reported outcomes in oncology.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e488-e494</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1470-2045(20)30319-3</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(20)30319-3</ELocationID>
            <Abstract>
                <AbstractText>Patient-reported outcome (PRO) measures describe how a patient feels or functions and are increasingly being used in benefit-risk assessments in the development of cancer drugs. However, PRO research objectives are often ill-defined in clinical cancer trials, which can lead to misleading conclusions about patient experiences. The estimand framework is a structured approach to aligning a clinical trial objective with the study design, including endpoints and analysis. The estimand framework uses a multidisciplinary approach and can improve design, analysis, and interpretation of PRO results. On the basis of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use E9(R1) addendum, we provide an overview of the estimand framework intended for a multistakeholder audience. We apply the estimand framework to a hypothetical trial for breast cancer, using physical function to develop specific PRO research objectives. This Policy Review is not an endorsement of a specific study design or outcome; rather, it is meant to show the application of principles of the estimand framework to research study design and add to ongoing discussion. Use of the estimand framework to review medical products and label PROs in oncology can improve communication between stakeholders and ultimately provide a clearer interpretation of patient experience in the development of oncological drugs.</AbstractText>
                <CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fiero</LastName>
                    <ForeName>Mallorie H</ForeName>
                    <Initials>MH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Office of Biostatistics, US Food and Drug Administration, Silver Spring, MD, USA. Electronic address: mallorie.fiero@fda.hhs.gov.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pe</LastName>
                    <ForeName>Madeline</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>European Organisation for Research and Treatment of Cancer, Brussels, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weinstock</LastName>
                    <ForeName>Chana</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Office of Oncologic Diseases, US Food and Drug Administration, Silver Spring, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>King-Kallimanis</LastName>
                    <ForeName>Bellinda L</ForeName>
                    <Initials>BL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Drug Evaluation and Research and Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Komo</LastName>
                    <ForeName>Scott</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Office of Biostatistics, US Food and Drug Administration, Silver Spring, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klepin</LastName>
                    <ForeName>Heidi D</ForeName>
                    <Initials>HD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gray</LastName>
                    <ForeName>Stacy W</ForeName>
                    <Initials>SW</Initials>
                    <AffiliationInfo>
                        <Affiliation>City of Hope, Duarte, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bottomley</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>European Organisation for Research and Treatment of Cancer, Brussels, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kluetz</LastName>
                    <ForeName>Paul G</ForeName>
                    <Initials>PG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Drug Evaluation and Research and Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sridhara</LastName>
                    <ForeName>Rajeshwari</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Office of Biostatistics, US Food and Drug Administration, Silver Spring, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Lancet Oncol</MedlineTA>
            <NlmUniqueID>100957246</NlmUniqueID>
            <ISSNLinking>1470-2045</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>03</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>20</Hour>
                <Minute>10</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002444</ArticleId>
            <ArticleId IdType="pii">S1470-2045(20)30319-3</ArticleId>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30319-3</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33002442</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1474-5488</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Lancet. Oncology</Title>
            </Journal>
            <ArticleTitle>Treatment after progression in the era of immunotherapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e463-e476</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1470-2045(20)30328-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(20)30328-4</ELocationID>
            <Abstract>
                <AbstractText>Immunotherapy represents a paradigm shift in oncology treatment. The goal of immunotherapy is to overcome immunosuppression induced by a tumour and its microenvironment, thereby allowing the immune system to target and kill cancer cells. The immunotherapy era began when the first immune checkpoint inhibitor, ipilimumab, was approved for use almost a decade ago. This therapeutic approach is associated with distinct types of response, including processes such as pseudoprogression (ie, increased tumour burden via radiology, which is not accompanied by clinical deterioration) and hyperprogression (ie, rapid progression of the disease as a result of immunotherapy). In this Review, we focus on therapeutic approaches for patients who progress on immunotherapy. We review the different types of clinical responses associated with immunotherapy and describe treatment options for this population.</AbstractText>
                <CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Billan</LastName>
                    <ForeName>Salem</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Head and Neck Center, Rambam Health Care Campus, Technion-Israel Institute of Technology, Haifa, Israel; Radiotherapy Institute, Rambam Health Care Campus, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: s_billan@rmc.gov.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaidar-Person</LastName>
                    <ForeName>Orit</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Cancer Radiation Unit, Radiation Department, Sheba Medical Center, Ramat Gan, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gil</LastName>
                    <ForeName>Ziv</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Head and Neck Center, Rambam Health Care Campus, Technion-Israel Institute of Technology, Haifa, Israel; Department of Otolaryngology Head and Neck Surgery, Rambam Health Care Campus, Technion-Israel Institute of Technology, Haifa, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Lancet Oncol</MedlineTA>
            <NlmUniqueID>100957246</NlmUniqueID>
            <ISSNLinking>1470-2045</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>03</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>20</Hour>
                <Minute>10</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002442</ArticleId>
            <ArticleId IdType="pii">S1470-2045(20)30328-4</ArticleId>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30328-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33002436</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1474-5488</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Lancet. Oncology</Title>
            </Journal>
            <ArticleTitle>Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1283-1295</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1470-2045(20)30465-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(20)30465-4</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">HER2-positive metastatic breast cancer is incurable and new treatments are needed. Addition of atezolizumab to trastuzumab emtansine might potentiate anticancer immunity and enhance the HER2-targeted cytotoxic activity of trastuzumab emtansine. We aimed to test this combination in HER2-positive advanced breast cancer that had progressed after previous treatment with trastuzumab and a taxane.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The KATE2 study is a randomised, double-blind, placebo-controlled, phase 2 study at 68 centres from nine countries across Asia, Australia, North America, and western Europe. Eligible patients were adults (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and centrally confirmed, measurable, HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. Patients were randomly assigned (2:1) either trastuzumab emtansine (3·6 mg/kg of bodyweight) plus atezolizumab (1200 mg) or trastuzumab emtansine plus placebo; all study drugs were administered by intravenous infusion every 3 weeks. Randomisation was done via an interactive voice and web response system using a permuted block scheme (block size of six) and was stratified by PD-L1 status, world region, and liver metastases. Patients, investigators, and study team members were masked to treatment allocation. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02924883, and the study has been completed.</AbstractText>
                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between Sept 26, 2016, and Aug 7, 2017, 330 patients were screened for the study, of whom 202 were randomly allocated either atezolizumab (n=133) or placebo (n=69). At the recommendation of the independent data monitoring committee, treatment assignment was unmasked on Dec 11, 2017, due to futility and the numerically higher frequency of adverse events among patients assigned atezolizumab. This date was set as the clinical cutoff for the primary analysis. Median follow-up was 8·5 months (IQR 6·1-11·5) for patients assigned atezolizumab and 8·4 months (5·3-11·1) for those assigned placebo. Median progression-free survival was 8·2 months (95% CI 5·8-10·7) for patients assigned atezolizumab versus 6·8 months (4·0-11·1) for those assigned placebo (stratified hazard ratio 0·82, 95% CI 0·55-1·23; p=0·33). The most common grade 3 or worse adverse events were thrombocytopenia (17 [13%] among 132 patients who received atezolizumab vs three [4%] among 68 who received placebo), increased aspartate aminotransferase (11 [8%] vs two [3%]), anaemia (seven [5%] vs 0), neutropenia (six [5%] vs three [4%]), and increased alanine aminotransferase (six [5%] vs two [3%]). Serious adverse events occurred in 43 (33%) of 132 patients who received atezolizumab and 13 (19%) of 68 patients who received placebo. One patient who received atezolizumab died due to a treatment-related adverse event (haemophagocytic syndrome).</AbstractText>
                <AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Addition of atezolizumab to trastuzumab emtansine did not show a clinically meaningful improvement in progression-free survival and was associated with more adverse events. Further study of trastuzumab emtansine plus atezolizumab is warranted in a subpopulation of patients with PD-L1-positive, HER2-positive advanced breast cancer.</AbstractText>
                <AbstractText Label="FUNDING" NlmCategory="BACKGROUND">F Hoffman-La Roche.</AbstractText>
                <CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Emens</LastName>
                    <ForeName>Leisha A</ForeName>
                    <Initials>LA</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: emensla@upmc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Esteva</LastName>
                    <ForeName>Francisco J</ForeName>
                    <Initials>FJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Perlmutter Cancer Center at New York University Langone Health, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beresford</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Royal United Hospital, Bath, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saura</LastName>
                    <ForeName>Cristina</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Laurentiis</LastName>
                    <ForeName>Michelino</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Sung-Bae</ForeName>
                    <Initials>SB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Im</LastName>
                    <ForeName>Seock-Ah</ForeName>
                    <Initials>SA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yifan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Roche (China) Holding, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salgado</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Gasthuis Zusters Antwerpen-Ziekenhuis Netwerk Antwerpen Hospitals, Antwerp, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mani</LastName>
                    <ForeName>Aruna</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genentech, South San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shah</LastName>
                    <ForeName>Jigna</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genentech, South San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lambertini</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>F Hoffmann-La Roche, Basel, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Haiying</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genentech, South San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Haas</LastName>
                    <ForeName>Sanne L</ForeName>
                    <Initials>SL</Initials>
                    <AffiliationInfo>
                        <Affiliation>F Hoffmann-La Roche, Basel, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patre</LastName>
                    <ForeName>Monika</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>F Hoffmann-La Roche, Basel, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loi</LastName>
                    <ForeName>Sherene</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Research, Peter MacCallum Cancer Center, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02924883</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Lancet Oncol</MedlineTA>
            <NlmUniqueID>100957246</NlmUniqueID>
            <ISSNLinking>1470-2045</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>03</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>20</Hour>
                <Minute>10</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002436</ArticleId>
            <ArticleId IdType="pii">S1470-2045(20)30465-4</ArticleId>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30465-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33002425</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1658-3876</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Sep</Month>
                        <Day>26</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Hematology/oncology and stem cell therapy</Title>
            </Journal>
            <ArticleTitle>Vitamin D baseline levels at diagnosis of breast cancer: A systematic review and meta-analysis.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S1658-3876(20)30147-3</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hemonc.2020.08.005</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Vitamin D is a steroid hormone that exerts its actions through ligation of the vitamin D receptor (VDR), a transcription factor of the nuclear receptor family. VDR has not only physiologic actions in calcium metabolism but also several other cellular effects through extensive binding to the DNA and modification of genome expression. In cancer, it has neoplasia-suppressive effects and various mechanisms of action mediating cancer cell inhibition have been described. Vitamin D deficiency has been linked to increased risk of breast cancer. A role of the vitamin once the disease has been diagnosed is also probable.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review and meta-analysis of studies that report on vitamin D levels (in the form of its main circulating metabolite, 25-hydroxyvitamin D [25-OHD]) in patients with newly diagnosed breast cancer was performed. Outcomes of interest included the levels of serum 25-OHD in patients with breast cancer, those of matched controlled, in studies that included controls, as well as respective percentages of patients and controls with deficient and insufficient 25-OHD levels.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 25 studies (10 with controls and 15 without controls) provided data on the outcomes of interest. Populations from all continents, besides Australia, were represented in the studies. The mean level of 25-OHD in patients with breast cancer was 26.88 ng/mL (95% CI 22.8-30.96 ng/mL) and the mean level of 25-OHD in control patients was 31.41 ng/mL (95% CI 19.31-43.5 ng/mL). In the patients with breast cancer group, 45.28% (95% CI 24.37%-53.51%) had levels of 25-OHD below 20 ng/mL, whereas this percentage was 33.71% (95% CI 21.61%-45.82%) in controls. Similarly, 67.44% (95% CI 48.32%-86.55%) of patients with breast cancer had a baseline level of 25-OHD below 30 ng/mL, whereas this percentage was 33.71% (95% CI 21.61%-45.82%) in controls.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A high prevalence of vitamin D insufficiency is observed in patients with newly diagnosed breast cancer and may be linked pathophysiologically with breast cancer development or progression. Therapeutic benefits may be provided by manipulation of the vitamin D pathway in breast cancer.</AbstractText>
                <CopyrightInformation>Copyright © 2020. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Voutsadakis</LastName>
                    <ForeName>Ioannis A</ForeName>
                    <Initials>IA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Algoma District Cancer Program, Sault Area Hospital, Sault Ste. Marie, ON, Canada; Section of Internal Medicine, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada. Electronic address: ivoutsadakis@nosm.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Hematol Oncol Stem Cell Ther</MedlineTA>
            <NlmUniqueID>101468532</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Diagnosis</Keyword>
            <Keyword MajorTopicYN="N">Serum 25-OHD levels</Keyword>
            <Keyword MajorTopicYN="N">Serum 25-hydroxyvitamin D</Keyword>
            <Keyword MajorTopicYN="N">Vitamin D</Keyword>
        </KeywordList>
        <CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>04</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>20</Hour>
                <Minute>10</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002425</ArticleId>
            <ArticleId IdType="pii">S1658-3876(20)30147-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.hemonc.2020.08.005</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33002342</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-7634</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer medicine</Title>
            </Journal>
            <ArticleTitle>New small-molecule compound Hu-17 inhibits estrogen biosynthesis by aromatase in human ovarian granulosa cancer cells.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.3492</ELocationID>
            <Abstract>
                <AbstractText>Estrogen-dependent cancers (breast, endometrial, and ovarian) are among the leading causes of morbidity and mortality in women worldwide. Aromatase is the main enzyme that catalyzes the biosynthesis of estrogen, which drives proliferation, and antiestrogens can inhibit the growth of these estrogen-dependent cancers. Hu-17, an aromatase inhibitor, is a novel small-molecule compound that suppresses viability of and promotes apoptosis in ovarian cancer cells. Therefore, this study aimed to predict targets of Hu-17 and assess its intracellular signaling in ovarian cancer cells. Using the Similarity Ensemble Approach software to predict the potential mechanism of Hu-17 and combining phospho-proteome arrays with western blot analysis, we observed that Hu-17 could inhibit the ERK pathway, resulting in reduced estrogen synthesis in KGN cells, a cell line derived from a patient with invasive ovarian granulosa cell carcinoma. Hu-17 reduced the expression of CYP19A1 mRNA, responsible for producing aromatase, by suppressing the phosphorylation of cAMP response element binding-1. Hu-17 also accelerated aromatase protein degradation but had no effect on aromatase activity. Therefore, Hu-17 could serve as a potential treatment for estrogen-dependent cancers albeit further investigation is warranted.</AbstractText>
                <CopyrightInformation>© 2020 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Xi</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-5990-2549</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Central Laboratory, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Jiansheng</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Haiwei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Health Sciences, School of Medicine (SJTUSM)/Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Shang</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-4363-0902</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yi</LastName>
                    <ForeName>Yanghua</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Center for Marine Drugs, School of Pharmacy, Second Military Medical University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Du</LastName>
                    <ForeName>Yanzhi</ForeName>
                    <Initials>Y</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-7322-3390</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>17DZ2271100</GrantID>
                    <Agency>Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81671414</GrantID>
                    <Agency>the National Natural Science Foundation</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Med</MedlineTA>
            <NlmUniqueID>101595310</NlmUniqueID>
            <ISSNLinking>2045-7634</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">
CYP19A1
</Keyword>
            <Keyword MajorTopicYN="N">apoptosis</Keyword>
            <Keyword MajorTopicYN="N">estrogen</Keyword>
            <Keyword MajorTopicYN="N">ovarian granulosa cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>17</Hour>
                <Minute>19</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002342</ArticleId>
            <ArticleId IdType="doi">10.1002/cam4.3492</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Title>REFERENCES</Title>
            <Reference>
                <Citation>Wray N, Markovic M, Manderson L. Discourses of normality and difference: responses to diagnosis and treatment of gynaecological cancer of Australian women. Social Sci Med. 2007;64(11):2260-2271.</Citation>
            </Reference>
            <Reference>
                <Citation>Ahmed N, Kadife E, Raza A, Short M, Jubinsky PT, Kannourakis G. Ovarian cancer, cancer stem cells and current treatment strategies: a potential role of magmas in the current treatment methods. Cells. 2020;9(3):719.</Citation>
            </Reference>
            <Reference>
                <Citation>Dong X, Men X, Zhang W, Lei P. Advances in tumor markers of ovarian cancer for early diagnosis. Indian J Cancer. 2014;51(Suppl 3):e72-e76.</Citation>
            </Reference>
            <Reference>
                <Citation>Futagami M, Yokoyama Y, Shimada M, et al. Contributions of the Japanese Gynecologic Oncology Group (JGOG) in improving the quality of life in women with gynecological malignancies. Curr Oncol Rep. 2017;19(4):25.</Citation>
            </Reference>
            <Reference>
                <Citation>Lin LL, Lakomy DS, Ning MS, Simpkins F, Jhingran A. Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin. Int J Gynecol Cancer. 2020;30(4):409-423.</Citation>
            </Reference>
            <Reference>
                <Citation>Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925.</Citation>
            </Reference>
            <Reference>
                <Citation>Boyd LR, Muggia FM. Carboplatin/paclitaxel induction in ovarian cancer: the finer points. Oncology. 2018;32(8):418-420, 22-4.</Citation>
            </Reference>
            <Reference>
                <Citation>Levy A, Leynes C, Baig M, Chew SA. The application of biomaterials in the treatment of platinum-resistant ovarian cancer. ChemMedChem. 2019;14(21):1810-1827.</Citation>
            </Reference>
            <Reference>
                <Citation>Bulun SE, Chen D, Lu M, et al. Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Molecular Biol. 2007;106(1-5):81-96.</Citation>
            </Reference>
            <Reference>
                <Citation>Stocco C. Aromatase expression in the ovary: hormonal and molecular regulation. Steroids. 2008;73(5):473-487.</Citation>
            </Reference>
            <Reference>
                <Citation>Seidman AD. When to combine endocrine therapy with a new agent for hormone receptor-positive metastatic breast cancer in postmenopausal women. Oncology. 2016;30(3):224-228.</Citation>
            </Reference>
            <Reference>
                <Citation>Zhu J, Zhao C, Kharman-Biz A, et al. The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor alpha and modulates estrogen-stimulated breast cancer cell proliferation. Oncogene. 2014;33(34):4340-4351.</Citation>
            </Reference>
            <Reference>
                <Citation>Simpkins F, Garcia-Soto A, Slingerland J. New insights on the role of hormonal therapy in ovarian cancer. Steroids. 2013;78(6):530-537.</Citation>
            </Reference>
            <Reference>
                <Citation>Xu CY, Jiang ZN, Zhou Y, Li JJ, Huang LM. Estrogen receptor alpha roles in breast cancer chemoresistance. Asian Pacific J Cancer Prevention: APJCP. 2013;14(7):4049-4052.</Citation>
            </Reference>
            <Reference>
                <Citation>Balam FH, Ahmadi ZS, Ghorbani A. Inhibitory effect of chrysin on estrogen biosynthesis by suppression of enzyme aromatase (CYP19): a systematic review. Heliyon. 2020;6(3):e03557.</Citation>
            </Reference>
            <Reference>
                <Citation>Zeng C, Xu JN, Zhou Y, Yang HX, Zhou YF, Xue Q. C-Jun NH2-terminal kinase and p38 inhibition suppresses prostaglandin E2-stimulated aromatase and estrogen receptor levels in human endometriosis. J Clin Endocrinol Metabolism. 2015;100(11):E1404-E1414.</Citation>
            </Reference>
            <Reference>
                <Citation>Howell A. Adjuvant aromatase inhibitors for breast cancer. Lancet. 2005;366(9484):431-433.</Citation>
            </Reference>
            <Reference>
                <Citation>Jordan VC. Antiestrogens: clinical applications of pharmacology. J Soc Gynecologic Investigation. 2000;7(1 Suppl):S47-S48.</Citation>
            </Reference>
            <Reference>
                <Citation>Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nature Rev Cancer. 2003;3(11):821-831.</Citation>
            </Reference>
            <Reference>
                <Citation>Derks MGM, Blok EJ, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(9):1211-1220.</Citation>
            </Reference>
            <Reference>
                <Citation>Bahrami N, Chang G, Kanaya N, et al. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane. J Steroid Biochem Molecular Biol. 2020;200:105641.</Citation>
            </Reference>
            <Reference>
                <Citation>Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. New Eng J Med. 2011;364(25):2381-2391.</Citation>
            </Reference>
            <Reference>
                <Citation>Aktas B, Sorkin M, Pusztai L, Hofstatter EW. Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. Eur J Cancer Prev. 2016;25(1):3-8.</Citation>
            </Reference>
            <Reference>
                <Citation>Foglietta J, Inno A, de Iuliis F, et al. Cardiotoxicity of aromatase inhibitors in breast cancer patients. Clin Breast Cancer. 2017;17(1):11-17.</Citation>
            </Reference>
            <Reference>
                <Citation>Figg WD 2nd, Cook K, Clarke R. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer. Cancer Biol Ther. 2014;15(12):1586-1587.</Citation>
            </Reference>
            <Reference>
                <Citation>Di Liberto M, Svetaz L, Furlan RL, et al. Antifungal activity of saponin-rich extracts of Phytolacca dioica and of the sapogenins obtained through hydrolysis. Natural Product Commun. 2010;5(7):1013-1018.</Citation>
            </Reference>
            <Reference>
                <Citation>Lounkine E, Keiser MJ, Whitebread S, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012;486(7403):361-367.</Citation>
            </Reference>
            <Reference>
                <Citation>Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175-181.</Citation>
            </Reference>
            <Reference>
                <Citation>DeGraw AJ, Keiser MJ, Ochocki JD, Shoichet BK, Distefano MD. Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. J Med Chem. 2010;53(6):2464-2471.</Citation>
            </Reference>
            <Reference>
                <Citation>Zhang J, Liu J, Zhu K, et al. Effects of BMAL1-SIRT1-positive cycle on estrogen synthesis in human ovarian granulosa cells: an implicative role of BMAL1 in PCOS. Endocrine. 2016;53(2):574-584.</Citation>
            </Reference>
            <Reference>
                <Citation>Wang W, Guo C, Zhu P, et al. Phosphorylation of STAT3 mediates the induction of cyclooxygenase-2 by cortisol in the human amnion at parturition. Sci Signal. 2015;8(400):ra106.</Citation>
            </Reference>
            <Reference>
                <Citation>Zhu K, Li S, Liu J, Hong Y, Chen ZJ, Du Y. Role of RAB5A in FSHR-mediated signal transduction in human granulosa cells. Reproduction. 2018;155(6):505-514.</Citation>
            </Reference>
            <Reference>
                <Citation>Qian L, Liu Y, Xu Y, et al. Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways. Cancer Lett. 2015;368(1):126-134.</Citation>
            </Reference>
            <Reference>
                <Citation>Zhai J, Liu J, Cheng X, et al. Zinc finger gene 217 (ZNF217) Promoted Ovarian Hyperstimulation Syndrome (OHSS) through Regulating E2 Synthesis and Inhibiting Thrombospondin-1 (TSP-1). Sci Rep. 2017;7(1):3245.</Citation>
            </Reference>
            <Reference>
                <Citation>Eke I, Schneider L, Forster C, Zips D, Kunz-Schughart LA, Cordes N. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells. Cancer Res. 2013;73(1):297-306.</Citation>
            </Reference>
            <Reference>
                <Citation>Nishi Y, Yanase T, Mu Y, et al. Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology. 2001;142(1):437-445.</Citation>
            </Reference>
            <Reference>
                <Citation>Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 2003;278(33):30458-30468.</Citation>
            </Reference>
            <Reference>
                <Citation>Gubbay O, Rae MT, McNeilly AS, Donadeu FX, Zeleznik AJ, Hillier SG. cAMP response element-binding (CREB) signalling and ovarian surface epithelial cell survival. J Endocrinol. 2006;191(1):275-285.</Citation>
            </Reference>
            <Reference>
                <Citation>Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001;2(8):599-609.</Citation>
            </Reference>
            <Reference>
                <Citation>Hunzicker-Dunn M, Maizels ET. FSH signaling pathways in immature granulosa cells that regulate target gene expression: branching out from protein kinase A. Cell Signal. 2006;18(9):1351-1359.</Citation>
            </Reference>
            <Reference>
                <Citation>McGuire WP 3rd, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer. 2003;89(Suppl 3):S3-8.</Citation>
            </Reference>
            <Reference>
                <Citation>Dai CH, Chen P, Li J, et al. Co-inhibition of pol theta and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival. Oncotarget. 2016;7(40):65157-65170.</Citation>
            </Reference>
            <Reference>
                <Citation>Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Rev Cancer. 2004;4(4):253-265.</Citation>
            </Reference>
            <Reference>
                <Citation>Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16(2):453-461.</Citation>
            </Reference>
            <Reference>
                <Citation>Matikas A, Foukakis T, Michalakis I, Georgoulias V. Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2017;17(4):319-326.</Citation>
            </Reference>
            <Reference>
                <Citation>Briest S, Davidson NE. Aromatase inhibitors for breast cancer. Rev Endocrine Metabolic Disorders. 2007;8(3):215-228.</Citation>
            </Reference>
            <Reference>
                <Citation>Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist. 2004;9(2):126-136.</Citation>
            </Reference>
            <Reference>
                <Citation>Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nature Rev Cancer. 2015;15(5):261-275.</Citation>
            </Reference>
            <Reference>
                <Citation>Lu DF, Yang LJ, Wang F, Zhang GL. Inhibitory effect of luteolin on estrogen biosynthesis in human ovarian granulosa cells by suppression of aromatase (CYP19). J Agricultural Food Chem. 2012;60(34):8411-8418.</Citation>
            </Reference>
            <Reference>
                <Citation>Michael MD, Kilgore MW, Morohashi K, Simpson ER. Ad4BP/SF-1 regulates cyclic AMP-induced transcription from the proximal promoter (PII) of the human aromatase P450 (CYP19) gene in the ovary. J Biol Chem. 1995;270(22):13561-13566.</Citation>
            </Reference>
            <Reference>
                <Citation>Huang X, Jin J, Shen S, et al. Modulation of expression of 17-Hydroxylase/17,20 lyase (CYP17) and P450 aromatase (CYP19) by inhibition of MEK1 in a human ovarian granulosa-like tumor cell line. Gynecol Endocrinol. 2016;32(3):201-205.</Citation>
            </Reference>
            <Reference>
                <Citation>Guo J, Yuan Y, Lu D, et al. Two natural products, trans-phytol and (22E)-ergosta-6,9,22-triene-3beta,5alpha,8alpha-triol, inhibit the biosynthesis of estrogen in human ovarian granulosa cells by aromatase (CYP19). Toxicol Appl Pharmacol. 2014;279(1):23-32.</Citation>
            </Reference>
            <Reference>
                <Citation>Demosthenous C, Han JJ, Hu G, Stenson M, Gupta M. Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma. Oncotarget. 2015;6(42):44703-44713.</Citation>
            </Reference>
            <Reference>
                <Citation>Nai W, Threapleton D, Lu J, et al. Identification of novel genes and pathways in carotid atheroma using integrated bioinformatic methods. Sci Rep. 2016;6:18764.</Citation>
            </Reference>
            <Reference>
                <Citation>Wang X, Chen S. Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. Cancer Res. 2006;66(21):10281-10286.</Citation>
            </Reference>
            <Reference>
                <Citation>Toda K, Takeda K, Okada T, et al. Targeted disruption of the aromatase P450 gene (Cyp19) in mice and their ovarian and uterine responses to 17beta-oestradiol. J Endocrinol. 2001;170(1):99-111.</Citation>
            </Reference>
            <Reference>
                <Citation>Li F, Ye L, Lin SM, Leung LK. Dietary flavones and flavonones display differential effects on aromatase (CYP19) transcription in the breast cancer cells MCF-7. Molecular Cellular Endocrinol. 2011;344(1-2):51-58.</Citation>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33002289</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1099-0461</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of biochemical and molecular toxicology</Title>
            </Journal>
            <ArticleTitle>Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e22638</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jbt.22638</ELocationID>
            <Abstract>
                <AbstractText>Despite advances in treatment, breast cancer remains the widest spread disease among females with a high mortality rate. We investigated the potential effects of gallic acid (GA) as supportive therapy in the management of breast cancer. Anti-cancer activity with GA alone or in combination with paclitaxel and/or carboplatin was assessed by MTT assay and flow cytometry using annexin V/propidium iodide. The mechanism underlying the antiproliferative effects was investigated by measuring the expression of the pro-apoptotic marker (Bax), CASP-3, anti-apoptotic (Bcl-2), and, tumor suppressor (p53) by real-time polymerase chain reaction (RT-PCR) and western blot analysis. Cell cycle analysis was performed for the MCF-7 breast cancer cell line. GA, paclitaxel, and carboplatin alone or in combination arrested cell cycle progression at the G2/M phase and induced Pre-G1 apoptosis. RT-PCR showed that the triplet combination significantly raised P53, Bax, and CASP-3 mRNA expression (20.1 ± 1.41, 16.6 ± 0.43, and 20.04 ± 1.61, respectively) in MCF-7 cells when compared to single or combined treatment (p &lt; .0001) while anti-apoptotic Bcl-2 mRNA levels were decreased in all treated groups compared to untreated cells. Western blot data of tested apoptotic factors were consistent with RT-PCR results. For the first time, we show that a minimum non-toxic concentration of GA increased the efficacy of paclitaxel- and carboplatin-induced MCF-7 apoptotic cell death.</AbstractText>
                <CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Aborehab</LastName>
                    <ForeName>Nora M</ForeName>
                    <Initials>NM</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8871-7756</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elnagar</LastName>
                    <ForeName>Mohamed R</ForeName>
                    <Initials>MR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Waly</LastName>
                    <ForeName>Nermien E</ForeName>
                    <Initials>NE</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1722-3142</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology, Faculty of Medicine, Helwan University, Cairo, Egypt.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Education, Creighton School of Medicine, Omaha, Nebraska, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Biochem Mol Toxicol</MedlineTA>
            <NlmUniqueID>9717231</NlmUniqueID>
            <ISSNLinking>1095-6670</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bax</Keyword>
            <Keyword MajorTopicYN="N">MCF-7</Keyword>
            <Keyword MajorTopicYN="N">P53</Keyword>
            <Keyword MajorTopicYN="N">carboplatin</Keyword>
            <Keyword MajorTopicYN="N">gallic acid</Keyword>
            <Keyword MajorTopicYN="N">paclitaxel</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>17</Hour>
                <Minute>18</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002289</ArticleId>
            <ArticleId IdType="doi">10.1002/jbt.22638</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Title>REFERENCES</Title>
            <Reference>
                <Citation>J. Chen, Y. Duan, X. Zhang, Y. Ye, B. Ge, J. Chen, Food Funct. 2015, 6, 995.</Citation>
            </Reference>
            <Reference>
                <Citation>Q. Xiang, J. Tang, Q. Luo, J. Xue, Y. Tao, H. Jiang, J. Tian, C. Fan, Biomed. Pharmacother. 2019, 111, 813.</Citation>
            </Reference>
            <Reference>
                <Citation>S. Sharifi, J. Barar, M. S. Hejazi, N. Samadi, Asian Pac. J. Cancer Prev. 2014, 15, 8617.</Citation>
            </Reference>
            <Reference>
                <Citation>T. S. Foster, J. D. Miller, M. E. Boye, M. B. Blieden, R. Gidwani, M. W. Russell, Cancer Treat. Rev. 2011, 37, 405.</Citation>
            </Reference>
            <Reference>
                <Citation>H. Chavoshi, V. Vahedian, S. Saghaei, M. B. Pirouzpanah, M. Raeisi, N. Samadi, Asian Pac. J. Cancer Prev. 2017, 18, 2243.</Citation>
            </Reference>
            <Reference>
                <Citation>C. N. Frederiks, S. W. Lam, H. J. Guchelaar, E. Boven, Cancer Treat. Rev. 2015, 41, 935.</Citation>
            </Reference>
            <Reference>
                <Citation>P. Prabhakaran, F. Hassiotou, P. Blancafort, L. Filgueira, Front. Oncol. 2013, 3, 134.</Citation>
            </Reference>
            <Reference>
                <Citation>S. Dasari, T. P. B, Eur. J. Pharmacol. 2014, 740, 364.</Citation>
            </Reference>
            <Reference>
                <Citation>K. S. Albain, S. M. Nag, G. Calderillo-Ruiz, J. P. Jordaan, A. C. Llombart, A. Pluzanska, J. Rolski, A. S. Melemed, J. M. Reyes-Vidal, J. S. Sekhon, L. Simms, J. O'Shaughnessy, J. Clin. Oncol. 2008, 26, 3950.</Citation>
            </Reference>
            <Reference>
                <Citation>R. B. Mokhtari, S. Kumar, S. S. Islam, M. Yazdanpanah, K. Adeli, E. Cutz, H. Yeger, BMC Cancer 2013, 13, 378.</Citation>
            </Reference>
            <Reference>
                <Citation>N. Robert, B. Leyland-Jones, L. Asmar, R. Belt, D. Ilegbodu, D. Loesch, R. Raju, E. Valentine, R. Sayre, M. Cobleigh, K. Albain, C. McCullough, L. Fuchs, D. Slamon, J. Clin. Oncol. 2006, 24, 2786.</Citation>
            </Reference>
            <Reference>
                <Citation>H. Burris, D. Yardley, S. Jones, G. Houston, C. Broome, D. Thompson, F. A. Greco, M. White, J. Hainsworth 3rd, J. Clin. Oncol. 2004, 22, 1621.</Citation>
            </Reference>
            <Reference>
                <Citation>A. K. Conlin, A. D. Seidman, A. Bach, D. Lake, M. Dickler, G. D'Andrea, T. Traina, M. Danso, A. M. Brufsky, M. Saleh, A. Clawson, C. A. Hudis, Clin. Breast Cancer 2010, 10, 281.</Citation>
            </Reference>
            <Reference>
                <Citation>A. L. Frazier, S. Stoneham, C. Rodriguez-Galindo, H. Dang, C. Xia, T. A. Olson, M. J. Murray, J. F. Amatruda, F. Shaikh, F. Pashankar, D. Billmire, M. Krailo, D. Stark, M. F. H. Brougham, J. C. Nicholson, J. P. Hale, Eur. J. Cancer 2018, 98, 30.</Citation>
            </Reference>
            <Reference>
                <Citation>N. T. Telang, H. B. Nair, G. Y. C. Wong, Oncol. Lett. 2019, 17, 5261.</Citation>
            </Reference>
            <Reference>
                <Citation>L. S. Adams, S. Phung, N. Yee, N. P. Seeram, L. Li, S. Chen, Cancer Res. 2010, 70, 3594.</Citation>
            </Reference>
            <Reference>
                <Citation>M. N. Motiwala, R. V. D, Synergy 2015, 2, 1.</Citation>
            </Reference>
            <Reference>
                <Citation>S. Verma, A. Singh, M. A, Environ. Toxicol. Pharmacol. 2013, 35, 473.</Citation>
            </Reference>
            <Reference>
                <Citation>J. D. Hsu, S. H. Kao, T. T. Ou, Y. J. Chen, Y. J. Li, C. J. Wang, J. Agric. Food Chem. 2011, 59, 1996.</Citation>
            </Reference>
            <Reference>
                <Citation>T. Mosmann, J. Immunol. Methods 1983, 65, 55.</Citation>
            </Reference>
            <Reference>
                <Citation>K. J. Livak, T. D. Schmittgen, Methods 2001, 25, 402.</Citation>
            </Reference>
            <Reference>
                <Citation>G. Sun, S. Zhang, Y. Xie, Z. Zhang, W. Zhao, Oncol. Lett. 2016, 11, 150.</Citation>
            </Reference>
            <Reference>
                <Citation>C. L. Tsai, Y.-M. Chiu, T.-Y. Ho, C.-T. Hsieh, D.-C. Shieh, Y.-J. Lee, G. J. Tsay, Y.-Y. Wu, Anticancer Res. 2018, 38, 2057.</Citation>
            </Reference>
            <Reference>
                <Citation>T. Kuittinen, P. Rovio, S. Staff, T. Luukkaala, A. Kallioniemi, S. Grénman, M. Laurila, J. Mäenpää, Anticancer Res. 2017, 37, 6575.</Citation>
            </Reference>
            <Reference>
                <Citation>H. Zhao, Q. Yang, Y. Hu, J. Zhang, Oncol. Rep. 2018, 40, 3223.</Citation>
            </Reference>
            <Reference>
                <Citation>P. Khongkow, A. R. Gomes, C. Gong, E. P. S. Man, J. W. H. Tsang, F. Zhao, L. J. Monteiro, R. C. Coombes, R. H. Medema, U. S. Khoo, E. W. F. Lam, Oncogene 2016, 35, 990.</Citation>
            </Reference>
            <Reference>
                <Citation>B. R. You, H. J. Moon, Y. H. Han, W. H. Park, Food Chem. Toxicol. 2010, 48, 1334.</Citation>
            </Reference>
            <Reference>
                <Citation>W. Luo, M. Zhao, B. Yang, J. Ren, G. Shen, G. Rao, Food Chem. 2011, 126, 277.</Citation>
            </Reference>
            <Reference>
                <Citation>M. J. Bak, S. Das Gupta, J. Wahler, N. Suh, Semin. Cancer Biol. 2016, 40-41, 170.</Citation>
            </Reference>
            <Reference>
                <Citation>M. Salucci, L. A. Stivala, G. Maiani, R. Bugianesi, V. Vannini, Br. J. Cancer 2002, 86, 1645.</Citation>
            </Reference>
            <Reference>
                <Citation>J. N. Sanchez-Carranza, J. Fernando Díaz, M. Redondo-Horcajo, I. Barasoain, L. Alvarez, P. Lastres, A. Romero-Estrada, P. Aller, L. González-Maya, Oncol. Rep. 2018, 39, 3007.</Citation>
            </Reference>
            <Reference>
                <Citation>N. Dashzeveg, Y. K, Cancer Lett. 2015, 367, 108.</Citation>
            </Reference>
            <Reference>
                <Citation>K. Wang, X. Zhu, K. Zhang, L. Zhu, F. Zhou, J. Biochem. Mol. Toxicol. 2014, 28, 387.</Citation>
            </Reference>
            <Reference>
                <Citation>L. Cao, S. Kim, C. Xiao, R. H. Wang, X. Coumoul, X. Wang, W. M. Li, X. L. Xu, J. A. De Soto, H. Takai, S. Mai, S. J. Elledge, N. Motoyama, C. X. Deng, EMBO J. 2006, 25, 2167.</Citation>
            </Reference>
            <Reference>
                <Citation>R. U. Janicke, Breast Cancer Res. Treat. 2009, 117, 219.</Citation>
            </Reference>
            <Reference>
                <Citation>J. Baharara, F. Namvar, T. Ramezani, M. Mousavi, R. Mohamad, Molecules 2015, 20, 2693.</Citation>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33002257</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1099-1611</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Psycho-oncology</Title>
            </Journal>
            <ArticleTitle>Mediating role of Body Image between Sexual Functioning and Marital Intimacy in Pakistani Women with Breast Cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/pon.5563</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The current study aimed to explore the mediating role of body image (dissatisfaction) between sexual functioning and marital intimacy in Pakistani women with breast cancer.</AbstractText>
                <AbstractText Label="DESIGN/PARTICIPANTS" NlmCategory="METHODS">Correlation Research Design was used. 118 women suffering from breast cancer with age (M = 39.58, SD = 11.06) were taken from both Government and Private Hospitals of Lahore, Pakistan. The participants were asked to fill out a set of questionnaires including a Demographic Form, Female Sexual Function Index, Body Image Scale, and Marital Intimacy Questionnaire.</AbstractText>
                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Correlation analysis revealed that there was a significant positive relationship between higher sexual functioning and positive determinants of marital intimacy (consensus, openness, affection and commitment). Body image dissatisfaction had a negative relationship with positive determinants of marital intimacy and positive relationship with intimacy problems (dimension of MIQ). SPSS (Process) revealed that sexual functioning came out to be a positive predictor of marital intimacy while body image (dissatisfaction) came out to be a negative predictor of positive dimensions of marital intimacy. There was a mediational role of body image (dissatisfaction) between sexual functioning and all dimensions of marital Intimacy.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">It was concluded that women who perceived their bodies positively had better marital intimacy, which lead to a healthy marital life. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tahir</LastName>
                    <ForeName>Khola</ForeName>
                    <Initials>K</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0001-8856-078X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>University of the Punjab, Lahore, Pakistan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khan</LastName>
                    <ForeName>Nashi</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Rashid Latif Khan University (RLKU), Dean, Faculty of Social Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Psychooncology</MedlineTA>
            <NlmUniqueID>9214524</NlmUniqueID>
            <ISSNLinking>1057-9249</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Body Image</Keyword>
            <Keyword MajorTopicYN="N">Breast Cancer</Keyword>
            <Keyword MajorTopicYN="N">Cancer</Keyword>
            <Keyword MajorTopicYN="N">Marital Intimacy</Keyword>
            <Keyword MajorTopicYN="N">Oncology</Keyword>
            <Keyword MajorTopicYN="N">Psycho-oncology</Keyword>
            <Keyword MajorTopicYN="N">Sexual Functioning</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>01</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>17</Hour>
                <Minute>17</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002257</ArticleId>
            <ArticleId IdType="doi">10.1002/pon.5563</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33002230</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-9098</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of surgical oncology</Title>
            </Journal>
            <ArticleTitle>Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jso.26236</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Breast conservative surgery (BCS) and sentinel lymph node biopsy (SLNB) after neoadjuvant treatment (NAT) is safe and effective for selected patients. This aim of this study is to evaluate the impact of anatomic site of response on outcomes and to assess the real population who may benefit from nonsurgical approaches after NAT.</AbstractText>
                <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">From a prospectively maintained database, patients with T1-4 N0-2 breast cancer undergoing NAT were identified. Clinicopathological and survival rates were compared in relation to response and anatomic site of response.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Six hundred and forty-six patients were included in the study. Pathologic complete response (pCR) was an independent factor for BCS and SLN. HER2 positive and TN tumors with cN0 achieving a breast pCR remain ypN0 (p = .002). Residual axillary disease was associated with breast residual tumor (p = .05) and subtype (p = .001). With a median follow up of 35.25 months, patients with any pCR had improved survival when compared with partial response, but not significant differences between pCR, axillary pCR, or breast pCR.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Achieving a pCR increases BCS and SLN. In selected subgroups, sparing any axillary surgery after NAT maybe feasible. In cN+ patients, any pCR was associated with survival, but not the anatomic site of response.</AbstractText>
                <CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Esgueva</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8622-064X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgical Oncology, Clinica Universidad de Navarra, Universidad de Navarra, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Siso</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgical Oncology, Hospital Universitario Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Espinosa-Bravo</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgical Oncology, Hospital Universitario Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sobrido</LastName>
                    <ForeName>Carolina</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Imaging Unit, Department of Radiology, Clinica Universidad de Navarra, Universidad de Navarra, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miranda</LastName>
                    <ForeName>Ignacio</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Imaging Unit, Department of Radiology, Hospital Universitario Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salazar</LastName>
                    <ForeName>Juan P</ForeName>
                    <Initials>JP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Imaging Unit, Department of Radiology, Hospital Universitario Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rubio</LastName>
                    <ForeName>Isabel T</ForeName>
                    <Initials>IT</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0035-0679</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgical Oncology, Clinica Universidad de Navarra, Universidad de Navarra, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Surg Oncol</MedlineTA>
            <NlmUniqueID>0222643</NlmUniqueID>
            <ISSNLinking>0022-4790</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">breast neoplasms</Keyword>
            <Keyword MajorTopicYN="N">de-escalation</Keyword>
            <Keyword MajorTopicYN="N">neoadjuvant therapy</Keyword>
            <Keyword MajorTopicYN="N">pathologic complete response</Keyword>
            <Keyword MajorTopicYN="N">survival</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>17</Hour>
                <Minute>17</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002230</ArticleId>
            <ArticleId IdType="doi">10.1002/jso.26236</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Title>REFERENCES</Title>
            <Reference>
                <Citation>Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004;22:2303-2312.</Citation>
            </Reference>
            <Reference>
                <Citation>Golshan M, Loibl S, Wong SM, et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the brightness randomized clinical trial. JAMA Surg. 2020;155:e195410.</Citation>
            </Reference>
            <Reference>
                <Citation>Early Breast Cancer Tialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomized trials. Lancet Oncol. 2018;19:27-39.</Citation>
            </Reference>
            <Reference>
                <Citation>Rubio IT, Wyld L, Cardoso F, et al. Perspectives on preoperative systemic treatment and breast conservative surgery: one step forward or two steps back? Breast. 2018;41:133-135.</Citation>
            </Reference>
            <Reference>
                <Citation>Boughey JC, Peintinger F, Meric-Bernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244:464-470.</Citation>
            </Reference>
            <Reference>
                <Citation>Rubio IT, Esgueva-Colmenarejo A, Espinosa-Bravo M, Salazar JP, Miranda I, Peg V. Intraoperative ultrasound-guided lumpectomy versus mammographic wire localization for breast cancer patients after neoadjuvant treatment. Ann Surg Oncol. 2016;23:38-43.</Citation>
            </Reference>
            <Reference>
                <Citation>Akay CL, Meric-Bernstam F, Hunt KK, et al. Evaluation of the MD Anderson prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012;19:901-907.</Citation>
            </Reference>
            <Reference>
                <Citation>Valachis A, Mamounas EP, Mittendorf EA, et al. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: an international collaboration and individual patient meta-analysis. Cancer. 2018;124:2923-2930.</Citation>
            </Reference>
            <Reference>
                <Citation>Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (alliance) prospective multicenter clinical trial. Ann Surg. 2014;260:608-614.</Citation>
            </Reference>
            <Reference>
                <Citation>Criscitiello C, Azim HA, de Azambuja E, Rubio IT. Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol. 2014;25:910-911.</Citation>
            </Reference>
            <Reference>
                <Citation>Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483-2493.</Citation>
            </Reference>
            <Reference>
                <Citation>Tan VKM, Goh BKP, Fook-Chong S, Khin LW, Wong WK, Yong WS. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer-a systematic review and meta-analysis. J Surg Oncol. 2011;104:97-103.</Citation>
            </Reference>
            <Reference>
                <Citation>Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558-566.</Citation>
            </Reference>
            <Reference>
                <Citation>Boughey JC. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA. 2013;310:1455-1461.</Citation>
            </Reference>
            <Reference>
                <Citation>Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicenter cohort study. Lancet Oncol. 2013;14:609-618.</Citation>
            </Reference>
            <Reference>
                <Citation>Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258-264.</Citation>
            </Reference>
            <Reference>
                <Citation>Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072-1078.</Citation>
            </Reference>
            <Reference>
                <Citation>Siso C, de Torres J, Esgueva-Colmenarejo A, et al. Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA trial): a new tool to guide the excision of the clipped node after neoadjuvant treatment. Ann Surg Oncol. 2018;25:784-791.</Citation>
            </Reference>
            <Reference>
                <Citation>Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261:378-382.</Citation>
            </Reference>
            <Reference>
                <Citation>Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263:802-807.</Citation>
            </Reference>
            <Reference>
                <Citation>Simons JM, Koppert LB, Luiten EJT, et al. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. Breast Cancer Res Treat. 2020;180:725-733.</Citation>
            </Reference>
            <Reference>
                <Citation>Kuerer HM, Krishnamurthy S, Rauch GM, Yang WT, Smith BD, Valero V. Optimal selection of breast cancer patients for elimination of surgery following neoadjuvant systemic therapy. Ann Surg. 2018;268:e61-e2.</Citation>
            </Reference>
            <Reference>
                <Citation>Heil J, Kuerer HM, Pfob A, et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020;31:61-71.</Citation>
            </Reference>
            <Reference>
                <Citation>Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 2017;152:665-670.</Citation>
            </Reference>
            <Reference>
                <Citation>Siso C, Esgueva A, Rodriguez R, Espinosa M, Córdoba O, Rubio I. Her2 positive and triple negative breast cancer patients with clinically negative nodes at diagnosis and breast pathologic complete response may spare axillary surgery after neoadjuvant treatment. Eur J Cancer. 2018;92:S21.</Citation>
            </Reference>
            <Reference>
                <Citation>Galimberti V, Ribeiro Fontana SK, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol. 2016;42:361-368.</Citation>
            </Reference>
            <Reference>
                <Citation>Lee MK, Srour MK, Walcott-Sapp S, et al. Impact of the extent of pathologic complete response on outcomes after neoadjuvant chemotherapy. J Surg Oncol. 2020;121:210-215.</Citation>
            </Reference>
            <Reference>
                <Citation>Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomized, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27-35.</Citation>
            </Reference>
            <Reference>
                <Citation>Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicenter, phase 3 trial. Lancet. 2012;379:633-640.</Citation>
            </Reference>
            <Reference>
                <Citation>King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015;12:335-643.</Citation>
            </Reference>
            <Reference>
                <Citation>Rubio IT, Kontos M, Vrancken-Peeters M, et al. Missed opportunities and challenges for surgical breast cancer research in the era of personalized cancer treatment. Eur J Surg Oncol. 2019;2020(46):501-503.</Citation>
            </Reference>
            <Reference>
                <Citation>Petruolo O, Sevilimedu V, Montagna G, Le T, Morrow M, Barrio AV. How often does modern neoadjuvant chemotherapy downstage patients to breast-conserving surgery? Ann Surg Oncol. 2020.</Citation>
            </Reference>
            <Reference>
                <Citation>Wapnir IL, Kurian AW, Lichtensztajn DY, Clarke CA, Gomez SL. Rising bilateral mastectomy rates among neoadjuvant chemotherapy recipients in California from 1998 to 2012. Ann Surg. 2017;266:353-360.</Citation>
            </Reference>
            <Reference>
                <Citation>Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23:3467-3674.</Citation>
            </Reference>
            <Reference>
                <Citation>Samiei S, van Nijnatten TJA, de Munck L, et al. Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg. 2020;271:574-580.</Citation>
            </Reference>
            <Reference>
                <Citation>Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg. 2018;153:1120-1126.</Citation>
            </Reference>
            <Reference>
                <Citation>Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018;268:591-601.</Citation>
            </Reference>
            <Reference>
                <Citation>Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30:3242-3249.</Citation>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33002044</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
            </Journal>
            <ArticleTitle>Silencing miR-202-3p increases MMP-1 and promotes a brain invasive phenotype in metastatic breast cancer cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e0239292</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0239292</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Brain metastasis (BM) is a major cause of morbidity and mortality in breast cancer (BC) and its molecular mechanism remains poorly understood. Transmigration of metastatic cells through the brain endothelium is an essential step in BM. Metalloproteinase-1 (MMP-1) overexpression plays a key role in promoting trans-endothelial migration by degrading the inter-endothelial junctions and disrupting the endothelial integrity. However, little is known about the molecular mechanisms that induce MMP-1 in metastatic cells granting them a brain invasive phenotype. MiR-202-3p is downregulated in brain metastases compared to primary breast tumors and directly targets MMP-1. Here, we unraveled a critical role of miR-202-3p loss in MMP-1 upregulation promoting transmigration of metastatic cells through the brain endothelium.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A variant of the MDA-MB-231 human BC cell line (MDA-MB-231-BrM2) selected for its propensity to form brain metastases was found to express high levels of MMP-1 and low levels of miR-202-3p compared to the parental cells. Using a gain-and-loss of function approach, we modulated levels of miR-202-3p and examined the resultant effect on MMP-1 expression. Effect of miR-202-3p modulation on integrity of the brain endothelium and the transmigrative ability of BC cells were also examined.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Loss of miR-202-3p in breast cancer cells enhanced their transmigration through the brain endothelium by upregulating MMP-1 and disrupting the inter-endothelial junctions (claudin-5, ZO-1 and ß-catenin). Restoring miR-202-3p exerted a metastasis-suppressive effect and preserved the endothelial barrier integrity.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study identified a critical regulatory role of miR-202-3p in brain metastasis and shed light on miR-202-3p/MMP-1 axis as a novel prognostic and therapeutic target that can be exploited to predict and prevent brain metastasis in breast cancer patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Harati</LastName>
                    <ForeName>Rania</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6672-2944</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hafezi</LastName>
                    <ForeName>Shirin</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mabondzo</LastName>
                    <ForeName>Aloïse</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicines and Healthcare Technologies, CEA, Paris-Saclay University, Gif-sur-Yvette, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tlili</LastName>
                    <ForeName>Abdelaziz</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8039-3013</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Applied Biology, College of Sciences, University of Sharjah, Sharjah, United Arab Emirates.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>17</Hour>
                <Minute>16</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33002044</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0239292</ArticleId>
            <ArticleId IdType="pii">PONE-D-20-14854</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33001984</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1549-1676</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>17</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>PLoS medicine</Title>
            </Journal>
            <ArticleTitle>Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e1003363</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1003363</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Metastatic breast cancer (mBC) is a heterogenous disease with increasing availability of targeted therapies as well as emerging genomic markers of therapeutic resistance, necessitating timely and accurate molecular characterization of disease. As a minimally invasive test, analysis of circulating tumour DNA (ctDNA) is well positioned for real-time genomic profiling to guide treatment decisions. Here, we report the results of a prospective testing program established to assess the feasibility of ctDNA analysis to guide clinical management of mBC patients.</AbstractText>
                <AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">Two hundred thirty-four mBC patients (median age 54 years) were enrolled between June 2015 and October 2018 at the Peter MacCallum Cancer Centre, Melbourne, Australia. Median follow-up was 15 months (range 1-46). All patient samples at the time of enrolment were analysed in real time for the presence of somatic mutations. Longitudinal plasma testing during the course of patient management was also undertaken in a subset of patients (n = 67, 28.6%), according to clinician preference, for repeated molecular profiling or disease monitoring. Detection of somatic mutations from patient plasma was performed using a multiplexed droplet digital PCR (ddPCR) approach to identify hotspot mutations in PIK3CA, ESR1, ERBB2, and AKT1. In parallel, subsets of samples were also analysed via next-generation sequencing (targeted panel sequencing and low-coverage whole-genome sequencing [LC-WGS]). The sensitivity of ddPCR and targeted panel sequencing to identify actionable mutations was compared. Results were discussed at a multidisciplinary breast cancer meeting prior to treatment decisions. ddPCR and targeted panel sequencing identified at least 1 actionable mutation at baseline in 80/234 (34.2%) and 62/159 (39.0%) of patients tested, respectively. Combined, both methods detected an actionable alteration in 104/234 patients (44.4%) through baseline or serial ctDNA testing. LC-WGS was performed on 27 patients from the cohort, uncovering several recurrently amplified regions including 11q13.3 encompassing CCND1. Increasing ctDNA levels were associated with inferior overall survival, whether assessed by ddPCR, targeted sequencing, or LC-WGS. Overall, the ctDNA results changed clinical management in 40 patients including the direct recruitment of 20 patients to clinical trials. Limitations of the study were that it was conducted at a single site and that 31.3% of participants were lost to follow-up.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this study, we found prospective ctDNA testing to be a practical and feasible approach that can guide clinical trial enrolment and patient management in mBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zivanovic Bujak</LastName>
                    <ForeName>Andjelija</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1107-0744</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weng</LastName>
                    <ForeName>Chen-Fang</ForeName>
                    <Initials>CF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silva</LastName>
                    <ForeName>Maria João</ForeName>
                    <Initials>MJ</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0803-6561</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yeung</LastName>
                    <ForeName>Miriam</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-9455-1887</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lo</LastName>
                    <ForeName>Louisa</ForeName>
                    <Initials>L</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-7426-7953</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ftouni</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8043-5164</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Litchfield</LastName>
                    <ForeName>Cassandra</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-9374-1681</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ko</LastName>
                    <ForeName>Yi-An</ForeName>
                    <Initials>YA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuykhoven</LastName>
                    <ForeName>Keilly</ForeName>
                    <Initials>K</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5167-4468</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Geelen</LastName>
                    <ForeName>Courtney</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chandrashekar</LastName>
                    <ForeName>Sushma</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dawson</LastName>
                    <ForeName>Mark A</ForeName>
                    <Initials>MA</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5464-5029</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Centre for Cancer Research, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loi</LastName>
                    <ForeName>Sherene</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6137-9171</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>Stephen Q</ForeName>
                    <Initials>SQ</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7335-2168</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dawson</LastName>
                    <ForeName>Sarah-Jane</ForeName>
                    <Initials>SJ</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8276-0374</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Centre for Cancer Research, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS Med</MedlineTA>
            <NlmUniqueID>101231360</NlmUniqueID>
            <ISSNLinking>1549-1277</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CoiStatement>I have read the journal's policy and the authors of this manuscript have the following competing interests: M.A.D. has been a member of advisory boards for CTX CRC, Storm Therapeutics, Celgene, Cambridge Epigenetix, and GSK. S. L. receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merk, Roche-Genentech, Puma Biotechnology, Pfizer, and Eli Lilly. She has acted as a consultant (not compensated) to Seattle Genetics, Pfizer, Novartis, BMS, Merck, AstraZeneca, and Roche-Genentech. She has acted as a consultant (paid to her institution) to Aduro Biotech. S.Q.W. has received travel support from BioRad. S-J. D. has received research funding to her institution from Roche-Genentech and CTX CRC. She has been a member of advisory boards for AstraZeneca.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>17</Hour>
                <Minute>15</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001984</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pmed.1003363</ArticleId>
            <ArticleId IdType="pii">PMEDICINE-D-19-03963</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33001787</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1527-1323</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>40</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Radiographics : a review publication of the Radiological Society of North America, Inc</Title>
            </Journal>
            <ArticleTitle>Anatomy, Imaging, and Pathologic Conditions of the Brachial Plexus.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1686-1714</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1148/rg.2020200012</ELocationID>
            <Abstract>
                <AbstractText>The brachial plexus is an intricate anatomic structure with an important function: providing innervation to the upper extremity, shoulder, and upper chest. Owing to its complex form and longitudinal course, the brachial plexus can be challenging to conceptualize in three dimensions, which complicates evaluations in standard orthogonal imaging planes. The components of the brachial plexus can be determined by using key anatomic landmarks. Applying this anatomic knowledge, a radiologist should then be able to identify pathologic appearances of the brachial plexus by using imaging modalities such as MRI, CT, and US. Brachial plexopathies can be divided into two broad categories that are based on disease origin: traumatic and nontraumatic. In the traumatic plexopathy group, there are distinct imaging findings and management methods for pre- versus postganglionic injuries. For nontraumatic plexopathies, having access to an accurate patient history is often crucial. Knowledge of the timing of radiation therapy is critical to diagnosing post-radiation therapy brachial plexopathy. In acute brachial neuritis, antecedent stressors occur within a specific time frame. Primary and secondary tumors of the brachial plexus are not uncommon, with the most common primary tumors being peripheral nerve sheath tumors. Direct extension and metastasis from primary malignancies such as breast and lung cancer can occur. Although diagnosing a brachial plexus anomaly is potentially perplexing, it can be straightforward if it is based on foundational knowledge of anatomy, imaging findings, and pathologic features. <sup>©</sup>RSNA, 2020.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gilcrease-Garcia</LastName>
                    <ForeName>Brian M</ForeName>
                    <Initials>BM</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-3155-069X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill (B.M.G., S.D.D.); and Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd, Box 8131, St Louis, MO 63110 (M.S.P.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deshmukh</LastName>
                    <ForeName>Swati D</ForeName>
                    <Initials>SD</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0001-5712-3421</Identifier>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill (B.M.G., S.D.D.); and Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd, Box 8131, St Louis, MO 63110 (M.S.P.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parsons</LastName>
                    <ForeName>Matthew S</ForeName>
                    <Initials>MS</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-1619-9697</Identifier>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill (B.M.G., S.D.D.); and Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd, Box 8131, St Louis, MO 63110 (M.S.P.).</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Radiographics</MedlineTA>
            <NlmUniqueID>8302501</NlmUniqueID>
            <ISSNLinking>0271-5333</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>17</Hour>
                <Minute>14</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001787</ArticleId>
            <ArticleId IdType="doi">10.1148/rg.2020200012</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33001739</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">2687-8941</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>JCO global oncology</Title>
            </Journal>
            <ArticleTitle>Observational Study to Evaluate the Clinical Efficacy of Thermalytix for Detecting Breast Cancer in Symptomatic and Asymptomatic Women.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1472-1480</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1200/GO.20.00168</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the sensitivity and specificity of Thermalytix, an artificial intelligence-based computer-aided diagnostics (CADx) engine, to detect breast malignancy by comparing the CADx output with the final diagnosis derived using standard screening modalities.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This multisite observational study included 470 symptomatic and asymptomatic women who presented for a breast health checkup in two centers. Among them, 238 women had symptoms such as breast lump, nipple discharge, or breast pain, and the rest were asymptomatic. All participants underwent a Thermalytix test and one or more standard-of-care tests for breast cancer screening, as recommended by the radiologists. Results from Thermalytix and standard modalities were obtained independently in a blinded fashion for comparison. The ground truth used for analysis (normal or malignant) was the final impression of an expert clinician based on the symptoms and the available reports of standard modalities (mammography, ultrasonography, elastography, biopsy, fine-needle aspiration cytology, and so on).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">For the 470 women, Thermalytix resulted in a sensitivity of 91.02% (symptomatic, 89.85%; asymptomatic, 100%) and specificity of 82.39% (symptomatic, 69.04%; asymptomatic, 92.41%) in detection of breast malignancy. Thermalytix showed an overall area under the curve (AUC) of 0.90, with an AUC of 0.82 for symptomatic and 0.98 for asymptomatic women.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">High sensitivity and high AUC of Thermalytix in women of all age groups demonstrates the efficacy of the tool for breast cancer screening. Thermalytix, with its automated scoring and image annotations of potential malignancies and vascularity, can assist the clinician in better decision making and improve quality of care in an affordable and radiation-free manner. Thus, we believe Thermalytix is poised to be a promising modality for breast cancer screening.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kakileti</LastName>
                    <ForeName>Siva Teja</ForeName>
                    <Initials>ST</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-1955-3030</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Niramai Health Analytix, Koramangala, Bangalore, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Madhu</LastName>
                    <ForeName>Himanshu J</ForeName>
                    <Initials>HJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Niramai Health Analytix, Koramangala, Bangalore, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krishnan</LastName>
                    <ForeName>Lakshmi</ForeName>
                    <Initials>L</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-5907-6419</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Niramai Health Analytix, Koramangala, Bangalore, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Manjunath</LastName>
                    <ForeName>Geetha</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Niramai Health Analytix, Koramangala, Bangalore, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sampangi</LastName>
                    <ForeName>Sudhakar</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Health Care Global, Bangalore, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramprakash</LastName>
                    <ForeName>H V</ForeName>
                    <Initials>HV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Central Diagnostic Research Foundation Wellness, Bangalore, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JCO Glob Oncol</MedlineTA>
            <NlmUniqueID>101760170</NlmUniqueID>
            <ISSNLinking>2687-8941</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>17</Hour>
                <Minute>14</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001739</ArticleId>
            <ArticleId IdType="doi">10.1200/GO.20.00168</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">33001732</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1541-0048</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>110</Volume>
                    <Issue>S3</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of public health</Title>
            </Journal>
            <ArticleTitle>Breast Cancer Prevention and Treatment: Misinformation on Pinterest, 2018.</ArticleTitle>
            <Pagination>
                <MedlinePgn>S300-S304</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2105/AJPH.2020.305812</ELocationID>
            <Abstract>
                <AbstractText><i>Objectives.</i> To quantify and describe the incidence of misinformation about breast cancer on the social media platform Pinterest, a leading source of women's health (e.g., breast cancer) information.<i>Methods.</i> We performed a hand-coded content analysis on 797 Pinterest posts (&quot;pins&quot;) mentioning the terms &quot;breast cancer&quot; or &quot;breast&quot; and &quot;cancer,&quot; collected in November 2018.<i>Results.</i> From the original sample of 797, 178 (22.3%) made a factual claim about what social media users could do to prevent or treat breast cancer. Of these, more than half-91 (51.1%)-contained misinformation. Therefore, 11.4% of the sample overall contained misinformation related to breast cancer prevention or treatment.<i>Conclusions.</i> Pinterest is a significant vector of misinformation about breast cancer, especially given the platform's overwhelmingly female composition and its visual means of conveying information.<i>Public Health Implications.</i> Health practitioners should be aware of the myths circulating about breast cancer prevention and treatment and be prepared both to dismantle misinformation and to stress reliable health guidance. Meanwhile, Pinterest may wish to widen the criteria it uses for identifying health misinformation on its platform.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wilner</LastName>
                    <ForeName>Tamar</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tamar Wilner is with the School of Journalism and Media and the Center for Media Engagement, Moody College of Communication, University of Texas at Austin. Avery Holton is with the Department of Communication, University of Utah, Salt Lake City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holton</LastName>
                    <ForeName>Avery</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tamar Wilner is with the School of Journalism and Media and the Center for Media Engagement, Moody College of Communication, University of Texas at Austin. Avery Holton is with the Department of Communication, University of Utah, Salt Lake City.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Public Health</MedlineTA>
            <NlmUniqueID>1254074</NlmUniqueID>
            <ISSNLinking>0090-0036</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>17</Hour>
                <Minute>14</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001732</ArticleId>
            <ArticleId IdType="doi">10.2105/AJPH.2020.305812</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">33001611</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2448-5667</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>57</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                        <Day>30</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Revista medica del Instituto Mexicano del Seguro Social</Title>
            </Journal>
            <ArticleTitle>[Adherence to adjuvant hormonal therapy in patients with breast cancer].</ArticleTitle>
            <Pagination>
                <MedlinePgn>357-363</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adherence to hormonal therapy (HT) treatment is a complex and multifaceted issue that can determine variations in response to treatment. However, it is little known about it in routine clinical practice.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess adherence to HT from 1 to 5 years of 190 patients treated at the <i>Hospital de Clínicas</i> (in Montevideo, Uruguay), and to identify factors for the interruption of therapy.</AbstractText>
                <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">190 patients treated with HT due to S I-III breast cancer were included from 2002 to 2012. The Kaplan Meier method was used to assess the proportion of patients who discontinued HT, and the univariate analysis with log-rank test was used to identify factors leading to its interruption.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of 190 patients enrolled in the study, 95.3, 87.9, 80.6, 76.4, and 69.5% were still complying with their HT by the first, second, third, fourth and fifth year, respectively. Therapy continuity was greater in patients who received HT combined with tamoxifen and aromatase inhibitors vs. those who received a single drug (<i>p</i> = 0.017).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This real-life evaluation showed that HT adherence was reduced by 30.5% at 5 years, despite that there is a well-known benefit of this treatment on overall survival (OS), that it is well-tolerated, and provided for free. In view of the significant impact that HT interruption may have on OS, further investigation is required to determine what cause patients to discontinue their HT, in order to guide our efforts and enable us to increase and optimize adherence.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Camejo-Martínez</LastName>
                    <ForeName>Natalia</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Servicio de Oncología. Montevideo, Uruguay ncam3@yahoo.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castillo-Leska</LastName>
                    <ForeName>Cecilia</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Servicio de Oncología. Montevideo, Uruguay.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Artagaveytia-Cóppola</LastName>
                    <ForeName>Nora Amelia</ForeName>
                    <Initials>NA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Servicio de Oncología. Montevideo, Uruguay.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hernández-Ibero</LastName>
                    <ForeName>Ana Laura</ForeName>
                    <Initials>AL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Servicio de Oncología. Montevideo, Uruguay.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amarillo-Hernández</LastName>
                    <ForeName>Dahiana Lourdes</ForeName>
                    <Initials>DL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Servicio de Oncología. Montevideo, Uruguay.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Apud-Yumati</LastName>
                    <ForeName>Patricia Soledad</ForeName>
                    <Initials>PS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Servicio de Oncología. Montevideo, Uruguay.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Melo-Ramundo</LastName>
                    <ForeName>Florencia</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Servicio de Oncología. Montevideo, Uruguay.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Delgado-Pebe</LastName>
                    <ForeName>Lucia Beatriz</ForeName>
                    <Initials>LB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Servicio de Oncología. Montevideo, Uruguay.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>spa</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Adhesión a la hormonoterapia adyuvante en pacientes con cáncer de mama.</VernacularTitle>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Mexico</Country>
            <MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA>
            <NlmUniqueID>101243727</NlmUniqueID>
            <ISSNLinking>0443-5117</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <OtherAbstract Type="Publisher" Language="spa">
            <AbstractText Label="INTRODUCCIÓN" NlmCategory="UNASSIGNED">la adhesión al tratamiento con hormonoterapia (HT) es un tema complejo y polifacético que puede determinar variantes en la respuesta al tratamiento. Sin embargo, se sabe poco acerca de la misma en la práctica clínica habitual.</AbstractText>
            <AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">evaluar la adherencia a HT de uno a cinco años de 190 pacientes tratadas en el Hospital de Clínicas (de Montevideo, Uruguay) e identificar factores de interrupción de la terapia.</AbstractText>
            <AbstractText Label="MATERIAL Y MÉTODOS" NlmCategory="UNASSIGNED">se incluyeron, de 2002 a 2012, 190 pacientes tratadas con HT por cáncer de mama E I-III. Se utilizó el método de Kaplan Meier para valorar la proporción de pacientes que abandonó la HT y el análisis univariado con prueba de <i>log-rank</i> para identificar los factores que podrían influir en su interrupción.</AbstractText>
            <AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">de las 190 pacientes incluidas, las proporciones de quienes mantuvieron adhesión a la HT, desde el primero hasta el quinto año, fueron sucesivamente de 95.3, 87.9, 80.6, 76.4 y 69.5%. Las pacientes que recibieron HT combinada con tamoxifeno e inhibidores de la aromatasa tuvieron mayor continuidad en el tratamiento respecto de aquellas que recibieron una única droga (<i>p</i> = 0.017).</AbstractText>
            <AbstractText Label="CONCLUSIÓN" NlmCategory="UNASSIGNED">evaluamos la adhesión a la HT en la vida real y se redujo un 30.5% en cinco años, a pesar de su conocido beneficio en sobrevida global (SVG), de ser un tratamiento bien tolerado y brindado en forma gratuita. Se deben investigar los motivos de su interrupción, a fin de optimizar su adhesión y ahondar en los esfuerzos para aumentar su cumplimiento, dado el impacto que puede tener en la SVG.</AbstractText>
        </OtherAbstract>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Aromatase Inhibitors</Keyword>
            <Keyword MajorTopicYN="N">Breast Neoplasms</Keyword>
            <Keyword MajorTopicYN="N">Tamoxifen</Keyword>
            <Keyword MajorTopicYN="N">Treatment Adherence and Compliance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>16</Hour>
                <Minute>29</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001611</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33001587</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1939-005X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Wiley interdisciplinary reviews. Systems biology and medicine</Title>
            </Journal>
            <ArticleTitle>Spatiotemporal strategies to identify aggressive biology in precancerous breast biopsies.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e1506</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/wsbm.1506</ELocationID>
            <Abstract>
                <AbstractText>Over 90% of breast cancer is cured; yet there remain highly aggressive breast cancers that develop rapidly and are extremely difficult to treat, much less prevent. Breast cancers that rapidly develop between breast image screening are called &quot;interval cancers.&quot; The efforts of our team focus on identifying multiscale integrated strategies to identify biologically aggressive precancerous breast lesions. Our goal is to identify spatiotemporal changes that occur prior to development of interval breast cancers. To accomplish this requires integration of new technology. Our team has the ability to perform single cell in situ transcriptional profiling, noncontrast biological imaging, mathematical analysis, and nanoscale evaluation of receptor organization and signaling. These technological innovations allow us to start to identify multidimensional spatial and temporal relationships that drive the transition from biologically aggressive precancer to biologically aggressive interval breast cancer. This article is categorized under: Cancer &gt; Computational Models Cancer &gt; Molecular and Cellular Physiology Cancer &gt; Genetics/Genomics/Epigenetics.</AbstractText>
                <CopyrightInformation>© 2020 The Authors. WIREs Systems Biology and Medicine published by Wiley Periodicals LLC.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Frankhauser</LastName>
                    <ForeName>David E</ForeName>
                    <Initials>DE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jovanovic-Talisman</LastName>
                    <ForeName>Tijana</ForeName>
                    <Initials>T</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-1928-4763</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lai</LastName>
                    <ForeName>Lily</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yee</LastName>
                    <ForeName>Lisa D</ForeName>
                    <Initials>LD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Lihong V</ForeName>
                    <Initials>LV</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0001-9783-4383</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Engineering, California Institute of Technology, Pasadena, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mahabal</LastName>
                    <ForeName>Ashish</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Data Driven Discovery, California Institute of Technology, Pasadena, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Geradts</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Duke University, Durham, North Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rockne</LastName>
                    <ForeName>Russell C</ForeName>
                    <Initials>RC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomsic</LastName>
                    <ForeName>Jerneja</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jones</LastName>
                    <ForeName>Veronica</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sistrunk</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miranda-Carboni</LastName>
                    <ForeName>Gustavo</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology and Oncology, University of Tennessee, Memphis, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dietze</LastName>
                    <ForeName>Eric C</ForeName>
                    <Initials>EC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Erhunmwunsee</LastName>
                    <ForeName>Loretta</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hyslop</LastName>
                    <ForeName>Terry</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Duke University, Durham, North Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seewaldt</LastName>
                    <ForeName>Victoria L</ForeName>
                    <Initials>VL</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-7289-9268</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>3U01CA189283-S1</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P20 CA24619</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30CA033572</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA170851</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA192914</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA220693</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 CA221709</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01CA189283</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Wiley Interdiscip Rev Syst Biol Med</MedlineTA>
            <NlmUniqueID>101516550</NlmUniqueID>
            <ISSNLinking>1939-005X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">breast imaging</Keyword>
            <Keyword MajorTopicYN="N">early detection</Keyword>
            <Keyword MajorTopicYN="N">multiscale models</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>12</Hour>
                <Minute>19</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001587</ArticleId>
            <ArticleId IdType="doi">10.1002/wsbm.1506</ArticleId>
        </ArticleIdList>
        <ReferenceList/>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33001583</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1759-7714</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Thoracic cancer</Title>
            </Journal>
            <ArticleTitle>BCAR1 promotes proliferation and cell growth in lung adenocarcinoma via upregulation of POLR2A.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/1759-7714.13676</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study was designed to investigate the effects of a novel carcinogenetic molecule, p130cas (breast cancer antiestrogen resistance protein 1 or BCAR1) on proliferation and cell growth in lung adenocarcinoma. The study also aimed to identify the possible underlying signal networks of BCAR1.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">First, we evaluated proliferation, cell colony formation, apoptosis, and cell cycle after BCAR1 was knocked out (KO) using CRISPR-Cas9 technology in H1975 and H1299 human lung adenocarcinoma cells. Subsequently, BCAR1 was upregulated in 293T cells and immunoprecipitation-mass spectrometry (IP-MS) was used with bioinformatics analysis to screen for potential networks of BCAR1 interacting proteins. Ultimately, we validated the correlated expressions of BCAR1 and a selected hub gene, RNA polymerase II subunit A (POLR2A), in 54 lung adenocarcinoma tissues, as well as in H1975 and H1299 cells.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Cell proliferation of H1975 and H1299 was significantly inhibited following BCAR1-KO. Colony formation of H1975 cells was also significantly decreased following BCAR1-KO. IP-MS demonstrated 419 potential proteins that may interact with BCAR1. Among them, 68 genes were significantly positively correlated to BCAR1 expression, as verified by TCGA. Six hub genes were revealed by PPI String. High expression of POLR2A, MAPK3, MOV10, and XAB2 predicted poor prognosis in lung adenocarcinoma, as verified by the K-M plotter database. POLR2A and MAPK3 are involved in both catalytic activity and transferase activity. POLR2A and BCAR1 were significantly increased in lung cancer tissues as compared with matched normal tissues. High expression of POLR2A was significantly positively correlated to BCAR1 overexpression and predicted poor prognosis in 54 lung cancer cases. POLR2A expression was significantly decreased following BCAR1-KO in H1975 and H1299 cells.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">BCAR1 promotes proliferation and cell growth, probably via upregulation of POLR2A and subsequent enhancement of catalytic and transferase activities. However, additional robust studies are required to elucidate the mechanisms involved.</AbstractText>
                <CopyrightInformation>© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Mao</LastName>
                    <ForeName>Chun-Guo</ForeName>
                    <Initials>CG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thoracic Surgery Department, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Sha-Sha</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thoracic Surgery Department, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Cheng</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thoracic Surgery Department, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Long</LastName>
                    <ForeName>Tan</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thoracic Surgery Department, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Hua</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thoracic Surgery Department, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tan</LastName>
                    <ForeName>Qun-You</ForeName>
                    <Initials>QY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thoracic Surgery Department, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deng</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-3217-143X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Thoracic Surgery Department, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>cstc2018jcyjAX0592</GrantID>
                    <Agency>National Natural Science Foundation of Chongqing City</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81572285</GrantID>
                    <Agency>National Natural Science Foundations of China (NSFC)</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Singapore</Country>
            <MedlineTA>Thorac Cancer</MedlineTA>
            <NlmUniqueID>101531441</NlmUniqueID>
            <ISSNLinking>1759-7706</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BCAR1</Keyword>
            <Keyword MajorTopicYN="N">POLR2A</Keyword>
            <Keyword MajorTopicYN="N">cell growth</Keyword>
            <Keyword MajorTopicYN="N">cell proliferation</Keyword>
            <Keyword MajorTopicYN="N">lung adenocarcinoma</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>12</Hour>
                <Minute>18</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001583</ArticleId>
            <ArticleId IdType="doi">10.1111/1759-7714.13676</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Title>References</Title>
            <Reference>
                <Citation>Camacho LMP, Sciortino M, Tornillo G et al. p130Cas/BCAR1 scaffold protein in tissue homeostasis and pathogenesis. Gene 2015; 562 (1): 1-7.</Citation>
            </Reference>
            <Reference>
                <Citation>Matsui H, Harada I, Sawada Y. Src, p130Cas, and Mechanotransduction in cancer cells. Genes Cancer 2012; 3 (5-6): 394-401.</Citation>
            </Reference>
            <Reference>
                <Citation>Barrett A, Pellet-Many C, Zachary IC, Evans IM, Frankel P. p130Cas: A key signalling node in health and disease. Cell Signal 2013; 25 (4): 766-77.</Citation>
            </Reference>
            <Reference>
                <Citation>Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci 2010; 67 (7): 1025-48.</Citation>
            </Reference>
            <Reference>
                <Citation>Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 2009; 19 (2): 252-66.</Citation>
            </Reference>
            <Reference>
                <Citation>Heumann A, Heinemann N, Hube-Magg C et al. High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. BMC Cancer 2018; 18 (1): 37.</Citation>
            </Reference>
            <Reference>
                <Citation>Yin XY, Yang X, Cui Y, Zhang SM. Expression of three proteins in endometrioid adenocarcinoma and their significance in clinical nursing, diagnosis and treatment. Eur Rev Med Pharmacol Sci 2018; 22 (1): 55-61.</Citation>
            </Reference>
            <Reference>
                <Citation>Yaginuma T, Gao J, Nagata K et al. p130Cas induces bone invasion by oral squamous cell carcinoma by regulating tumor epithelial-mesenchymal transition and cell proliferation. Carcinogenesis 2020; 7 (3): 23-31.</Citation>
            </Reference>
            <Reference>
                <Citation>Gemperle J, Dibus M, Koudelkova L, Rosel D, Brabek J. The interaction of p130Cas with PKN3 promotes malignant growth. Mol Oncol 2019; 13 (2): 264-89.</Citation>
            </Reference>
            <Reference>
                <Citation>Camacho LMP, Pincini A, Tornillo G et al. p130Cas over-expression impairs mammary branching morphogenesis in response to estrogen and EGF. PLOS One 2012; 7 (12): e49817.</Citation>
            </Reference>
            <Reference>
                <Citation>Huang W, Deng B, Wang R et al. BCAR1 protein plays important roles in carcinogenesis and predicts poor prognosis in non-small-cell lung cancer. PLOS One 2012; 7 (4): e36124.</Citation>
            </Reference>
            <Reference>
                <Citation>Deng B, S Z, Jason W, Yang P. Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients. Ann Surg Oncol 2013; 3 (20): S701-8.</Citation>
            </Reference>
            <Reference>
                <Citation>Deng B, Tan QY, Wang RW et al. P130cas is required for TGF-beta1-mediated epithelial-mesenchymal transition in lung cancer. Oncol Lett 2014; 8 (1): 454-60.</Citation>
            </Reference>
            <Reference>
                <Citation>Shalem O, Sanjana NE, Hartenian E et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014; 343 (6166): 84-7.</Citation>
            </Reference>
            <Reference>
                <Citation>Li XF, Chen X, Bao J et al. PTEN negatively regulates the expression of pro-inflammatory cytokines and chemokines of fibroblast-like synoviocytes in adjuvant-induced arthritis. Artif Cells Nanomed Biotechnol 2019; 47 (1): 3687-96.</Citation>
            </Reference>
            <Reference>
                <Citation>Tomczak K, Czerwinska P, Wiznerowicz M. The cancer genome atlas (TCGA): An immeasurable source of knowledge. Contemp Oncol (Pozn) 2015; 19 (1A): A68-77.</Citation>
            </Reference>
            <Reference>
                <Citation>Szklarczyk D, Gable AL, Lyon D et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019; 47 (D1): D607-13.</Citation>
            </Reference>
            <Reference>
                <Citation>Nagy A, Lanczky A, Menyhart O, Gyorffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep 2018; 8 (1): 9227.</Citation>
            </Reference>
            <Reference>
                <Citation>Lindskog C, Edlund K, Mattsson JS, Micke P. Immunohistochemistry-based prognostic biomarkers in NSCLC: Novel findings on the road to clinical use? Expert Rev Mol Diagn 2015; 15 (4): 471-90.</Citation>
            </Reference>
            <Reference>
                <Citation>Miao Y, Li AL, Wang L et al. Expression of p130cas, E-cadherin and beta-catenin and their correlation with clinicopathological parameters in non-small cell lung cancer: p130cas over-expression predicts poor prognosis. Folia Histochem Cytobiol 2012; 50 (3): 392-7.</Citation>
            </Reference>
            <Reference>
                <Citation>Bae YH, Mui KL, Hsu BY et al. A FAK-Cas-Rac-lamellipodin signaling module transduces extracellular matrix stiffness into mechanosensitive cell cycling. SCI Signal 2014; 7 (330): a57.</Citation>
            </Reference>
            <Reference>
                <Citation>Wang M, Liu ZM, Li XC, Yao YT, Yin ZX. Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells. J Chemother 2013; 25 (3): 162-9.</Citation>
            </Reference>
            <Reference>
                <Citation>Kim SJ, Kim SY, Kim JH, Kim DJ. Effects of smoking cessation on gene expression in human leukocytes of chronic smoker. Psychiatry Investig 2014; 11 (3): 290-6.</Citation>
            </Reference>
            <Reference>
                <Citation>Zhu G, He Y, Yang S et al. Identification of gene and MicroRNA signatures for oral cancer developed from oral leukoplakia. Biomed Res Int 2015; 2015 (11): 841956.</Citation>
            </Reference>
            <Reference>
                <Citation>El-Aarag SA, Mahmoud A, Hashem MH et al. In silico identification of potential key regulatory factors in smoking-induced lung cancer. BMC Med Genomics 2017; 10 (1): 40.</Citation>
            </Reference>
            <Reference>
                <Citation>He Q, Zhao L, Liu X et al. MOV10 binding circ-DICER1 regulates the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4 expression change. J Exp Clin Cancer Res 2019; 38 (1): 9.</Citation>
            </Reference>
            <Reference>
                <Citation>Perez-Anorve IX, Gonzalez-De LRC, Soto-Reyes E et al. New insights into radioresistance in breast cancer identify a dual function of miR-122 as a tumor suppressor and oncomiR. Mol Oncol 2019; 13 (5): 1249-67.</Citation>
            </Reference>
            <Reference>
                <Citation>Nakatsu Y, Asahina H, Citterio E et al. XAB2, a novel tetratricopeptide repeat protein involved in transcription-coupled DNA repair and transcription. J Biol Chem 2000; 275 (45): 34931-7.</Citation>
            </Reference>
            <Reference>
                <Citation>Siebring-van OE, Blijlevens M, de Menezes RX et al. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment. Mol Oncol 2017; 11 (5): 534-51.</Citation>
            </Reference>
            <Reference>
                <Citation>Zhao DY, Gish G, Braunschweig U et al. SMN and symmetric arginine dimethylation of RNA polymerase II C-terminal domain control termination. Nature 2016; 529 (7584): 48-53.</Citation>
            </Reference>
            <Reference>
                <Citation>McLaughlin RP, He J, van der Noord VE et al. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. Breast Cancer Res 2019; 21 (1): 77.</Citation>
            </Reference>
            <Reference>
                <Citation>Xu J, Liu Y, Li Y et al. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nat Nanotechnol 2019; 14 (4): 388-97.</Citation>
            </Reference>
            <Reference>
                <Citation>Liu Y, Zhang X, Han C et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 2015; 520 (7549): 697-701.</Citation>
            </Reference>
            <Reference>
                <Citation>Errico A. Colorectal cancer: POLR2A deletion with TP53 opens a window of opportunity for therapy. Nat Rev Clin Oncol 2015; 12 (7): 374.</Citation>
            </Reference>
            <Reference>
                <Citation>Yoo SS, Hong MJ, Lee JH et al. Association between polymorphisms in microRNA target sites and survival in early-stage non-small cell lung cancer. Thorac Cancer 2017; 8 (6): 682-6.</Citation>
            </Reference>
            <Reference>
                <Citation>Limviphuvadh V, Tan CS, Konishi F et al. Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy. BMC Cancer 2018; 18 (1): 555.</Citation>
            </Reference>
            <Reference>
                <Citation>Barbieri I, Tzelepis K, Pandolfini L et al. Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control. Nature 2017; 552 (7683): 126-31.</Citation>
            </Reference>
            <Reference>
                <Citation>Rai K, Akdemir KC, Kwong LN et al. Dual roles of RNF2 in melanoma progression. Cancer Discov 2015; 5 (12): 1314-27.</Citation>
            </Reference>
            <Reference>
                <Citation>Southworth T, Plumb J, Gupta V et al. Anti-inflammatory potential of PI3Kdelta and JAK inhibitors in asthma patients. Respir Res 2016; 17 (1): 124.</Citation>
            </Reference>
            <Reference>
                <Citation>Kessler BE, Mishall KM, Kellett MD et al. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK&gt;p130Cas&gt;c-Jun signaling axis. Oncogene 2019; 38 (14): 2565-79.</Citation>
            </Reference>
            <Reference>
                <Citation>Frischknecht L, Britschgi C, Galliker P et al. BRAF inhibition sensitizes melanoma cells to alpha-amanitin via decreased RNA polymerase II assembly. Sci Rep 2019; 9 (1): 7779.</Citation>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33001531</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4741</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The breast journal</Title>
            </Journal>
            <ArticleTitle>Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/tbj.14068</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine if clinicopathologic (CP) factors could identify patients at &quot;very low&quot; and/or &quot;very high&quot; pretest probability of a high Oncotype DX (ODX) score.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective analysis of all patients that had ODX testing 2008-2018 at a single institution.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 215 patients, all 16 (7.4%) with &quot;all high&quot; risk CP factors had high ODX scores, and all 45 (20.9%) over age 50 with &quot;all low&quot; risk CP factors had ODX recommendations for no chemotherapy.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Oncotype DX results did not change chemotherapy recommendations in those with &quot;very low&quot; or &quot;very high&quot; pretest probability of high ODX scores.</AbstractText>
                <CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kapadia</LastName>
                    <ForeName>Sonam</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-0547-5470</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gudiwada</LastName>
                    <ForeName>Sai Priyanka</ForeName>
                    <Initials>SP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Harbor-UCLA Medical Center, Torrance, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaji</LastName>
                    <ForeName>Amy H</ForeName>
                    <Initials>AH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chlebowski</LastName>
                    <ForeName>Rowan T</ForeName>
                    <Initials>RT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Division of Medical Oncology, Harbor-UCLA Medical Center, Torrance, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Venegas</LastName>
                    <ForeName>Rose</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Harbor-UCLA Medical Center, Torrance, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ozao-Choy</LastName>
                    <ForeName>Junko</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dauphine</LastName>
                    <ForeName>Christine</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-1766-6680</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Breast J</MedlineTA>
            <NlmUniqueID>9505539</NlmUniqueID>
            <ISSNLinking>1075-122X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ODX</Keyword>
            <Keyword MajorTopicYN="N">adjuvant chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">oncotype DX</Keyword>
            <Keyword MajorTopicYN="N">pre-test probability</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>12</Hour>
                <Minute>18</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001531</ArticleId>
            <ArticleId IdType="doi">10.1111/tbj.14068</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Title>REFERENCES</Title>
            <Reference>
                <Citation>Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.</Citation>
            </Reference>
            <Reference>
                <Citation>Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-3734.</Citation>
            </Reference>
            <Reference>
                <Citation>Sparano JA, Gray RJ, Makower DF. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373:2005-2014.</Citation>
            </Reference>
            <Reference>
                <Citation>Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006;7(4):347-350.</Citation>
            </Reference>
            <Reference>
                <Citation>Tang G, Shak S, Paik S, et al. Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat. 2011;127:133-142.</Citation>
            </Reference>
            <Reference>
                <Citation>NCCN National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer - BINV-6 section. Version 3.2020 - March 6, 2020. http://www.nccn.org. Accessed April 30, 2020.</Citation>
            </Reference>
            <Reference>
                <Citation>Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):545-553.</Citation>
            </Reference>
            <Reference>
                <Citation>Cardinal L. Diagnostic testing in the context of high-value care: incorporating prior probability. J Community Hosp Int Med Perspectives. 2016;6:33674.</Citation>
            </Reference>
            <Reference>
                <Citation>Liao GS, Dai MS, Hsu HM, et al. Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer. Eur J Surg Oncol. 2017;43(10):1855-1861.</Citation>
            </Reference>
            <Reference>
                <Citation>Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in estrogen receptor positive breast cancer patients: prospective comparison of the Breast Cancer Index (BCI), Oncotype DX recurrence score, and IHC4 in TransATAC. Lancet Oncol. 2013;14(11):1067-1076.</Citation>
            </Reference>
            <Reference>
                <Citation>Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111-121.</Citation>
            </Reference>
            <Reference>
                <Citation>Park J, Look KA. Health care expenditure burden of cancer care in the United States. Inquiry. 2019;56:46958019880696.</Citation>
            </Reference>
            <Reference>
                <Citation>Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the US: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2006-2014.</Citation>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33001390</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1437-160X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Rheumatology international</Title>
            </Journal>
            <ArticleTitle>Rituximab as a treatment option in a patient with rheumatoid arthritis and a history of malignancy-intracranial chondrosarcoma/osteochondroma-case based review.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-020-04706-1</ELocationID>
            <Abstract>
                <AbstractText>When compared to general population, patients with rheumatoid arthritis are at higher risk of some malignancies (especially lymphomas and lung cancer). Genetic predisposition, chronic inflammatory stimuli and viral infections are some of the reasons untreated patients are at higher risk. Clinical studies and national/international registries collect the data about the malignancies with higher incidence (such as lung, skin and breast cancer) but on the other hand, malignancies with lower incidence (such as sarcomas) are rarely reported. We report a case of a 47-year-old male with a history of a malignant intracranial chondrosarcoma/osteochondroma who developed seropositive rheumatoid arthritis. Due to progression of erosions, the patient was initialy treated with conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and later on with rituximab. The patient's rheumatoid arthritis went and remained in remission on maintenance therapy with rituximab (every 6-8 months) and low-dose methotrexate with no relapse of malignant intracranial chondrosarcoma/osteochondroma. Rituximab should be considered as a treatment option in patients with rare and agressive malignancies, such as sarcomas.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Barešić</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6281-5705</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ježić</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-0075-9001</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia. jezic.ivana02@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simetić</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Herceg</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anić</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Rheumatol Int</MedlineTA>
            <NlmUniqueID>8206885</NlmUniqueID>
            <ISSNLinking>0172-8172</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Case-based review</Keyword>
            <Keyword MajorTopicYN="N">Chondrosarcoma</Keyword>
            <Keyword MajorTopicYN="N">Malignancy</Keyword>
            <Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword>
            <Keyword MajorTopicYN="N">Rituximab</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>12</Hour>
                <Minute>15</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001390</ArticleId>
            <ArticleId IdType="doi">10.1007/s00296-020-04706-1</ArticleId>
            <ArticleId IdType="pii">10.1007/s00296-020-04706-1</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33001337</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
            </Journal>
            <ArticleTitle>Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-020-05948-0</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Triple negative breast cancer (TNBC), an aggressive subtype of breast cancer, lacks the three major receptors for predicting outcome or targeting therapy. Hence, our aim was to evaluate the potential of estrogen receptor beta (ERβ) as a possible endocrine therapy target in TNBC.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The expression and prognostic effect of ERβ isoforms were analyzed using TCGA breast tumor data, and the expression of ERβ isoform mRNA and protein in TNBC cell lines was assayed. Endogenous ERβ2 and ERβ5 were knocked down with siRNA, and ERβ2, ERβ5, and ERβ1 were upregulated using a doxycycline-inducible lentiviral system. Cell proliferation, migration and invasion, and specific gene expressions were evaluated.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">ERβ2 and ERβ5 were the predominant endogenous forms of ERβ in TNBC tumors and cell lines. High ERβ2 predicted worse clinical outcome. Knockdown of endogenous ERβ2/ERβ5 in cell lines suppressed proliferation, migration and invasion, and downregulated proto-oncogene survivin expression. ERβ2/ERβ5 upregulation did the reverse, increasing survivin and these cell activities. ERβ1 was barely detectable in TNBC cell lines, but its upregulation reduced survivin, increased tumor suppressor expression (E-cadherin and cystatins), and suppressed proliferation, migration and invasion in both ligand-independent and dependent manners, suggesting the possible translational benefit of ERβ ligands.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ERβ2/ERβ5 and ERβ1 exhibit sharply contrasting activities in TNBC cells. Our findings imply that delineating the absolute amounts and relative ratios of the different ERβ isoforms might have prognostic and therapeutic relevance, and could enable better selection of optimal approaches for treatment of this often aggressive form of breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yan</LastName>
                    <ForeName>Shunchao</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dey</LastName>
                    <ForeName>Parama</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ziegler</LastName>
                    <ForeName>Yvonne</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiao</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Respiration, Shenyang Chest Hospital, Liaoning Province, Shenyang, 110044, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Sung Hoon</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Katzenellenbogen</LastName>
                    <ForeName>John A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Katzenellenbogen</LastName>
                    <ForeName>Benita S</ForeName>
                    <Initials>BS</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8847-2752</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA. katzenel@illinois.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA. katzenel@illinois.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>BCRF-084</GrantID>
                    <Agency>Breast Cancer Research Foundation</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>BCRF-083</GrantID>
                    <Agency>Breast Cancer Research Foundation</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>1R01 CA220284</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Estrogen receptor beta (ERβ)</Keyword>
            <Keyword MajorTopicYN="N">Invasion</Keyword>
            <Keyword MajorTopicYN="N">Migration</Keyword>
            <Keyword MajorTopicYN="N">Proliferation</Keyword>
            <Keyword MajorTopicYN="N">Triple negative breast cancer (TNBC)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>12</Hour>
                <Minute>15</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001337</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-020-05948-0</ArticleId>
            <ArticleId IdType="pii">10.1007/s10549-020-05948-0</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33001336</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
            </Journal>
            <ArticleTitle>Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from Neoadjuvant Chemotherapy to Surgery.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-020-05894-x</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The optimal time interval from neoadjuvant chemotherapy (NAC) to surgery in patients with breast cancer has not been established. We investigated whether different time intervals impact the rate of pathologic complete response (pCR), disease free survival (DFS), overall survival (OS), surgical complications, and rates of conversion from mastectomy to breast conserving surgery (BCS) in this population.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We identified patients who received NAC at the BC Cancer Agency followed by surgery from May 2012 to April 2018. Patients were grouped based on time interval between NAC and surgery: &lt; 4 weeks, 4-8 weeks, and &gt; 8 weeks. Kaplan Meier method was used to estimate DFS and OS. Rates of pCR between the time intervals were also compared.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 343 patients, 78 (22.8%) received surgery &lt; 4 weeks, 233 (67.9%) received surgery between 4-8 weeks, and 32 (9.3%) received surgery &gt; 8 weeks after NAC, with a median time to surgery (TTS) of 5.0 weeks. pCR was observed in 32.1%, 32.2%, and 28.1%, respectively (p = 0.90). Median follow-up time was 3.3 years. The 5-year DFS was 76%, 78%, and 70% (p = 0.89), respectively. The 5-year OS was 83%, 82%, and 78% (p = 0.33), respectively. No statistically significant differences were seen in surgical complications (p = 0.90), or rates of conversion from mastectomy to BCS (p = 0.19).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There were no statistically significant differences in pCR, DFS, OS, surgical complications, and rates of conversion from mastectomy to BCS, among breast cancer patients receiving surgery &lt; 4 weeks, 4-8 weeks, or &gt; 8 weeks after the last dose of NAC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lai</LastName>
                    <ForeName>Valerie</ForeName>
                    <Initials>V</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0187-8168</Identifier>
                    <AffiliationInfo>
                        <Affiliation>BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>University of British Columbia, Vancouver, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hajjaj</LastName>
                    <ForeName>Omar</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Le</LastName>
                    <ForeName>Dan</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>University of British Columbia, Vancouver, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shokoohi</LastName>
                    <ForeName>Aria</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>University of British Columbia, Vancouver, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chia</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>University of British Columbia, Vancouver, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simmons</LastName>
                    <ForeName>Christine</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. Christine.Simmons@bccancer.bc.ca.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>University of British Columbia, Vancouver, Canada. Christine.Simmons@bccancer.bc.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Neoadjuvant</Keyword>
            <Keyword MajorTopicYN="N">Overall survival</Keyword>
            <Keyword MajorTopicYN="N">Pathologic complete response</Keyword>
            <Keyword MajorTopicYN="N">Wait times</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>03</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>08</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>12</Hour>
                <Minute>15</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001336</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-020-05894-x</ArticleId>
            <ArticleId IdType="pii">10.1007/s10549-020-05894-x</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33001328</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1867-108X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Japanese journal of radiology</Title>
            </Journal>
            <ArticleTitle>Maximum slope of ultrafast dynamic contrast-enhanced MRI of the breast: Comparisons with prognostic factors of breast cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11604-020-01049-6</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To determine the relationship between the maximum slope (MS) of ultrafast dynamic contrast-enhanced (DCE)-MRI and prognostic factors of breast cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">One hundred thirteen patients with 118 breast cancers were included in this study. The ultrafast DCE sequence was acquired using a higher parallel imaging factor. Its spatial resolution was 0.9 × 0.9 × 2.5 mm and its temporal resolution was 8.3 s/phase. Each lesion was automatically segmented, and the ROI of highest enhancement in the lesion was identified. In this ROI, the MS was calculated. The MS of each lesion was compared with various prognostic factors of breast cancer.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The MS of invasive cancer (median: 9.81%/sec) was significantly higher than that of ductal carcinoma in situ (median: 7.26%/sec) (p = 0.001). In the ROC analysis, the area under the ROC curve (AUC) was 0.7295. The MS of invasive cancer with axillary lymph node (LN) metastasis (median: 11.97%/sec) was significantly higher than that without axillary LN metastasis (median: 9.425%/sec) (p = 0.0024). In the ROC analysis, the AUC was 0.7177. In addition, the MS became significantly higher as the level of the proliferation marker ki-67 increased (correlation coefficient: 0.3317) (p = 0.0009).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MS of ultrafast DCE-MRI is useful for predicting the prognostic factors of breast cancer. Higher maximum slope (MS) is significantly associated with an invasive breast cancer component. Higher MS is significantly associated with an axillary lymph node metastasis. MS becomes significantly higher with increasing ki-67 (a proliferation marker). Ultrafast MRI is useful for predicting the prognostic factors of breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yamaguchi</LastName>
                    <ForeName>Ken</ForeName>
                    <Initials>K</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2357-2285</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan. yamaguk@cc.saga-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakazono</LastName>
                    <ForeName>Takahiko</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Egashira</LastName>
                    <ForeName>Ryoko</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fukui</LastName>
                    <ForeName>Shuichi</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baba</LastName>
                    <ForeName>Koichi</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamamoto</LastName>
                    <ForeName>Takahiro</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ajisai Clinic, 1-9-38 Ekimaechuo, Saga, 840-0801, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Irie</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Jpn J Radiol</MedlineTA>
            <NlmUniqueID>101490689</NlmUniqueID>
            <ISSNLinking>1867-1071</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Kinetics</Keyword>
            <Keyword MajorTopicYN="N">Magnetic resonance imaging</Keyword>
            <Keyword MajorTopicYN="N">Maximum slope</Keyword>
            <Keyword MajorTopicYN="N">Prognosis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>12</Hour>
                <Minute>15</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001328</ArticleId>
            <ArticleId IdType="doi">10.1007/s11604-020-01049-6</ArticleId>
            <ArticleId IdType="pii">10.1007/s11604-020-01049-6</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33001309</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-1084</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European radiology</Title>
            </Journal>
            <ArticleTitle>Prediction of breast cancer molecular subtypes on DCE-MRI using convolutional neural network with transfer learning between two centers.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00330-020-07274-x</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To apply deep learning algorithms using a conventional convolutional neural network (CNN) and a recurrent CNN to differentiate three breast cancer molecular subtypes on MRI.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 244 patients were analyzed, 99 in training dataset scanned at 1.5 T and 83 in testing-1 and 62 in testing-2 scanned at 3 T. Patients were classified into 3 subtypes based on hormonal receptor (HR) and HER2 receptor: (HR+/HER2-), HER2+, and triple negative (TN). Only images acquired in the DCE sequence were used in the analysis. The smallest bounding box covering tumor ROI was used as the input for deep learning to develop the model in the training dataset, by using a conventional CNN and the convolutional long short-term memory (CLSTM). Then, transfer learning was applied to re-tune the model using testing-1(2) and evaluated in testing-2(1).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In the training dataset, the mean accuracy evaluated using tenfold cross-validation was higher by using CLSTM (0.91) than by using CNN (0.79). When the developed model was applied to the independent testing datasets, the accuracy was 0.4-0.5. With transfer learning by re-tuning parameters in testing-1, the mean accuracy reached 0.91 by CNN and 0.83 by CLSTM, and improved accuracy in testing-2 from 0.47 to 0.78 by CNN and from 0.39 to 0.74 by CLSTM. Overall, transfer learning could improve the classification accuracy by greater than 30%.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The recurrent network using CLSTM could track changes in signal intensity during DCE acquisition, and achieved a higher accuracy compared with conventional CNN during training. For datasets acquired using different settings, transfer learning can be applied to re-tune the model and improve accuracy.</AbstractText>
                <AbstractText Label="KEY POINTS" NlmCategory="CONCLUSIONS">• Deep learning can be applied to differentiate breast cancer molecular subtypes. • The recurrent neural network using CLSTM could track the change of signal intensity in DCE images, and achieved a higher accuracy compared with conventional CNN during training. • For datasets acquired using different scanners with different imaging protocols, transfer learning provided an efficient method to re-tune the classification model and improve accuracy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiological Sciences, University of California, Irvine, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jeon-Hor</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, E-Da Hospital and I-Shou University, No. 1, Yida Road, Jiaosu Village, Yanchao District, 8244, Kaohsiung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Yezhi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, First Affiliate Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>Siwa</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Imaging, Taichung Tzu-Chi Hospital, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Jiejie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, First Affiliate Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chow</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiological Sciences, University of California, Irvine, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiological Sciences, University of California, Irvine, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kwong</LastName>
                    <ForeName>Tiffany</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiological Sciences, University of California, Irvine, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yeh</LastName>
                    <ForeName>Dah-Cherng</ForeName>
                    <Initials>DC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Imaging, Taichung Tzu-Chi Hospital, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Xinxin</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiological Sciences, University of California, Irvine, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parajuli</LastName>
                    <ForeName>Ritesh</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, University of California, Irvine, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mehta</LastName>
                    <ForeName>Rita S</ForeName>
                    <Initials>RS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, University of California, Irvine, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Meihao</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, First Affiliate Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China. wzwmh@wmu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Min-Ying</ForeName>
                    <Initials>MY</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3069-0271</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiological Sciences, University of California, Irvine, CA, USA. msu@uci.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>John Tu and Thomas Yuen Center for Functional Onco-Imaging, 164 Irvine Hall, University of California, Irvine, CA, 92697-5020, USA. msu@uci.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 CA127927</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21 CA208938</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Eur Radiol</MedlineTA>
            <NlmUniqueID>9114774</NlmUniqueID>
            <ISSNLinking>0938-7994</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>
            <Keyword MajorTopicYN="N">Machine learning</Keyword>
            <Keyword MajorTopicYN="N">Magnetic resonance imaging</Keyword>
            <Keyword MajorTopicYN="N">Receptor, ErbB-2</Keyword>
            <Keyword MajorTopicYN="N">Receptors, estrogen</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>12</Hour>
                <Minute>15</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001309</ArticleId>
            <ArticleId IdType="doi">10.1007/s00330-020-07274-x</ArticleId>
            <ArticleId IdType="pii">10.1007/s00330-020-07274-x</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33001307</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-1084</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European radiology</Title>
            </Journal>
            <ArticleTitle>Radiological review of prior screening mammograms of screen-detected breast cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00330-020-07130-y</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To perform a radiological review of mammograms from prior screening and diagnosis of screen-detected breast cancer in BreastScreen Norway, a population-based screening program.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We performed a consensus-based informed review of mammograms from prior screening and diagnosis for screen-detected breast cancers. Mammographic density and findings on screening and diagnostic mammograms were classified according to the Breast Imaging-Reporting and Data System®. Cases were classified based on visible findings on prior screening mammograms as true (no findings), missed (obvious findings), minimal signs (minor/non-specific findings), or occult (no findings at diagnosis). Histopathologic tumor characteristics were extracted from the Cancer Registry of Norway. The Bonferroni correction was used to adjust for multiple testing; p &lt; 0.001 was considered statistically significant.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included mammograms for 1225 women with screen-detected breast cancer. Mean age was 62 years ± 5 (SD); 46% (567/1225) were classified as true, 22% (266/1225) as missed, and 32% (392/1225) as minimal signs. No difference in mammographic density was observed between the classification categories. At diagnosis, 59% (336/567) of true and 70% (185/266) of missed cancers were classified as masses (p = 0.004). The percentage of histological grade 3 cancers was higher for true (30% (138/469)) than for missed (14% (33/234)) cancers (p &lt; 0.001). Estrogen receptor positivity was observed in 86% (387/469) of true and 95% (215/234) of missed (p &lt; 0.001) cancers.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We classified 22% of the screen-detected cancers as missed based on a review of prior screening mammograms with diagnostic images available. One main goal of the study was quality improvement of radiologists' performance and the program. Visible findings on prior screening mammograms were not necessarily indicative of screening failure.</AbstractText>
                <AbstractText Label="KEY POINTS" NlmCategory="CONCLUSIONS">• After a consensus-based informed review, 46% of screen-detected breast cancers were classified as true, 22% as missed, and 32% as minimal signs. • Less favorable prognostic and predictive tumor characteristics were observed in true screen-detected breast cancer compared with missed. • The most frequent mammographic finding for all classification categories at the time of diagnosis was mass, while the most frequent mammographic finding on prior screening mammograms was a mass for missed cancers and asymmetry for minimal signs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hovda</LastName>
                    <ForeName>Tone</ForeName>
                    <Initials>T</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0001-9786-9455</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Vestre Viken Hospital Trust, PO Box 800, 3004, Drammen, Norway.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Clinical Medicine, University of Oslo, PO Box 1171, Blindern, 0318, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsuruda</LastName>
                    <ForeName>Kaitlyn</ForeName>
                    <Initials>K</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0001-8749-6237</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Section for Breast Cancer Screening, Cancer Registry of Norway, PO Box 5313, Majorstuen, 0304, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, PO Box 1122, Blindern, 0317, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoff</LastName>
                    <ForeName>Solveig Roth</ForeName>
                    <Initials>SR</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0001-7928-3821</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Åsehaugen 5, 6017, Ålesund, Norway.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU, Trondheim, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sahlberg</LastName>
                    <ForeName>Kristine Kleivi</ForeName>
                    <Initials>KK</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-7281-2759</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Research and Innovation, Vestre Viken Hospital Trust, PO Box 800, 3004, Drammen, Norway.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Trust, PO Box 4950, 0424, Oslo, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hofvind</LastName>
                    <ForeName>Solveig</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-0178-8939</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Section for Breast Cancer Screening, Cancer Registry of Norway, PO Box 5313, Majorstuen, 0304, Oslo, Norway. solveig.hofvind@kreftregisteret.no.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Health Science, Oslo Metropolitan University, PO Box 4, St. Olavs Plass, 0130, Oslo, Norway. solveig.hofvind@kreftregisteret.no.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Eur Radiol</MedlineTA>
            <NlmUniqueID>9114774</NlmUniqueID>
            <ISSNLinking>0938-7994</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast neoplasm</Keyword>
            <Keyword MajorTopicYN="N">Digital mammography</Keyword>
            <Keyword MajorTopicYN="N">Female</Keyword>
            <Keyword MajorTopicYN="N">Mammography</Keyword>
            <Keyword MajorTopicYN="N">Mass screening</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>03</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>07</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>05</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>12</Hour>
                <Minute>15</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001307</ArticleId>
            <ArticleId IdType="doi">10.1007/s00330-020-07130-y</ArticleId>
            <ArticleId IdType="pii">10.1007/s00330-020-07130-y</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33001299</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1534-4681</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of surgical oncology</Title>
            </Journal>
            <ArticleTitle>ASO Author Reflections: Clinical Correlates of Moderate-Penetrance Genes in Breast Cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1245/s10434-020-09187-x</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bergstrom</LastName>
                    <ForeName>Colin P</ForeName>
                    <Initials>CP</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3271-0915</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. cbergstr1288@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pence</LastName>
                    <ForeName>Colton</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Texas Southwestern Medical School, Dallas, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Syed</LastName>
                    <ForeName>Samira</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Parkland Health and Hospital System, Dallas, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Surg Oncol</MedlineTA>
            <NlmUniqueID>9420840</NlmUniqueID>
            <ISSNLinking>1068-9265</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>12</Hour>
                <Minute>15</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001299</ArticleId>
            <ArticleId IdType="doi">10.1245/s10434-020-09187-x</ArticleId>
            <ArticleId IdType="pii">10.1245/s10434-020-09187-x</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">33001269</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1433-7339</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Oct</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</Title>
            </Journal>
            <ArticleTitle>Development of a plain-language guide for discussing breast cancer genetic counseling and testing with patients with limited health literacy.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00520-020-05800-7</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Due to limited health literacy and resulting ineffective communication between healthcare professionals and patients, not all eligible patients are offered breast cancer genetic counseling and testing. We aimed to develop a plain-language guide to increase effective communication about genetic counseling and testing with breast cancer patients with limited health literacy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Together with oncological healthcare professionals, we drafted a list of jargon words frequently used during (breast) cancer genetic counseling. In a focus group interview with breast cancer counselees with limited health literacy, who had received genetic counseling before, we reformulated these words in plain language. Low-literate individuals, who are not familiar with breast cancer care or genetic counseling, reflected on the draft of the guide. Completeness, acceptability, and perceived usability were tested in an online questionnaire among healthcare professionals.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The result is a plain-language guide for genetic counseling and testing with 33 frequently used jargon words and a reformulation of these words in plain language. Acceptability and perceived usefulness of the guide among healthcare professionals (n = 58) were high.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The plain-language guide provides opportunities to facilitate communication about genetic counseling and testing with patients with limited health literacy and could enhance opportunities for patients to make informed decisions to participate in genetic testing. As the intention from healthcare professionals to use the plain-language guide is high, implementation of the guide in a real-life setting seems promising.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van der Giessen</LastName>
                    <ForeName>J A M</ForeName>
                    <Initials>JAM</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-0883-3192</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. J.A.M.vandergiessen@umcutrecht.nl.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ausems</LastName>
                    <ForeName>M G E M</ForeName>
                    <Initials>MGEM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Riel</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Jong</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Reading &amp; Writing Foundation, Den Haag, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fransen</LastName>
                    <ForeName>M P</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Dulmen</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Institute for Health Sciences, Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Nivel (Netherlands Institute for Health Services Research), Utrecht, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Health and Social Sciences, University of South-Eastern Norway, Drammen, Norway.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>2016-204</GrantID>
                    <Agency>Pink Ribbon Foundation, with a donation from Vriendenloterij.</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Support Care Cancer</MedlineTA>
            <NlmUniqueID>9302957</NlmUniqueID>
            <ISSNLinking>0941-4355</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Access to care</Keyword>
            <Keyword MajorTopicYN="N">Genetic counseling and testing</Keyword>
            <Keyword MajorTopicYN="N">Genetic literacy</Keyword>
            <Keyword MajorTopicYN="N">Health literacy</Keyword>
            <Keyword MajorTopicYN="N">Plain language</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2020</Year>
                <Month>06</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>09</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>12</Hour>
                <Minute>14</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">33001269</ArticleId>
            <ArticleId IdType="doi">10.1007/s00520-020-05800-7</ArticleId>
            <ArticleId IdType="pii">10.1007/s00520-020-05800-7</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
